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CHAPTER 1 
GENERAL INTRODUCTION 
Infections are a major cause of morbidity and mortality in patients who are 
granulocytopenic due to malignant disease or treatment with anticancer 
chemotherapeutic agents [35, 36, 71, 73, 109]. The course of these infec-
tions is fulminant and if not treated adequately early mortality is high 
[116, 121]. In these cases antibiotics are given empirically and blind at 
the first signs of fever [ 121]. At the time~ therapy is initiated the 
identity and susceptibility of the causative organism are mostly not known. 
Therefore antibiotic combinations are used to ensure broad coverage against 
the possible pathogens [35, 36, 72, 73]. Another consideration for the use 
of antibiotic combinations forms a possible synergistic interaction of the 
antimicrobial agents used and the prevention of treatment failures due to 
monodrug resistance [13, 66]. 
Antibiotics are generally administered intermittently. Dosage schedules are 
based on knowledge about the pharmacokinetic properties of the antibiotics 
used and the in vitro susceptibility of the infecting strain. In addition, 
dosage has sometimes to be limited to avoid toxicity as is for instance 
the case with aminoglycosides. However, data about the kinetics of anti-
bacterial activity of antibiotics are less taken into account. The practice 
of antibiotic dosage mentioned is mostly successful in immunocompetent 
patients. However, a substantial number of treatment failures are reported 
in patients with impaired host defenses, especially in case of severe 
granulocytopenia. Antibiotic treatment is still not always successful in 
these patients despite the introduction of new and potent antibiotics [37, 
73]. So next to the use of highly active antimicrobial agents, more is 
needed to improve the outcome of antibiotic treatment in these patients. 
One of the approaches may be intensification of treatment by modification 
of the dosage schedule. The schedule of drug administration may play an 
important role in the outcome of antibiotic treatment of serious infec-
tions, particularly in the immunocompromised host, as in these patients 
recovery from infection depends to a high degree on antibiotics. It is not 
clearly established whether or not repeated high antibiotic serum 
concentrations of short duration are superior to continuously maintained 
antibiotic serum concentrations at lower level. 
As clinical trials are difficult to perform, experimental infection models 
7 
are used, which allow comparison of the efficacy of different antibiotics 
and antimicrobial treatment schedules under similar conditions of intensity 
and duration of infection. Already in the early years after the discovery 
of penicillin infection models were used to study the relevance of the 
antibiotic dosage schedule for the therapeutic activity. The studies were 
limited to the effect of penicillins against streptococci in animals with 
intact host defenses. Since then numerous antibiotics of different classes 
have been developed for the treatment of various infections. 
Various infection models have been used to study the impact of dosage 
regimens on the therapeutic efficacy of different classes of antibiotics. 
The experimental studies, especially those in animals with intact host 
defenses, yielded somewhat contradictory results. The discrepancies 
observed in individual studies may be explained by differences in the 
infection model and animal species, in the virulence of the bacterial 
strains, and in the mode or duration of antibiotic administration. In 
addition data about the impact of the dosage schedule on the in vivo 
activity in relation to the class of antibiotic have been mainly derived 
from studies either performed in infection models with limited clinical 
relevance or from therapy experiments in which only one class of antibiotic 
was studied. 
The present study was performed in a model of Klebsiella pneumoniae 
pneumonia and septicemia in rats. This experimental model was used because 
in leukopenic patients septicemia is a real threat, and K.pneumoniae is one 
of the pathogens that may be recovered [68, 74, 99, 116, 122, 124]. The 
experimental design including the infectious disease model is described in 
chapter 2. The role of the antibiotic dosage schedule as a determinant of 
therapeutic activity was investigated in relation to various factors such 
as the severity of infection (chapter 3) , the presence of host defense 
factors (chapter 4), and the kinetics of antibacterial activity in vitro 
and in vivo for different classes of antibiotics (chapter 5) . From the 
three classes of antibiotics, the 8-lactams, the aminoglycosides and the 
quinolones, ceftazidime, gentamicin and ciprofloxacin were selected as 
investigational drug, respectively, because of their antibacterial activity 
against clinically important pathogens and their broad antibacterial 
spectrum. In addition, the in vitro susceptibility in terms of MBC values 
of the K.pneumoniae strain used was similar for the three drugs tested, 
which facilitated a good evaluation of their therapeutic efficacy. The 
therapeutic effect of ceftazidime, gentamicin and ciprofloxacin in relation 
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to the duration of infection and the bacterial growth rate is described in 
chapter 6. Finally in chapter 7 the experimental results obtained are 
discussed with reference to the observations of other investigators. 
The chapters 3 through 6 represent the appendix papers. 
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CHAPTER 2 
EXPERIMENTAL DESIGN 
Bacteria. A Klebsiella pneurnoniae strain (ATCC 43816, capsular sere-
type 2) was used in all experiments. Stationary-phase cultures were 
prepared by incubation for 16 h at 37°C in Todd-Hewitt broth (Oxoid Ltd., 
London, England). After proper dilution and reincubation for 2 hat 37°C 
suspensions of logarithmically growing bacteria were obtained. 
Infectious disease model of K.pneumoniae pneumonia and septicemia in rats. 
Female R strain albino rats (specific pathogen free; 14 to 18 weeks old; 
weight, 185 to 215 g; bred at REPGO-TNO, Rijswijk, The Netherlands) were 
used in all experiments. 
Experimental pneumonia was produced in the following manner. Rats were 
anesthetized with fluanisone (HypnorrnR; Duphar B.V., Amsterdam, The 
Netherlands) and pentobarbital (Abbott Laboratories, North Chicago, Ill.). 
The left main stern bronchus was intubated and the left lung was inoculated 
with 0. 02 rnl of a saline suspension of K. pneurnoniae. The number of CFU 
(8 x 104 in all therapy studies and most experiments related to the 
kinetics of bactericidal activity) used to inoculate the left lung in the 
different experiments was confirmed by plate counts on blood agar. After 
inoculation the narcotic antagonists Nalorphine bromide and Pentetrazolum 
(Onderlinge Pharrnaceutische Groothandel, Utrecht, The Netherlands) were 
injected. 
Numbers of bacteria in pleural fluid, blood, and left lung were quantitated 
as follows. Animals were sacrificed, and samples of pleural fluid and blood 
were taken. Pleural exudate was obtained by washing the chest cavity with 
physiological saline. Blood clotting was prevented by mixing 0. 2 ml of 
blood with 0.2 rnl of 3.8% sodium citrate. Then the left lung was removed 
after macroscopic examination, weighed, and homogenized in 20 rnl of 
physiological saline for 30 s at 10,000 rpm in a VirTis homogenizer (The 
Virtis Co., Inc., Gardiner, N.Y.). Volumes of 200 ~1 of undiluted samples 
or serial ten-fold dilutions of pleural washing fluid, blood and lung-
homogenate in saline were spread on bloodagar plates. 
The histological features of the pneumonic lesions were studied. Lungs were 
fixed by injecting the trachea with 10% formalin under constant pressure to 
reexpand the lungs. Segments of the left lung were then dehydrated in 
11 
ethanol and toluol, embedded in paraffin, sectioned and stained with haema-
toxylin-eosin or by the Gram stain technique. 
The efficacy of inoculation of the left lung with a volume of 0.02 ml after 
intubation of the left main stem bronchus was verified with DionosilR, a 
contrast medium for bronchography. As shown in figure 2. 1 the volume 
inoculated is rapidly distributed in the left lung exclusively. 
Figure 2.1 Chest roentgenograms of rats after inoculation of the left lung 
with a volume of 0.02 ml of DionosilR a contrast medium for bronchography. 
The contrast liquid is spread in the intubated left lung exclusively. 
A. Ventral B. Lateral 
After inoculation of the left lung with 0. 02 ml of a saline suspension 
containing 8 x 104 viable K.pneumoniae organisms (range 6 x 104 - 10 x 104), 
infection developed within 24 h. Macroscopic examination at 72 h after 
inoculation revealed that large parts of the lung were involved 
(figure 2.2). In figure 2.3 the course of the untreated infection is shown. 
Within 5 to 6 days animals died spontaneously from infection. After 
bacterial inoculation, total· body weight decreased constantly, and rectal· 
temperature usually fell below normal values after an initial rise. On days 
4 and 5, some rats had increased temperatures, whereas others had subnormal 
temperatures. Involvement of the lung tissue in the infectious process was 
reflected by a proportional increase in weight (up to sixfold) of the left 
lung. On day 5 an average number of 2 x 10 10 K.pneumoniae organisms were 
12 
Figure 2.2 
K.pneumoniae. 
Left lung at 72 h after inoculation with 8 x 1 o4 CFU of 
cultured from the lung and all rats had bacteria in the blood and pleural 
fluid. A control experiment revealed that the technique of intubation in 
itself did not influence total body weights or rectal temperatures. The 
K.pneumoniae strain used was highly pathogenic for the lung, which is 
reflected in a 100% lethal dose of 8 x 10 4 CFU after inoculation of lungs 
as compared to a 50% lethal dose of 7 x 1 o6 CFU after intraperitoneal 
inoculation. Histological examination of the pneumonic lesion in immuno-
competent rats revealed that few organisms were present in the alveoli 12 
to 14 h after bacterial inoculation. In the hemorrhagic area edema fluid 
and a light polymorphonuclear infiltrate were present. From day 2 after 
inoculation, the outer· edema zone of the lesion was characterized by a 
cellular infiltrate composed almost exclusively of polymorphonuclear 
leukocytes and a few macrophages. More to the center of the lesion, edema-
filled alveoli were packed with leukocytes and small lung abscesses 
demonstrating numerous polymorphonuclear leukocytes and large numbers of 
gram-negative bacilli were common (figure 2.4). 
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Figure 2.3 Course of K.pneumoniae pneumonia and septicemia in immuno-
competent rats after inoculation with 8 x 10 4 CFU of K.pneumoniae at day 0. 
(A) Total body weight loss (percentage) of five rats during infection. (B) 
Rectal temperature of five rats during infection (normal temperature, 
37.4 ± 0.34°C). The following determinations were made after sacrificing 
15 rats in groups of five. (C) Weight of the left lung (normal weight, 
0.6 ± 0.15 g). (D) Number of viable K.pneumoniae in the left lung. (E) 
Number of viable K.pneumoniae per ml of blood. (F) Culture of pleural 
fluid. 
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A 
B 
Figure 2.4 Sections of the left lung from rats 48 h after inoculation with 
8 x 104 CFU of K.pneumoniae. 
A. Section stained with hematoxylin-eosin (x 40). 
B. Section stained with gram stain (x 400). 
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Impairment of host defenses. Leukopenia was induced by intraperitoneal 
injections of cyclophosphamide (CY) (Koch-Light Limited, Haverhill, 
Suffolk, England) in two doses of 90 and 60 mg/kg at five days and one day 
before bacterial inoculation, respectively. Quantitation of blood leuko-
cytes was done in blood samples obtained by orbital puncture under light 
C02 anesthesia from five rats, and collected in polypropylene vials 
containing 1 mg of disodium EDTA per ml. For total leukocyte counts, blood 
was diluted 1: 10 with Turk solution ( 0. 1% crystal violet in 1% acetic 
acid), and numbers of leukocytes were determined in duplicate in a Biirker 
hemocytometer. The total numbers of granulocytes and monocytes were 
calculated from the total number of leukocytes and differential counts of 
400 leukocytes in cytocentrifuge preparations of buffy coats obtained by 
centrifugation of blood samples for 10 min at 1500 x g in hematocrit tubes. 
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Figure 2. 5 Total granulocyte ( --) and monocyte ( ___ ) counts following 
CY injections given intraperitoneally 5 days (90 mg/kg/day) and 1 day 
(60 mg/kg/day) before bacterial inoculation at day 0. 
Each value represents the mean ± SEM for five rats. 
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As shown in figure 2.5, CY-treatment resulted in a substantial reduction.in 
the number of blood granulocytes and monocytes to less than 100 and 30/mm3, 
respectively, five days after the first CY injection. At that time rats 
were inoculated with K.pneumoniae. Granulocytopenia and monocytopenia 
continued for four days, with a return of circulating granulocytes and 
monocytes after a period of 4 to 6 days. Compared to the course of 
infection in immunocompetent rats, CY-induced leukopenia resulted in a 
rapid bacterial multiplication in the lung followed by septicemia at an 
early stage of the infection (table 2.1). The increase in the numbers of 
K.pneumoniae in the left lung during the first 5 h after inoculation was 
similar in both CY-treated and untreated rats. However, from that time the 
numbers of K.pneumoniae in the left lung increased more rapidly in 
leukopenic rats than in immunocompetent rats. By 34 h an average number of 
5 x 108 was cult~red from the left lung of both leukopenic rats and animals 
with intact host defenses. At 24 h after inoculation K.pneumoniae was 
cultured from the blood of all leukopenic rats, whereas the blood of 
immunocompetent rats was sterile. At 29 h and 34 h after bacterial 
inoculation about half of the leukopenic rats had bacteria in the pleural 
fluid, whereas the pleural fluid of all normal rats was sterile. The mean 
time to death ± standard deviation (SD) recorded for CY-treated rats was 
2.3 ± 0.3 days, compared with 5.1 ± 1.3 days for untreated rats. CY in 
itself was not bactericidal as sera obtained from CY-treated rats either 
15 min or 1 day after the second CY injection did not affect the growth of 
K.pneumoniae in broth. Histological studies at 2 days after bacterial 
inoculation revealed that large numbers of gram-negative bacteria, 
polymorphonuclear leukocytes, and a few macrophages were present in the 
left lung of rats with intact host defenses. Lungs of leukopenic rats did 
not show any substantial cellular infiltrate at the site of infection, 
whereas large numbers of gram-negative bacteria were present. 
Antibiotic susceptibility test. The MICs of the antibiotics were defined 
as the lowest concentrations that suppressed visible growth after incuba-
tion of 5 x 105 CFU/ml for 18 h at 37°C in tubes containing 4 ml of Iso-
Sensitest broth (Oxoid Ltd., London, England). The MBCs were defined as 
the lowest concentrations that killed 99.9% of the original inoculum. MBC 
was determined by spreading subculture volumes of 200 ~1 onto Iso-Sensitest 
agar (Oxoid) plates. The concentrations of the serial dilutions decreased 
by steps of 0.2 ~g/ml. 
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The effect of the drugs on the short-term growth of K.pneumoniae was 
studied both in Iso-Sensi test broth and in Hanks balanced salt solution 
(HBSS) (Oxoid) with 90% normal rat serum at 37°C. A stationary phase 
culture was diluted in Iso-Sensitest broth to a concentration of 5 x 104 or 
2 x 106 CFU/ml, respectively. After reincubation for 2 h at 37°C the number 
of CFU was 106 or 4 x 107 respectively, and antibiotic was added (zero 
time). Killing experiments were started with an inoculum of 5 x 105 CFU per 
ml. During incubation, the numbers of viable organisms were then determined 
at regular intervals by plate counts on Iso-Sensitest agar. Before plating 
antibiotic concentrations were reduced to an inactive level by centrifuga-
tion of 1 ml samples for 2 min at 10,000 g followed by replacement of the 
drug containing medium by physiological saline. 
Antibiotic treatment. Antibiotics were administered in different ways. In 
experiments related to therapeutic efficacy, antibiotic was administered 
either intramuscularly into the thigh muscles of the rear legs at regular 
intervals or by way of continuous infusion. The time of start of treatment 
is indicated in the individual chapters. Antibiotics were given during four 
or eight days. Because intravenous infusion techniques did not function 
properly over a period of four days, an alternative technique developed by 
Thonus et al. [ 1 1 4] was used. In brief, six weeks prior to its use, a 
tissue cage constructed from perforated Teflon (length, 40 mm; outer 
diameter 7 mm; inner diameter, 5 mm; 30% perforation) connected to 50 mm of 
polyethylene tube was implanted subcutaneously. Rats were anesthetized 
prior to treatment with antibiotics. The distal portion of the polyethylene 
tube was recovered via an incision in the neck of the animal and connected 
to a 1 2-ml syringe. This syringe was placed on a Varifusor pump (Breda 
Scientific, Breda, The Netherlands). Drug at the required concentration 
was infused at a constant rate of 0.113 ml/h. By this technique antibiotic 
reached the serum from the subcutaneous implanted tissue cage and prolonged 
steady state levels were reached within 3 h after start of the infusion 
(figure 2.6). 
In experiments related to the kinetics of antibacterial activity anti-
biotics at various doses were administered intravenously as a single injec-
tion into the tail vein, at different times after bacterial inoculation. 
Parameters of in vivo activity of antibiotic. In experiments related to 
therapeutic efficacy response to antimicrobial treatment was evaluated in 
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Figure 2.6 Concentration of ceftazidime in serum after administration by 
way of continuous infusion (infusion rate 0.113 ml/h) at 1.08 mg/kg/day. 
Each value represents the mean ± SEM for five rats. 
different ways. In some experiments the therapeutic efficacy was evaluated 
with respect to the total daily dose that protected 50% of the animals from 
death until 16 days after termination of a four-day treatment (PD5ol- The 
50% protective dose was chosen because it is a sensitive parameter which is 
minimally influenced by incidental survivors or deaths in the individual 
treatment groups. Po50 values were calculated according to the method of 
Spearman-Karber as described by Sachs [105]. In short, groups of 10 rats 
were treated with twofold increasing doses. The lowest dose resulted in 0% 
survival, whereas the highest dose cured all rats (100% survival). PD50 
values and standard deviations were calculated by use of the following 
formulas. 
m = xk - d (S - 0.5) 
Sm= 1 :0~I)i (100-pi) ni-1 
where 
m is the estimate of the logarithm of PD50 
Sm is the standard deviation 
Xk is the logarithm of the smallest dose such that all doses greater than 
or equal produce 100% reaction 
d is the logarithm of the ratio of each consecutive pair of doses 
S is the sum of the relative portions of reacting individuals 
Pi is the frequency, in percent of reactions with the ith dose (i= 0, 1, 2, 
... k) 
ni is the number of test animals tested with the ith dose (i= 0, 1, 2, 
... k) 
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In other experiments therapeutic efficacy was evaluated with respect to the 
relative number of surviving animals. The Fisher test was then used for 
statistical analysis. 
In experiments related to the kinetics of antibacterial activity response 
to antimicrobial treatment was evaluated by calculating the number of 
bacteria in the lung, blood, and pleural fluid at various intervals after 
administration. For statistical analysis the Mann-Whitney test or two sided 
analysis of variance was used. 
Measurement of antibiotic concentrations in serum and in lungs of infected 
rats. Blood specimens, obtained by puncture of the retro-orbital plexus 
under light C02 anesthesia were collected from each rat, and serum was 
separated. For determination of antibiotic concentrations in lung tissue 
the left lung was removed, exsanguinated, and homogenized in a Potter 
Elvejhem homogenizer in saline. After centrifugation for 2 min at 10,000 g 
the supernatant was collected and used for determination of antibiotic 
concentrations. All tests were done according to a standard large-plate 
agar diffusion procedure with use of a diagnostic-sensitivity agar (Oxoid) 
and an Escherichia coli test strain susceptible to 0.025 ~g of ciprofloxa-
cin/ml and 0.2 ~g of ceftazidime/ml or a Staphylococcus epidermidis strain 
susceptible to 0.125 ~g of gentamicin/ml [5]. Standard samples for 
determination of antibiotic concentrations in serum were prepared in pooled 
normal rat serum. Standard samples for determination of drug concentrations 
in lung tissue were prepared as follows. Antibiotics in standard concen-
trations were added to homogenates of lungs of untreated rats. After 
incubation for h at 37°C and centrifugation for 2 min at 1 0, 000 g 
supernatants were collected. Samples of 100 ~1 were assayed. For determina-
tion of concentrations in serum below 0.2 ~g ceftazidime/ml some modifica-
tions were introduced in order to increase the sensitivity of the test. The 
volume of the sample was increased up to 225 ~1. This volume consisted of 
200 ~1 of testserum collected from rats to which 25 ~1 of a ceftazidime 
solution of 0.8 or 1 ~g per ml was added. Correlation coefficients of the 
calculated regression lines w.ere >0.99 in all determinations. Determination 
of samples with known concentrations of ceftazidime in serum with both the 
original and the modified method yielded similar results. The Mann-Whitney 
test was used for statistical analysis. 
21 

CHAPTER 3 
IMPACT OF THE DOSAGE SCHEDULE ON THE THERAPEUTIC EFFECT OF ANTIBIOTIC IN 
RELATION TO THE SEVERITY OF INFECTION 
efficacy of ceftazidime in immunocompetent rats with Klebsiella pneumoniae 
pneumonia and septicemia 
INTRODUCTION 
The impact of the dosage schedule of B-lactam antibiotics on the in vivo 
efficacy in immunocompetent animals has been studied by several inves-
tigators [2, 33, 34, 48, 49, 65, 106, 107, 108, 111, 112, 113, 128]. 
The experimental studies show somewhat contradictory results. This can be 
partially explained by the use of different infection models and animal 
species, and by differences in mode and duration of antibiotic administra-
tion. Another important factor may be the variation in severity of infec-
tion related to differences in virulence between the individual bacterial 
strains used and in delay periods before start of treatment. 
In clinical practice antibiotic treatment is initiated once infection is 
suspected or proven. An increase in the time period between the onset of 
infection and the initiation of treatment is expected to affect the 
effectiveness of antimicrobial treatment, especially in case of acute 
infections. In the present study the impact of the dosage schedule of 
ceftazidime on the therapeutic efficacy in relation to the severity of 
infection was investigated in an experimental Klebsiella pneumoniae 
pneumonia and septicemia in immunocompetent rats. Efficacy was evaluated in 
terms of PD50 values obtained after a four-day treatment starting at 5 h or 
34 h after bacterial inoculation. Ceftazidime was administered either 
intermittently at 8-h or 6-h intervals or by continuous infusion. 
MATERIALS AND METHODS 
The following methods are described in chapter 2: MIC/MBC determination, 
quantitation of numbers of bacteria in pleural fluid, blood and the left 
lung, histological examination of the lung, antibiotic administration, 
evaluation of therapeutic efficacy by calculating PD50 values and measure-
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ment of antibiotic concentrations in serum. 
Antimicrobial treatment with ceftazidime (Glaxo Pharmaceuticals, Ltd., 
Greenford, England) was started either 5 h or 34 h after bacterial inocula-
tion of the left lung with 8 x 104 CFU of K.pneumoniae. Antibiotic was 
administered for a period of 4 days, either intermittently at 8-h or 6-h 
intervals, or by continuous infusion. Therapeutic response was evaluated 
with respect to the calculated PD5o values. 
RESULTS 
Course of the untreated infection. The course of the untreated infection, 
as expressed by the increase in numbers of bacteria in the left lung and 
the blood is shown in figure 3.1. At 5 h after bacterial inoculation the 
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Figure 3.1 Numbers of bacteria in the left lung (A) and blood (B) of 
immunocompetent rats after inoculation of the left lung with 8 x 104 CFU of 
K.pneumoniae at 0 h. 
Values are median values of five rats. 
Within parentheses: numbers of blood cultures positive/numbers tested. 
number of K.pneumoniae organisms in the left lung had increased about 
7-fold. Blood and pleural fluid were sterile. Histological studies of the 
pulmonary lesion at that time revealed no signs of tissue necrosis. A 
moderate number of polymorphonuclear leukocytes and a few macrophages were 
observed at the site of infection. However, at 34 h after bacterial 
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inoculation the number of K.oneumoniae organisms in the lung had increased 
4,000-fold, up to 2 x 108 CFU. One out of five rats had bacteria in the 
blood. Histological studies of the lung, performed at that time revealed 
the presence of large numbers of polymorphonuclear leukocytes and gram-
negative bacilli and a few macrophages. Tissue necrosis had occurred to 
some extent. 
Therapeutic efficacy of ceftazidime. Ceftazidime was administered in 
twofold increasing doses to groups of ten rats. A dose range which resulted 
in a survival rate from 0% up to 100% was given. PD5o values were cal-
culated from the survival rates obtained for the individual doses. These 
are shown in appendix paper I, together with the mean time to death 
values. Response to the different treatment schedules of ceftazidime is 
shown in table 3.1. It is demonstrated that when treatment was started at 
Table 3.1 Efficacy of ceftazidime treatment schedulesa 
Start of 
treatment (h) 
5 
34 
Po50 (mg/kg/dayl 
intermittent 
administration 
8-h intervals 
1. 42 
13.06 
6-h intervals 
0.35 
3.50 
continuous 
administration 
0.36 
1. 08 
aceftazidime was administered over a period of 4 days either as intermit-
tent bolus injections at 8-h or 6-h intervals or by continuous infusion 
starting at different times after inoculation of the left lung with 
8 x 104 CFU of K.pneumoniae at 0 h. 
5 h after bacterial inoculation ceftazidime was equally effective when 
administered at 6-h intervals or by continuous infusion, PD5o values being 
0.35 and 0.36 mg/kg/day, respectively (P >0.05). Treatment at 8-h intervals 
was less effective resulting in a PD5o value of 1.42 mg/kg/day (P <0.001). 
Delay of start of treatment until 34 h after bacterial inoculation resulted 
in a decrease of the therapeutic activity of ceftazidime. However, this 
decrease was much greater with intermittent than with continuous administra-
tion. When ceftazidime was administered at 6-h or 8-h intervals the PD50 had 
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Figure 3.2 Serum concentration-time profiles of ceftazidime in immuno-
competent rats after administration of PDso doses obtained when antibiotic 
treatment was started at 5 h (A) or 34 h (B) after bacterial inoculation of 
the left lung with 8 x 104 CFU of K.pneumoniae. 
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to be increased about a factor 10 up to 3.5 and 13.5 mg/kg/day, respective-
ly. However, continuous infusion of ceftazidime resulted only in a 3-fold 
increase of the PD50 up to 1.08 mg/kg/day (P <0.001). 
The ceftazidime serum concentration-time profiles observed after administra-
tion of Po50 doses are shown in figure 3.2 (mean values ± SD are described 
in more detail in appendix paper I). Administration of 0.09 and 0.47 mg of 
ceftazidime/kg (doses corresponding to the PD50 values obtained for treat-
ment at 6-h or 8-h intervals, starting at 5 h), resulted in peak concentra-
tions of 0.14 and 1.3 ~g/ml of serum, respectively. Time periods of drug 
concentrations in excess of the MBC of 0. 4 ~g/ml for the K.pneumoniae 
strain used were 0 and 60 min, respectively. Injection of 0.88 and 4.35 mg 
of ceftazidime/kg (doses corresponding to the PD5o values obtained for 
treatment at 6-h or 8-h intervals, starting at 34 h) resulted in peak 
concentrations in serum of 2.6 and 14 ~g/ml, respectively. Time periods of 
drug concentrations in excess of the MBC were about 65 and 110 min, 
respectively. Continuous infusion of PDso doses of 0. 36 and 1 . 08 mg of 
ceftazidime/kg/day (obtained for start of treatment at 5 h or 34 h after 
inoculation) resulted in steady state levels in serum of 0.03 and 
0.07 ~g/ml, respectively, both levels being constantly below the MBC of the 
K.pneumoniae strain. 
DISCUSSION 
Several investigators have studied the impact of the dosage schedule of 
B-lactam antibiotics on the in vivo efficacy in immunocompetent animals [2, 
33, 34, 48, 49, 65, 106, 107, 108, 111, 112, 113, 128). However, the 
experimental studies show somewhat contradictory results. Due to the use of 
different infection models and different treatment schedules they are 
difficult to compare. Therefore in the present study several antibiotic 
dosage regimens were compared in relation to the severity of infection in 
one infectious disease model. It was demonstrated that in K.pneumoniae 
pneumonia and septicemia in immunocompetent rats the efficacy of cefta-
zidime decreased when start of treatment was delayed. However, this 
reduction in activity was much greater with intermittent than with 
continuous treatment, as was expressed by a better efficacy of continuously 
infused ceftazidime. 
An improvement in in-vivo activity obtained by more frequent administra-
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tion of B-lactam antibiotics has also been observed by other investigators 
for penicillin G in a model of intraperitoneal infection in rats caused by 
Streptococcus pneumoniae [ 1 08] and a Streptococcus pyogenes thigh muscle 
infection in mice [33], for ampicillin in a Streptococcus faecalis endo-
carditis in rats [113] as well as for various B-lactams in a thigh muscle 
infection in mice caused by Pseudomonas aeruginosa [49]. Our experimental 
data can not directly be related to those of Jawetz [65], Zubrod [128], and 
Eagle et al. [34], because in their studies in addition to the variation in 
dosage frequency also the duration of treatment was varied. In a way our 
findings correspond to the observations of Eagle et al. in that the in-vivo 
efficacy of penicillin G in their experiments appeared to be mainly 
determined by the time period that active drug levels in serum were present 
during the treatment. Schmidt et al. [ 1 07] using penicillin G in a rat 
model of pneumococcal pneumonia and Genge et al. [48] using methicillin in 
a Staphylococcus ~ endocarditis in rats found, applying different 
treatment schedules, that there was an optimal dosing interval. However, in 
the study of Schmidt the difference in efficacy between the dosage schedules 
was small, whereas in the study of Genge treatment schedules were compared 
at only one total dose. In contrast to the experimental data discussed, 
Sande et al. [106] and TaUber et al. [112] treating a meningitis in rabbits 
caused by S.pneumoniae with penicillin G or ampicillin, respectively, 
demonstrated that the efficacy of these drugs in sterilizing the CSF did 
not depend on the frequency of drug administration. However these studies 
have to be considered with caution as Sande et al. compared different 
treatment schedules at only one total dose of penicillin G. In addition, 
experimental data derived from an experimental meningitis in rabbits may be 
exclusive for this particular model as suggested by Tai.iber et al. and 
supported by investigations of this author and others [111]. Finally 
Bakker-Woudenberg et al. found no improved efficacy of penicillin G when 
administered by continuous infusion as compared to dosing at 12-h intervals 
in a pneumococcal pneumonia in immunocompetent rats [2]. The discrepancy 
between the results obtained by the investigators mentioned are probably 
due to variations in infection models which differed in respect of 
bacterial species, experimental animals, route of inoculation, or treatment 
schedules, in which different antibiotics were given by different schedules 
and for different periods of time. 
From the present study it can also be concluded that ceftazidime cured 
animals when administered continuously at doses that resulted in steady 
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state serum levels staying continuously below the MIC of the infecting 
strain. Even the 100% protective dose obtained for ceftazidime when started 
at 5 h after inoculation resulted in sub-MIC steady state serum levels 
(appendix paper II). Several other investigators have also found in 
experimental infections that substantial survival rates were obtained 
despite antibiotic concentrations in serum did not reach the MIC [22, 85, 
126]. In-vivo efficacy of low concentrations of B-lactam antibiotics may be 
explained by effects of antibiotic on the bacterial growth rate or 
sensitization of bacteria to the phagocytic process as described by several 
investigators [16, 70, 84, 92] and reviewed by Milatovic [86], Lorian [81], 
and Atkinson et al. [1]. 
In conclusion it is demonstrated in an experimental K.pneumoniae pneumonia 
and septicemia in immunocompetent rats that continuous administration of 
ceftazidime was more effective than intermittent administration at 
relatively long intervals, a difference that increased when the start of 
treatment was delayed. The therapeutic efficacy of ceftazidime decreased 
with increasing severity of the infection. This decrease was moderate when 
ceftazidime was administered by continuous infusion but substantial when 
the drug was given intermittently. It appeared that the activity of cefta-
zidime was mainly dependent on the maintenance of appropriate antibiotic 
concentrations during the entire treatment interval. 
In order to obtain substantial survival rates antibiotic concentrations in 
serum needed not to be continuously above the MIC of the infecting strain. 
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CHAPTER 4 
IMPACT OF THE DOSAGE SCHEDULE ON THE THERAPEUTIC EFFECT OF ANTIBIOTIC IN 
RELATION TO HOST DEFENSE MECHANISMS 
efficacy of ceftazidime in immunocompetent versus leukopenic rats with 
Klebsiella pneumoniae pneumonia and septicemia 
INTRODUCTION 
It is shown in chapter 3 for immunocompetent rats, that the therapeutic 
effect of ceftazidime depends mainly on the time an appropriate drug level 
is maintained. The superiority of continuous administration over intermit-
tent administration at relatively long intervals was more pronounced when 
start of treatment was delayed. It may be expected that in immunocompro-
mised patients the schedule of antibiotic administration may also be an 
important determinant for therapeutic efficacy in serious infection. With 
current antibiotic treatments therapeutic failure still occurs in these 
patients probably due to the failure of the host defense system to provide 
adequate support to antibiotic therapy. The question is whether the results 
of antimicrobial treatment can be improved by intensification of antibiotic 
treatment as a result of modification of the dosage schedule. It is not 
clearly established whether or not repeated high antibiotic serum concen-
trations of short duration are superior to continuously maintained anti-
biotic serum concentrations at a lower level. Experimental studies in 
infection models on the impact of the antibiotic dosage schedule on the 
therapeutic activity of antibiotics in relation to host defense mechanisms 
are limited [2, 49]. The present study was undertaken first to investigate 
the impact of the dosage schedule of ceftazidime on its therapeutic 
efficacy in relation to host defense factors by comparing the activity of 
different treatment schedules in immunocompetent versus leukopenic rats 
with Klebsiella pneumoniae pneumonia and septicemia. Efficacy was evaluated 
in terms of Po50 values obtained after a four-day treatment starting at 5 h 
after bacterial inoculation. Ceftazidime was administered either intermit-
tently at 6-h intervals or by continuous infusion. In addition, the 
efficacy of treatment with ceftazidime was studied in relation to the dura-
tion of leukopenia, as it is not clearly established whether antimicrobial 
treatment should be continued when leukopenia persists [31, 47, 100, 121]. 
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MATERIALS AND METHODS 
The following methods are described in chapter 2: MBC determination, 
quanti tation of numbers of bacteria in the pleural fluid, blood and the 
left lung, histological examination of the lung, antibiotic administration 
and evaluation of therapeutic efficacy by calculating PD50 values and 
measurement of ceftazidime concentrations in serum. 
Immunocompetent and leukopenic rats were treated with antibiotic as 
follows. Administration of ceftazidime was started at 5 h after inoculation 
of the left lung with 8 x 104 CFU of K.pneumoniae. Antibiotic was 
administered for a period of 4 days, either intermittently at 6-h intervals 
or by continuous infusion. Therapeutic activity was evaluated with respect 
to the calculated PD50 values. 
Experiments on the efficacy of ceftazidime treatments of various duration 
in relation to the persistence of leukopenia were performed as follows. 
Leukopenia was induced by intraperitoneal injections of CY in two doses of 
90 or 60 mg/kg at five days and one day before bacterial inoculation, 
respectively. From that time leukopenia persisted for 4 days. Prolonged 
leukopenia for an addi tiona! period of 4 days was obtained by a third 
intraperitoneal injection of 60 mg CY/kg at 4 days after the second CY 
injection (figure 4.1; see also figure 2.4). Ceftazidime was administered 
by continuous infusion for a period of 4 or 8 days, starting 5 h after 
inoculation of the left lung with 8 x 104 CFU of K.pneumoniae. Therapeutic 
activity was evaluated with respect to the relative number of surviving 
animals. 
RESULTS 
Course of the untreated infection. The course of the untreated infection 
in immunocompetent and in leukopenic rats is shown in figure 4. 2. The 
number of bacteria in the left lung increased 7-fold within 5 h after 
inoculation' in both leukopenic and immunocompetent rats. However, after 
that time, due to leukopenia, bacterial numbers in the lung increased more 
rapidly in CY-treated rats. In addition, in leukopenic rats septicemia 
occurred at an early stage and was more severe compared to rats with intact 
host defense. Leukopenic rats died soon as expressed by a mean time to 
death± standard deviation of 2.3 ± 0.3 days, compared to 5.1 ± 1.3 days 
32 
2000 
"'0 1500 0 
0 
..0 
-0 
"' E 
E 
........ (/) 
Q) 
>. () 
0 
~ 
:::l 
Q) 
....J 
-5 -1 0 4 8 
Time (days) 
Figure 4.1 . Total granulocyte (-.-.-. ) and monocyte ( ---) .counts following 
CY injections given intraperitoneally 5 days before (90 mg/kg), 1 day before 
( 60 mg/kg), and 4 days·· after ( G·o mg/kg) bacteriar ·inoculation on day 0. 
Each value represents the mean ± SEM for five rats. 
for immunocompetent rats. Histological studies at 2 days after bacterial 
inoculation revealed that large numbers of gram-negative bacteria, poly-
morphonuclear leukocytes, and a few macrophages were .present in the left 
lung of rats with intact host defenses. In contrast' large numbers of gram-
negative bacteria but no ·substantial cellular infiltrate was present in 
lungs of leukopenic rats. 
Therapeutic efficacy. Ceftazidime was administered in twofold increasing 
doses to groups of ten rats: A dose range which resulted in a· survival rate 
from 0% up to 100% was given. PDSO values were calculated from the survival 
rates obtained for the individual doses. These are shown in appendix paper 
II . together with the mean time to death values. The ·efficacy of the dif-
ferent ceftazidime treatment· schedules is shown in table 4.1. In immune-
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Figure 4.2 Numbers of bacteria in the left lung (A) and blood (B) of 
immunocompetent ( --) or leukopenic ( ___ ) rats after inoculation of the 
left lung with 8 x 104 CFU of K.pneumoniae at 0 h. 
Values are median values of five rats. 
Within parentheses; numbers of blood cultures positive/numbers tested. 
Table 4.1 Efficacy of ceftazidime treatment schedulesa in immunocompetent 
and leukopenic rats 
Rats 
immunocompetent 
leukopenic 
intermittent 
administration 
0.35 
24.37 
Po50 (mg/kg/day) 
continuous 
administration 
0.36 
1. 52 
aceftazidime was administered over a period of 4 days, either as inter-
mittent bolus injections at 6-h intervals or by continuous infusion. 
Treatment was started at 5 h after inoculation of the left lung with 
8 x 104 CFU of K.pneumoniae. 
competent rats intermittent and continuous administration of ceftazidime 
were equally effective. PDso values were 0.35 and 0.36 mg/kg per day, 
respectively (P >0.05). Due to leukopenia the therapeutic efficacy of both 
treatment schedules decreased. Compared to the Po50 values inimmunocompetent 
rats the PDso in leukopenic rats had to be increased 70-fold when ceftazi-
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dime was given intermittently and only 4-fold when administered continuous-
ly. In leukopenic rats continuous infusion of ceftazidime appeared to be 
highly superior to administration at 6-h intervals, PD5o values being 
1 .52 and 24.37 mg/kg per day for the respective treatment schedules 
(P <0.001). 
The ceftazidime serum concentration-time profiles observed after administra-
tion of Po50 doses are shown in figure 4.3 (mean values ± SD are described 
in more detail in appendix paper II). Administration of 0.9 and 6.1 mg of 
ceftazidime/kg (doses corresponding to the PD50 values obtained for immuno-
competent and leukopenic rats after intermittent dosage) resulted in serum 
peak levels of 0. 14 and 14 )lg/ml, respectively. After injection of the 
respective doses drug concentrations in serum did not reach the MBC of 
0.4 )lg/ml for the infecting strain or were above the MBC for about 170 min 
during the treatment interval, respectively. Continuous infusion of PD50 
doses of 0. 36 and 1 . 52 mg/kg per day (obtained for immunocompetent and 
leukopenic rats) resulted in steady state levels in serum of 0. 03 and 
0.19 )lg/ml, respectively. 
The results of ceftazidime treatments of various duration in relation to 
the persistence of neutropenia are shown in table 4.2. A total daily dose 
Table 4.2 Efficacy of ceftazidime treatmentsa of various duration in 
relation to the persistence of leukopenia 
Persistence of Duration of 
leukopenia treatment 
(days) (days) 
4 4 
8 4 
8 8 
No. of 
survivors 
20 
3 
15 
Time to 
death 
(days)b 
7.3 ± 1.0 
8.0 ± 1. 0 
aTo groups of 20 rats each 3. 75 mg of ceftazidime per kg per day was 
administered by continuous infusion. Treatment was started 5 h after 
inoculation of the left lung with 8 x 104 CFU of K.pneumoniae. 
bMean ± SD; based on the time of bacterial inoculation (day 0). 
of 3.75 mg of ceftazidime per kg administered by continuous infusion over a 
period of 4 days cured all rats that were leukopenic for only 4 days. This 
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Figure 4. 3 Serum concentration-time profiles of ceftazidime after 
administrati.on of Po50 doses to infected immunocompetent. (A) or, leukopenic 
(B) rats. 
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ceftazidime treatment schedule was not successful in rats with leukopenia 
persisting for 8 days,· resulting in significant increase. in mortality of 
rats (P <().05) .. On the other hand. mortality decreased significantly, when 
ceftazidime treatment . was- _continued until the return -of circulating leuko-
cytes at day 8 (P <0.05). Thf: survj.val rates -of rats treated during the 
entire leukopenic period of either. 4 or 8 days.· were not significantly 
different (P >0.05). 
DISCUSSION 
Studies on the impact of.th~:dosage schedule of f!-lactam antibiotics on the 
therapeutic activity in relation to the host .. defense factors ar~: limited 
[2, 49]. The present study demonstrates. that ceftazidime. was equally 
effective in treating, a K.pneumoniae pneumonia and septicemia in immuno-
competent rats when administered .e:i,ther at 6,.-h intervals cOr by continuous 
infusion. _However,_ wh~n host defenses were,impaired by means of CY-induced 
leukopenia treatment by continuousinfusion_was highly superior_ as compared 
to intermittent. treatment. As compar~:d to immunocompetent rats the Po50 
dose in leukopenic rats had to be. increased only_a factor 4 in casecefta-
zidime was administered continuously, whereas the Po50 had to be increaE;ed 
70-fold after administration. of this drug at 6-h int~rvals. These results 
are in agreement with those -of Bakker-Woucjenberg et al, [ 2.] and Gerber et 
al. [49]. In immunocompetent rats with pneumococcal .pneumonia lungs were 
sterilized by equal total daily doses_ of penicillin G administered._ either 
at 12-h intervals or by continuous i:n,fusic;m [ 2], Rats with impaired phago-
cytosis were also cured by about the same -total daily dose. of penicillin 
provided this drug was .-administered continuously. On the con:trary - with 
intermittent administration the efficacy of penicillin w,as highly reduc::ed 
as compared to its activity in rats with intact host defenses. Gerber et 
al. came to similar conclusions with respect to the treatment of a thigh 
infection caused by P.aeruginosa in mice with intact host defenses [49]. A 
regimen in which ticarcillin was injected in small doses at very short 
intervals was only slightly more effective than the same amount of drug 
injected as a single bolus injection. On the contrary, in leukopenic mice 
the fractionated dosage regimen was far more effective in reducing the 
number of bacteria at the site of infection. 
It is not clearly established whether antimicrobial treatment of neutro-
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penic patients from whom no pathogen is isolated and who become afebrile 
after initial therapy, should be continued in case neutropenia persists 
[31, 47, 100, 121]. Pizzo et al. continued or discontinued antibiotic 
therapy in cancer patients with prolonged granulocytopenia, who became 
afebrile during initial antimicrobial treatment [100]. Only in the group in 
which antimicrobial treatment was discontinued did infectious sequelae 
develop. They suggested that granulocytopenic cancer patients may profit 
from the prolongation of antimicrobial treatment when granulocytopenia 
persists. The data of the present study on the efficacy of ceftazidime 
treatments of various duration in relation to the persistence of leukopenia 
in rats also suggest that treatment should be continued until the return of 
circulating leukocytes. However, prolonged antibiotic treatment may cause 
an increase in adverse side-effects. This must be outweighed against the 
risk on development of infections. In addition, the main factor determining 
the risk on development of serious infection in persistent granulocytopenic 
patients after stopping antibiotic treatment may be the number of days they 
are afebrile after initial therapy as recently suggested by DiNubile [31]. 
In conclusion, it is demonstrated in rats with K.pneumoniae pneumonia and 
septicemia that the therapeutic efficacy of ceftazidime decreased when host 
defenses were impaired. This decrease was only moderate when ceftazidime 
was administered by continuous infusion, but much more pronounced when 
treatment was intermittent. In other words, in animals with impaired host 
defenses continuous administration of ceftazidime was far more effective 
than intermittent administration .at relatively long intervals. So it 
appeared that the activity of ceftazidime was mainly dependent on the 
maintenance of appropriate antibiotic concentrations during the entire 
treatment interval. It was also observed that continuation of treatment in 
granulocytopenic rats with ceftazidime by continuous infusion until the 
return of circulating leukocytes gave rise to a significant reduction in 
mortality. 
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CHAPTER 5 
IMPACT OF THE DOSAGE SCHEDULE ON THE THERAPEUTIC EFFECT IN RELATION TO THE 
KINETICS OF ANTIBACTERIAL ACTIVITY IN VITRO AND IN VIVO FOR DIFFERENT 
CLASSES OF ANTIBIOTICS 
efficacy of ceftazidime, gentamicin, and ciprofloxacin in leukopenic rats 
with Klebsiella pneumoniae pneumonia and septicemia 
INTRODUCTION 
From the experimental studies described in chapters 3 and 4 it can be 
concluded that the antibiotic dosage schedule is an important determinant 
for the therapeutic activity of the B-lactam ceftazidime. It appeared that 
the therapeutic effect of ceftazidime is dependent on the maintenance of 
antibiotic concentrations in plasma during the entire treatment interval. 
Data derived from various experimental studies suggest that the role of the 
dosage schedule in relation to the therapeutic efficacy is dependent on the 
class of antibiotic [ 49, 52, 120]. However, these data have been mainly 
derived from studies performed in infection models with limited clinical 
relevance or from studies in which only one class of antibiotic was 
investigated. In the present study the impact of the dosage schedule ori the 
therapeutic efficacy of antibiotics of three different classes was 
investigated in a Klebsiella pneumoniae pneumonia and septicemia in leuko-
penic rats. The in vitro susceptibility in terms of MBC values of the 
K.pneumoniae strain used for the selected drugs ceftazidime, gentamicin and 
ciprofloxacin was similar. The efficacy of the drugs was evaluated in terms 
of PDSO doses obtained after a four day treatment, starting 5 h after 
bacterial inoculation of the lung. Drugs were administered either intermit-
tently at 6-h intervals or by way of continuous infusion. The therapeutic 
activity observed for the different treatment schedules after a four-day 
treatment was compared with the kinetics of antibacterial activity of the 
antibiotics against the K.pneumoniae strain in vitro as well as in lungs of 
leukopenic rats. 
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MATERIALS AND METHODS 
The following methods ·are described in chapter 2: MIC/MBC determination, 
measurement. of the effect of antibiotics on. short .term~ growth of bacteria, 
quantitation of numbers of bacteria in the left lung, antibiotic administra-
tion, ·ev'aluationof in vivo bactericidal activity and therapeutic efficacy 
by calculating PD50 values and' measurement of antibiotic concentrations in 
serum. 
The antibiotics used were ceftazidime, gentamicin (Schering Corporation, 
Kenilsworth N.Y., United States) and ciprofloxacin (Bayer AG, Leverkusen, 
Federal Republic of Germany). 
The postantibiotic effect (PAE) was determined as follows. A stationary 
phase culture of K.pneumoniae was. diluted in Iso-Sensitest broth to a 
concentration of 5 x 106 CFU/ml. After reincubation for 2 h at 37°C the 
number-of CFU was 108 per ml and antibiotic was added .. PAE experiments were 
started·at an inoculum of 5 x 107 CFU/ml. After 1 h the cultures containing 
ceftazidime and gentamicin. were diluted l.OO~fold in fresh prewarmed medium, 
and the cultures· containing ~ciproflo"xacin 250-fold. Bacterial cultures 
without antibiotic were treated similarly. Control experiments revealed 
that at the dilutions used. the. highest residual antibiotic concentrations 
obtained for all experiments ·did not affect the growth of logarithmically 
growing K~pneumoniae. PAE was quant"itated as , described by Craig and 
Gudmundsson for PAE measurement by viable· counts [25]. They used the 
following equation to quantify the :E>AE:_PAE. = T-C, where T and C represent 
the times required for the CFU count to increase 1 log1 o above the count 
observed immediately· after · dilution for the test culture and control 
culture, respectively. 
The ·antibacterial activity in vivo of the selected drugs ceftazidime, 
gentamicin, and·ciprofloxacin was examined in leukopenic rats in different 
ways. The kinetics .of antibacterial activity was investigated by administra-
tion of antibiotic at·various doses intravenously at 1'h after inoculation 
of the left lung with 8 x 104 CFU of logarithmically growing K.pneumoniae. 
Antibiotic-activity was measured with respect to the numbers of CFU in the 
left lung at various intervals after administration. Statistical-analysis 
was performed by use of two-sided analysis of variance and the Mann-Whitney 
test. The therapeutic efficacy of the antibiotics was studied by administra-
tion of antibiotic for a period of 4 days, starting at 5 h after bacterial 
inoculation of the left lung with 8 x 104 CFU of K.pneumoniae. Antibiotic 
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was administered either intermittently at 6-h intervals or by continuous 
infusion. Therapeutic efficacy was evaluated with respect to the calculated 
Po50 values. 
RESULTS 
Effect of ceftazidime, gentamicin, and ciprofloxacin against K.pneumoniae 
in vit:i:o. The MICs as well as the MBCs of ceftazidime and gentamicin for 
the K.pneumoniae strain were both 0. 4 ]lg/ml. The MIC and MBC of cipro-
floxacin were both 0. 2 ]lg/ml. Kinetics of bactericidal activity of the 
three drugs at concentrations of !, 1, 'and 2 times the MBC against 
K.pneumoniae in broth is shown in figure 5.<1. Bacterial killing by cefta-
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Figure 5.1 Effect ·of ceftazidirne (A), gentamicin (B), or ciprofloxacin (C) 
at concentrations indicated against K.pneumoniae in broth. Bacterial growth 
without antibiotic <----l. 
zidime was slow but continued during· the 4 h in-cubation period, and was 
relatively· independent on the concentration, On the contrary both genta-
micin and ciprofloxacin demonstrated a rapid bacterial killing that wa:s 
related to the concentration of antibiotic, The killing rate by cipro-
floxacin was extremely high. Although the bactericidal activities of cefta-
zidirne, gentamicin and ciprofloxacin in HBSS with 90% serum (figure 5.2) 
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Figure 5.2 Effect of ceftazidime (A), gentamicin (B), or ciprofloxacin 
(C) at concentrations indicated against K.pneumoniae in HBSS with 90% rat 
serum. Bacterial growth without antibiotic<---->. 
were not identical as compared to those in broth, no major differences were 
observed between the killing patterns in both media. As shown in figure 5.3 
0 2 3 4 5 6 0 2 4 5 6 
Time(h) Time (h) 
Figure 5. 3 PAE determinations of ceftazidime ( -- _) , gentamicin ( -·-) , 
or ciprofloxacin ( _, __ ) after h exposure of K.pneumoniae to drug 
concentrations of 2 times the MBC (A) or 5 times the MBC (B). Cultures were 
diluted at 1 h 1 00-fold for ceftazidime and gentamicin, and 250-fold for 
ciprofloxacin. 
Controls without antibiotic(----). 
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a PAE was not observed for the three antibiotics. Exposure of the bacteria 
during 1 h to 2 times the MBC for ceftazidirne, gentamicin and ciprofloxacin 
or 5 times the MBC for ceftazidime and gentamicin did not result in a sub-
stantial delay of regrowth as compared to bacteria not exposed to anti-
biotic. 
Effect of ceftazidime, gentamicin, and ciprofloxacin against K.pneumoniae 
in lungs of leukopenic rats. The antibacterial activity of ceftazidime, 
gentamicin and ciprofloxacin against K.pneumoniae in lungs of leukopenic 
rats after intravenous administration of different doses at h after 
bacterial inoculation is shown in figure 5.4. Bacterial killing by cefta-
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Figure 5.4 Numbers of K.pneumoniae in the lungs of untreated leukopenic 
rats (--), and after intravenous administration of ceftazidime (A), 
gentamicin (B), or ciprofloxacin (C), i~ -~6ses of 0.3 mg/kg (---), 
1.0 mg/kg (-·-), 3.0 mg/kg (-··-), or 9.0 ltig/kg (------) at 1 h after 
inoculation of lungs with K.pneutnoniae in the ldgll.rithmic phase of growth. 
Each point represents the geometric mean t S!M for five rats. 
zidime was not strongly related to the d~~e -'ad~inistered although at the 
different doses used ceftazidime peak concentrati~ns in serum ranged from 1 
to 48 J..L9"/ml (figure 5.5) (the numerical daf.a·az.~;described in more detail 
.~ ,: 
in appendix paper IV). A si.;Jnificant increa$E! ~n tiacterial killing rate was 
only observed during the- first 
3.0 mg/kg compared to 1.0 mg/kg 
hour after: adrltiriistration of the dosage l . 
(P <0.65 by' ~~~Whitney) (figure 5.4A). A 
~~ 
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Figure 5.5 Concentrations of ceftazidime in serum of leukopenic rats after 
intravenous administration in doses of 0. 3 mg/kg ( -·· -), 1. 0 mg/kg 
(---), 3.0 mg/kg (---),or 9.0 mg/kg (--). 
Each point represents the mean ±-SEM for five rats. 
further increase of the dose up to 9.0 mg/kg did not result in a greater 
decrease in the numbers of bacteria in the lung ( P > 0. 05) . In contrast to 
ceftazidime killing rates by gentamicin and ciprofloxacin increased with 
each dose increment from 0.3 up to 9.0 mg/kg (P <0.05) (figures 5.4 B and 
C). At similar doses bacterial killing by ciprofloxacin was more rapid 
than that by gentamicin, whereas gentamicin exerted a higher bacterial 
killing rate compared to ceftazidime from the 3.0 mg/kg dose (P <0.05). 
Bacterial killing by ceftazidime continued untn·· 2 h ·after injection 
(P <0.05 by two-sided ana.lysis of variance)., the killing rate between .the 
first- and second hour after. administration being independent on the dose 
administered (P >0. 05). In contrast, the -bacterial killing by gentamicin 
and ciprofloxacin was completed within 1 h after administration, thereafter 
no further decrease in· bacterial numbers· occurred,. irrespective· the dose 
administered (P >0.05). 
Figure 5.6 shows the numbers of bacteria in the.left lung at various inter:-
vals until 9 h after intravenous administration· of 3·. 0 mg/kg of cefta-
zidime, gentamicin,. or ciprofloxacin at .. 1 h after bacterial inoculation. 
Substantial regrowth of bacteria in the left lung did not occur ,• although 
antibiotic concentrations .±ri the lung were below .the MBC from 2. 5 h. after 
antibiotic .administration ·(data not shown). Bacterial counts started to 
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Figure 5.6 Numbers of K.pneumoniae in :the lungs of untreated leukopenic 
rats ( --.), and after intravenous administration of ceftazidime (---), 
gentamicin (-·-), or ciprofloxacin (.:'....;.'·-) in doses of 3 mg/kg at 1 h 
after inoculation of the lungs with K: pneumoniae in the logari tiimic phase 
of growth. 
Each point' represents the geometric mean± SEMfor five rats: 
increase from the third hour after injection of ciprofloxacin. This 
increase was significant, although sma·ll (P'(0;05 by Mann-:...whitney). 
The concentrations of cefta.zidime, gentamicin andciprofloxacin in serum of 
rats at various intervals. after intravenous administration· of 3 mg/kg are 
shown in figure 5. 7 (the numerical ·data are described iii more detail in 
appendix paper IV). serum concentrations at5 min after administration were 
13. 1, . 14 .1, and 0. 94 ].lg/ml, respectively .. Kinetics of ceftazid'ime and 
gentamicin in serum were comparable, with estimated elimination half-lifes 
(.ttBl (measured from 15 min after administration) of -30 min. Ciprofloxadn 
serum ·concentrations were about 14-fold lower as compared to those of 
ceftazidime and gentamicin, within 5 mih after administration of a similar 
dose of · 3. 0 mg/kg. The estima·ted ttB o'f ciprofloxacin was~ approximately 
100 min. 
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Figure 5.7 Concentrations of ceftazidime (---), gentamicin (---), or 
ciprofloxacin ( -·-) in serum of leukopenic rats after intravenous 
administration of 3 mg/kg at 0 h. 
Each point represents the mean ± SEM for five rats. 
Therapeutic efficacy of ceftazidime, gentamicin, and ciprofloxacin in 
K.pneumoniae pneumonia and septicemia in leukopenic rats. Antibiotics were 
administered in twofold increasing doses to groups of ten rats. A dose 
range which resulted in survival rates from 0% up to 100% was applied. PD50 
values were calculated from the survival rates obtained for the individual 
doses. These are shown in appendix paper IV together with the mean time to 
death values. The therapeutic efficacy of ceftazidime, gentamicin, and 
ciprofloxacin determined in terms of Po50 values is shown in table 5.1. The 
therapeutic effect of ceftazidime was dependent on the dosage regimen, 
being far more effective when administered by continuous infusion as 
compared to intermittent treatment at 6-h intervals, resulting in PD50 
values of 1.52 and 24.37 mg/kg/day, respectively (P <0.001). For gentamicin 
no significant difference in efficacy could be observed between both modes 
of administration, PD5o val~es being 3.8 and 2.8 mg/kg/day for continuous 
and intermittent administration, respectively (P >0. 05). The therapeutic 
efficacy of ciprofloxacin decreased slightly when administered by continuous 
infusion compared to intermittent administration, as demonstrated by PD50 
values of 6.5 and 3.3 mg/kg/day, respectively (P <0.05). 
The serum concentration-time profiles of ceftazidime, gentamicin and cipro-
floxacin observed after administration of Po50 doses, either intermittently 
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Table 5.1 Efficacy of ceftazidime, gentamicin, and ciprofloxacin treatment 
schedulesa in leukopenic rats 
Antibiotic 
ceftazidime 
gentamicin 
ciprofloxacin 
PD50 (mg/kg/day) 
intermittent 
administration 
24.37 
2.84 
3.27 
continuous 
administration 
1. 52 
3.80 
6.53 
aAntibiotics were administered over a period of 4 days, either as inter-
mittent bolus injections at 6-h intervals or by continuous infusion. 
Treatment was started at 5 h after inoculation of the left lung with 
8 x 104 CFU of K.pneumoniae 
or by continuous infusion, are shown in figure 5.8 (mean values ± SD are 
described in more detail in appendix paper IV). When administered intermit-
tently, the time periods that serum concentrations were above the MBC for 
the K.pneumoniae strain were about 170 and 75 min for ceftazidime and 
gentamicin, respectively. For ciprofloxacin serum concentrations were above 
the MBC for only about 40 min during the 6-h dosing interval. Steady state 
serum concentrations after administration of PD50 doses by continuous 
infusion were 0.19, 0.29, and 0.14 ~g/ml for ceftazidime, gentamicin, and 
ciprofloxacin, respectively. 
DISCUSSION 
The impact of the antibiotic dosage schedule on the treatment of serious 
infections is not clearly established. Particularly in the immune-
compromised host, the schedule of drug administration may play an important 
role in the outcome of antibiotic treatment of infections, as in these 
patients recovery from infection depends to a high degree on antibiotics, 
and therapeutic failure still occurs. 
During the past few years several investigators have studied the efficacy of 
different antibiotic dosage schedules in experimental gram-negative infec-
tions [18, 49, 52, 57, 64, 67, 79, 96, 101, 120]. In the present study the 
impact of the antibiotic treatment schedule of ceftazidime, gentamicin, and 
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Figure 5.8 Serum concentration-time profiles of ceftazidime (A), gentamicin 
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(B), or ciprofloxacin (C) after administration of PD50 doses. to infected 
leukopenic rats. 
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ciprofloxacin on the therapeutic efficacy was investigated in a model of 
K.pneumoniae pneumonia and septicemia in leukopenic rats. The in-vitro 
susceptibility in terms of MBC values for the K.pneumoniae strain used was 
similar for the three drugs. We observed that ceftazidime was far more 
effective when administered by continuous infusion compared to treatment at 
6-h intervals (see also chapter 4). It appeared that the therapeutic effect 
of ceftazidime is dependent on the maintenance of antibiotic concentrations 
in plasma during the entire treatment interval. This observation may be 
explained by the gradual and relatively dose-independent bactericidal 
effect of ceftazidime seen in the lungs of leukopenic rats after administra-
tion of a single dose. Despite a variation in serum peak concentrations 
from 1 to 48 ~g/ml at the ceftazidime doses used no major differences in 
bacterial killing rate were observed. This relatively dose-independent 
antibacterial effect in vivo corresponds to the concentration-independent 
bacterial killing pattern of ceftazidime in vitro at concentrations around 
the MBC. In contrast to ceftazidime the therapeutic efficacy of gentamicin 
was not related to the mode of administration. With gentamicin intermittent 
treatment resulting in relatively high peak concentrations at relatively 
long intervals seems to be permitted without loss of efficacy. This was 
confirmed by the high and dose-dependent bacterial killing rate of genta-
micin in lungs of leukopenic rats after intravenous administration of a 
single dose. Also in vitro, the bacterial killing rate of gentamicin was 
strongly related to the concentration used. These results show that the 
activity of gentamicin is strongly dependent on the peak concentration. The 
therapeutic efficacy of ciprofloxacin, when administered at 6-h intervals, 
was slightly increased compared to continuous treatment. This confirms the 
dose-dependent and very rapid killing of K.pneumoniae in lungs of leukopenic 
rats after a single intravenous injection of ciprofloxacin. At all doses 
tested ciprofloxacin exerted a high bacterial killing rate which increased 
with increasing doses. A similar pattern of bactericidal effect was found 
in vitro. 
Besides the bacterial killing rate and the dose-response effect, the rate 
of bacterial regrowth after exposure to antibiotic may also be an important 
determinant for the dosage-regimen-dependent therapeutic effect of anti-
biotic [ 26, 119] . In this respect we found no major differences between 
the three antibiotics used. In vitro, a PAE of the K.pneumoniae strain for 
the antibiotics was not observed. In addition, in vivo patterns of bacterial 
regrowth in the lung after administration of antibiotic were not substan-
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tially different. 
Our experimental data with regard to the impact of the antibiotic dosage 
schedule of ceftazidime and gentamicin on the therapeutic efficacy are in 
accordance with those of other investigations with respect to treatment of 
gram-negative infections with B-lactams or aminoglycosides [18, 49, 52, 
57, 79, 101, 120 ]. Gerber et al. demonstrated that ticarcillin was more 
effective in reducing the number of Pseudomonas aeruginosa organisms in 
thighs of leukopenic mice when the interval of administration was .reduced 
from 3 h to 1 h [52]. In contrast the activity of gentamicin was not 
dependent on the frequency of injection. Using the same infection model, 
they also demonstrated that the in vivo efficacy of gentamicin and also of 
netilmicin was mainly dependent on the total dose administered and not on 
the mode of administration either as a single bolus injection or at very 
short intervals to mimic human serum kinetics [49]. On the other hand the 
B-lactams ticarcillin and ceftazidime were more effective when administered 
in fractional doses which resulted in longer periods of active drug levels 
in serum as compared to administration as a single dose. Other investiga-
tors using models of thigh muscle infection and pneumonia in mice both 
caused by K.pneumoniae showed that the efficacy of the B-lactam cefazolin 
was related to the time period serum drug levels remained above the MIC of 
the infecting strain [79, 120]. On the other hand, the efficacy of genta-
micin was correlated with the total dose administered irrespective the 
frequency of administration. The conclusion derived from these experiments 
that the efficacy of B-lactam antibiotics increased with increasing dosing 
frequency, whereas the in-vivo efficacy of aminoglycosides was independent 
on the dosage interval, was also confirmed in an experimental thigh muscle 
infection in mice due to K.pneumonia [57] and pneumonia or endocarditis 
due to P.aeruginosa in rats or rabbits, respectively [101]. In contrast to 
these findings there are some experimental studies suggesting that the in 
vivo activity of the aminoglycoside tobramycin is dependent on the anti-
biotic dosage schedule used [67, 96]. In these experiments, however, long 
intervals of treatment were used when the short elimination half life of 
tobramycin in small experimental animals is taken into account. With 
respect to the quinolones we are not aware of studies concerning the impact 
of the dosage schedule of quinolones on the therapeutic efficacy in 
experimental infections. However, one study comparing the efficacy of the 
B-lactam BMY-28142 and the quinolone ciprofloxacin in a model of pseudomonas 
endocarditis, shows that although after administration of single doses the 
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ratio of concentrations of both antibiotics to the MBC at the site of 
infection were similar, ciprofloxacin was superior to BMY after a 5 day 
treatment at 8-h intervals [ 64] . In order to obtain the same effect as 
compared with ciprofloxacin BMY had to be administered for a longer period 
at shorter intervals. This finding is in accordance with our observation 
that ci,profloxacin was very effective in contrast to ceftazidime when rats 
were treated at 6-h intervals. 
Our results with respect to the kinetics of bactericidal activity of cefta-
zidime are in accordance with the slow and relatively dose-independent 
bacterial killing rate as observed generally for B-lactams in vivo [ 49, 
52, 64, 118] and in vitro [3, 55, 93, 125]. Our observations with respect 
to gentamicin are also in agreement with the findings of several 
investigators demonstrating a fast and dose-dependent bactericidal activity 
of aminoglycosides in vivo [49, 52] as well as a concentration-dependent 
bacterial killing rate in vitro [3, 10, 125]. Of interest in this respect 
is the study by Moore et al. who demonstrated a strong correlation between 
the peaklevel to MIC ratio in serum of a number of aminoglycosides and the 
clinical outcome of the treatment of gram-negative infections at 8-h inter-
vals [87]. With respect to ciprofloxacin several studies demonstrate a 
comparable dose-dependent bactericidal activity in vivo [64], a dose 
response effect which was also observed in vitro [20, 64]. 
In general, in accordance with our findings in vitro, gram-negative bacteria 
are founo to regrow immediately after B-lactam concentrations have fallen 
below active levels. Contrary to our observations their regrowth is 
suppressed for variable periods of time after exposure to aminoglycosides 
and quinolones [19, 91]. However, PAEs of aminoglycosides in vitro appeared 
to be of short duration (exept for pseudomonas) and may vary between the 
individual strains [19]. There is also strain variation with respect to the 
presence of a PAE for quinolones against K.pneumoniae [76]. Like in vitro 
no major differences were found between the individual drugs tested with 
respect to the bacterial regrowth in lungs of leukopenic rats. 
The data derived from the experimental infection models may have implica-
tions for the treatment of infections in leukopenic patients. In general, 
B-lactams are administered at intervals and, taken into account the elimina-
tion half-lives, in relatively high doses resulting in high peak concen-
trations in order to provide active drug levels for most of the infecting 
strains until the next dose. The experimental studies show that for 
successful treatment with B-lactams it is of great importance that 
51 
antibiotic concentrations are maintained at a certain level during the 
period of treatment. High peak concentrations in plasma do not contribute 
to therapeutic effect. The data do further suggest that lower daily doses 
of B-lactams might even be permitted provided these are administered more 
frequently or B-lactams with long half lives are used. This might result in 
improvement of therapeutic effect, and may be favorable in terms of cost-
effectiveness. Bodey et al. showed that patients with persistent granuloc-
ytopenia responded better to a regimen including, besides carbenicillin, 
the constant infusion of cefamandol as compared to intermittent administra-
tion of this drug [15]. In a recent clinical study in patients with severe 
infections Hoepelman et al. demonstrated that a single daily treatment with 
the highly protein-bound drug ceftriaxone resulting in prolonged plasma 
concentrations, was more effective than a combination of gentamicin plus 
cefuroxime [59] . With regard to the aminoglycosides and the quinolones 
there is no experimental evidence that the dosage schedule is an important 
determinant for efficacy. In view of the fact that the bactericidal effect 
of these antibiotics is strongly related to the peak concentration, and 
their bacterial killing is very fast, it seems worthwile to investigate 
whether less frequent dosing with increased doses of these agents may be 
equally effective or even more efficacious in the immunocompromised host. 
In this respect several studies are of interest demonstrating that animal 
nephrotoxicity [6, 43, 58, 101, 103, 123] or ototoxicity [123] decreased 
with decreasing frequency of administration, despite higher individual 
doses of aminoglycosides. Less frequent dosing was not associated with loss 
of efficacy [58, 101] or resulted even in increased efficacy [101, 123]. 
Several human studies did also not reveal nephro- or ototoxicity despite 
relatively high doses of aminoglycosides given at 24-h intervals, which 
regimens proved to be effective [21, 40, 101]. 
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CHAPTER 6 
THERAPEUTIC EFFECT OF ANTIBIOTICS IN RELATION TO THE DURATION OF INFECTION 
AND THE BACTERIAL GROWTH RATE 
efficacy of ceftazidime, gentamicin, and ciprofloxacin in leukopenic rats 
with Klebsiella pneumoniae pneumonia and septicemia 
INTRODUCTION 
In a previous study described in chapter 5 it appeared, using three 
different classes of antibiotics, that not all bacteria were killed 
following an intravenous injection at 1 h after inoculation of the lung 
with Klebsiella pneumoniae. It is not clear which factors are responsible 
for the survival of bacteria at the site of infection. One explanation may 
be the absence of active antibiotic concentrations due to rapid drug 
elimination. Another possible factor is the occurrence of phenotypic 
resistance, a phenomenon reviewed by Greenwood [56]. Due to phenotypic 
heterogeneity within a susceptible bacterial population a fraction of the 
population may be resistant to concentrations of antibiotic that kill most 
of the bacteria. The role of both factors in survival of K.pneumoniae in 
the lung was investigated in the present study. Bacterial survival at the 
site of infection may also be the result of a change in the antibiotic 
susceptibility of the infecting strain or of changes in the activity of 
antibiotic due to local environmental factors, which as a consequence is 
only expressed in vivo. In the present study it was investigated whether 
the number of persisting bacteria varied with the duration of infection 
and, in addition whether the persisting bacteria could be eliminated by 
administration of an antibiotic with a different mode of action. 
One factor that probably progressively changes during the course of infec-
tion is the bacterial growth rate, which is substantially decreased in 
established infection [39, 82]. As changes in bacterial growth rate were 
not observed in the experiments in chapter 5, it was object of the present 
study to investigate whether changes in bacterial growth rate may have 
consequences for the antibacterial activity of antibiotic. For ciprofloxa-
cin a considerable bactericidal activity against bacteria in the so-called 
stationary phase of growth has been observed in vitro [20, 127]. In contrast 
several B-lactams, including ceftazidime, appeared not to be bactericidal 
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against nongrowing bacteria [ 23]. Therefore, in the present study the 
bactericidal activity of ciprofloxacin versus ceftazidime was determined 
in relation to the bacterial growth rate in vitro and in vivo in lungs of 
leukopenic rats. In addition the effect of delay of antibiotic administra-
tion from 1 h until 24 h after bacterial inoculation on the bactericidal 
effect of ciprofloxacin versus ceftazidime was investigated (data about the 
impact of the bacterial growth rate on the bactericidal activity of cipro-
floxacin versus ceftazidime are also described in appendix paper III). To 
study the impact of delay of start of treatment on the therapeutic activity 
of antibiotics, ciprofloxacin or ceftazidime was administered for a period 
of four days at 6-h intervals, starting at different times after bacterial 
inoculation with K.pneumoniae. 
MATERIALS AND METHODS 
Materials and methods that are described in chapter 2: MBC determination, 
quantitation of numbers of bacteria in the left lung and the blood, anti-
biotic administration as well as evaluation of in vivo bactericidal activity 
and therapeutic efficacy. The antibiotics used were ceftazidime, gentamicin, 
and ciprofloxacin. 
For determination of the antibacterial activity in vitro in relation to the 
bacterial growth rate, bacterial inocula were prepared as follows. A 
stationary phase culture was diluted to 107 CFU/ml in Iso-Sensitest broth 
and reincubated at 37°C. Logarithmically growing or stationary phase 
bacteria were obtained at 2 h before or 2 h after the stationary growth 
phase was achieved, respectively. Bacteria were centrifuged, washed, and 
suspended to their original number per milliliter in fresh warm (37°C) 
broth to which antibiotic was added, and reincubated. 
For population analysis related to antibiotic susceptibility CFU counts 
were determined simultaneously on antibiotic-free Iso-Sensitest agar plates 
and on agar plates containing various concentrations of the antibiotic 
studied. 
The in-vivo activity of the selected antibiotics was examined in leukopenic 
rats in different ways. Bactericidal activity of antibiotic was examined 
after intravenous injection at various times after inoculation of the left 
lung with K.pneumoniae organisms in the logarithmic or stationary growth 
phase. The numbers of bacteria in the lung were determined at various inter-
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vals after administration of antibiotic. The Mann-Whitney test was used for 
statistical analysis. Therapeutic efficacy of antibiotics was measured in 
terms of Po50 values after administration at 6-h intervals, for a period of 
4 days, starting at different times after bacterial inoculation. 
For the determination of antibiotic concentrations in lung tissue, the left 
lung was removed, exsanguinated, and homogenized in saline in a Potter-
Elvejhem homogenizer. After centrifugation for 2 min at 10,000 x g, the 
supernatant was collected and used for the determination of antibiotic 
concentrations. With the use of diagnostic sensitivity test agar (Oxoid) 
and an Escherichia coli test strain susceptible to 0.025 ~g of ciprofloxa-
cin and 0. 2 ~g of ceftazidime per ml, all tests were done by a standard 
large-plate agar diffusion procedure [5]. Standard samples were prepared as 
follows. Ciprofloxacin and ceftazidime in standard concentrations were 
added to homogenates of lungs of untreated rats. After incubation for 1 h 
at 37°C and centrifugation for '2 min at 10,000 x g, supernatants were 
collected. Samples of 100 ~1 were assayed. The Mann-Whitney test was used 
for statistical analysis. 
RESULTS 
Effect of ceftazidime, gentamicin, and ciprofloxacin against K.pneumoniae 
in lungs of leukopenic rats. The effect of ceftazidime, gentamicin, and 
ciprofloxacin against K.pneumoniae in lungs of leukopenic rats is shown in 
figure 6.1. One intravenous injection of 3 mg/kg at 1 h after bacterial 
inoculation killed a large part of the bacterial population, although not 
to the same extent for all three antibiotics. Whereas ceftazidime and genta-
micin killed about 90% of the bacterial population, ciprofloxacin killed 
about 99%. A second injection of 3 mg/kg at the time of the maximum 
bactericidal effect resulted in a slight, but not significant further reduc-
tion in numbers of bacteria for the three drugs tested. 
Population analysis related to antibiotic susceptibility of the three anti-
biotics did not reveal the selection of a resistant bacterial subpopulation 
at the time the maximum bactericidal effect was reached (figure 6. 2) . In 
contrast, a shift to a more susceptible population was observed. 
Figure 6.3 shows the bac~ericidal activity of ceftazidime, gentamicin, and 
ciprofloxacin in lungs of leukopenic rats after administration of 3 mg/kg 
at different times after inoculation with K.pneumoniae. At the time of 
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Figure 6.1 Numbers of K.pneumoniae in lungs of untreated leukopenic rats 
(----) and after intravenous administration of 3 mg/kg of ceftazidime (A), 
gentamicin (B), or ciprofloxacin (C). Ceftazidime was administered at h 
hand 3 h (--·--), and gentamicin or ciprofloxacin at h (---) or at 
(-- -l or at hand 2 h (--·--) after inoculation of lungs with 8 x 104 
K.pneumoniae in the logarithmic phase of growth. 
Each point represents the geometric mean ± SEM for five rats. 
injection of antibiotic the mean number of bacteria per left lung was 
similar in all experiments (2.2 x 105 CFU). Delay of antibiotic administra-
tion resulted in a decrease in bacterial killing for all three drugs tested. 
Killing by ceftazidime continued during 3 h except when administered at 1 h 
after inoculation. When injection of ceftazidime was delayed from 0 h until 
h after inoculation with K.pneumoniae bacterial killing decreased 
significantly (P < 0. 05) . Further delay of administration of ceftazidime 
resulted in a slight but not significant decrease of bactericidal activity 
(P >0.05). For gentamicin delay of administration also resulted in a 
decrease of bacterial killing in the lung. This decrease was significant 
for each successive hour injection of gentamicin was postponed (P <0.05). 
For ciprofloxacin similar results were obtained to those for gentamicin. 
Although after administration of 3 mg of ceftazidime/kg at 1 h a second 
dose of 3 mg of ceftazidime/kg at 2 h was not able to reduce the bacterial 
numbers in the lung significantly (figure 6.4A), a second dose of 3 mg of 
ciprofloxacin/kg at 2 h resulted in a significant additional bacterial 
killing (P <0.05) (figure 6.4B). Similar results were obtained for admini-
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stration of ciprofloxacin after gentamicin (figures 6.5A and 6.9B). 
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Figure 6.2 Susceptibility distribution of K.pneumoniae. Bacteria were 
isolated from lungs of leukopenic rats immediately before administration of 
antibiotic (control). Bacteria from treated rats were isolated 2 h after 
injection of 3 mg of ceftazidime/kg (A), h after injection of 3 mg of 
gentamicin/kg (B), or 1 h after injection of 3 mg of ciprofloxacin/kg (C). 
Antibiotics were administered intravenously at 1 h after inoculation of the 
lungs with 8 x 104 of logarithmically growing K.pneumoniae. 
Effect of ceftazidime and ciprofloxacin against K.pneumoniae in broth and 
in the lungs of leukopenic rats in relation to the bacterial growth rate. 
The effect of ciprofloxacin and ceftazidime against K.pneumoniae in broth 
in relation to the bacterial growth rate is shown in figure 6.6. Logarith-
mically growing bacteria in broth were killed by both ciprofloxacin and 
ceftazidime dependent on the concentration used (figure 6.6A and 6.6B, 
respectively). At all concentrations tested, the bacterial killing rate of 
ciprofloxacin was higher than that of ceftazidime. In addition, administra-
tion of ciprofloxacin resulted in immediate killing, whereas bacterial 
killing by ceftazidime was more gradual and time-dependent. When the 
K.pneumoniae organisms were in the stationary phase of growth, ceftazidime 
at the same concentrations was no longer bactericidal (figure 6.6D). On the 
contrary, ciprofloxacin was still able to kill the bacteria effectively 
(figure6.6C), although the bacterial killing was about 10 to 100-fold 
lower than observed for the logarithmically growing bacteria. 
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Figure 6.3 Numbers of K.:12neumoniae in lungs of untreated leukopenic rats 
(-----) and at various times after intravenous administration of 3 mg/kg of 
ceftazidime, gentamicin, or ciprofloxacin (---).Lungs of leukopenic rats 
were inoculated with K.:12neumoniae in the logarithmic phase of growth at the 
same time (0 h) or at various times before injection with antibiotic (-1 h, 
-2 h, or -3 h). Antibiotic was injected at 0 h. At the time of antibiotic 
administration the mean number of bacteria per left lung was 2.2x10S in all 
experiments. Each point represents the geometric mean ± SEM for five rats. 
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Figure 6.4 Numbers of K.pneumoniae in the lungs of untreated leukopenic 
rats (----) and at different times after administration of ceftazidime at 
h (---)or ceftazidime at 1 hand 2 h (-·-)(A), of ceftazidime at 
h (-- -) or ceftazidime at 1 h and ciprofloxacin at 2 h (-··-) (B) 
after inoculation of the lungs with 8 x 104 K.pneumoniae in the logarithmic 
phase of growth. Antibiotic was administered in doses of 3 mg/kg. 
Each point represents the geometric mean ± SEM for five rats. 
The bactericidal effect of ciprofloxacin and ceftazidime against 
K.pneumoniae in relatiqn to the bacterial growth rate in vivo is shown in 
figure 6. 7. Lungs were inoculated with 8 x 1 o4, logarithmically growing 
K.pneumoniae (figure 6.7A). At 1 h after inoculation, when the bacterial 
numbers in the lungs had increased about threefold up to 2. 2 x 1 o5 CFU, 
ciprofloxacin or ceftazidime was administered at a dose of 3 mg/kg. The 
actively growing bacteria were killed by both antibiotics, although cipro-
floxacin was significantly more effective (P <0.05). Inoculation of the 
lungs with 2.2 x 105 K.pneumoniae in the stationary phase of growth (figure 
6.78) resulted in a 1-h delay of bacterial growth in the lungs. When anti-
biotic was administered immediately after inoculation, it was observed 
that ceftazidime at a dose of 3 mg/kg was not able to kill the bacteria 
during the first hour, whereas ciprofloxacin was highly bactericidal during 
the first hour after inoculation. From the moment that bacterial numbers in 
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the lung increased, bacterial killing by ceftazidime was also observed. 
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Figure 6.5 Numbers of K.pneumoniae in the lungs of untreated leukopenic 
rats ( ..... --) and at different times after administration of gentamicin at 
1 h (---) or gentamicin at 1 hand 2 h (--·--) (A), of gentamicin at 1 h 
(-- -J or gentamicin at 1 h and ciprofloxacin at 2 h (--··- J (B) after 
inoculation of the lungs with 8 x 104 K.pneumoniae in the logarithmic phase 
of growth. Antibiotic was administered in doses of 3 mg/kg. 
Each point represents the geometric mean ± SEM for five rats. 
The effect of delaying antibiotic administration from 1 h up to 24 h after 
bacterial inoculation upon the antibacterial activity of ciprofloxacin and 
ceftazidime is shown in figure 6.8. At 1 h after inoculation with logarith-
mically growing bacteria the bacteria in the lungs had increased 3-fold in 
number and were killed by both antibiotics (figure 6.8A). At 24 h after 
inoculation in established lung infection, bacterial numbers had increased 
4000-fold and tissue necrosis was observed. All rats had bacteria in the 
blood. Ciprofloxacin administered at that time still had an antibacterial 
effect in the lungs (figure 6.8B) and in addition sterilized the blood of 
all rats. In contrast, ceftazidime was not effective in the lungs and blood 
cultures remained positive. This difference in efficacy could not be 
explained by higher concentrations of ciprofloxacin in lungs of leukopenic 
60 
E 
...... 
::l 
LL. 
1 Q10 
1 os 
() 106 
104 
1010 
108 E 
...... 
::l 
LL. 
() 
1 Q6 
104 
A 
' 
0 
' 
' 
' 
',,_ ,ug/ml 
----~-~~-- _____ .. 0.2 
2 3 
Time (h) 
c 
~: __ . ___ . 
· .. ·, ........... 
'\ . ~-~ .... 0.2 \\ "·, 
\"'· .............. 
. ,_ ....... 
\'"·. ·..... 0 4 
·.\·.............. ................ . \\..:..:_ ....... 0.8 
\.... - .... __ -. 1.6 
··-··- ............. ______ .. 
3.2 
,ug/ml 
0 2 3 
Time(h) 
0 2 3 
Time(h) 
D ,ug/ml 
~ ;a;;; • 0.2 ~ ,,.,..-.~~~-,:a 0.4 
0 2 3 
Time(h) 
0.8 
1.6 
3.2 
Figure 6.6 Effect of ciprofloxacin (A) or ceftazidime (B) against 
K.pneumoniae in the logarithmic phase of growth and of ciprofloxacin (C) or 
ceftazidime (D) against K.pneumoniae in the stationary phase of growth in 
broth. The solid line represents bacterial growth without antibiotic. 
rats as concentrations of ciprofloxacin and ceftazidime in lung tissue at 
various times after the intravenous administration of 3 mg/kg at 24 h after 
bacterial inoculation were not significantly different (table 6.1). 
Finally the effect of delay of start of treatment on the therapeutic 
efficacy of ceftazidime and ciprofloxacin is shown in table 6.2. The PD50s 
of ceftazidime after a four-day treatment at 6-h intervals, when starting 
at 5, 12 or 24 h after bacterial inoculation increased significantly 
(P <0.05), and were 24.4, 52.2 and 120 mg/kg/day, respectively. Delay of 
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Figure 6. 7 Numbers of K. pneumoniae in the lungs of untreated leukopenic 
rats (----) and after intravenous administration of ciprofloxacin (--·--) 
or ceftazidime (---) at 3 mg/kg at 1 h after inoculation of the lungs 
with 8x104 K.pneumoniae in the logarithmic phase of growth (A), or 
immediately after inoculation of the lungs with 2.2 x 105 K.pneumoniae in 
the stationary phase of growth (B). 
Each point represents the geometric mean ± SEM for five rats. 
start of treatment with ciprofloxacin from 5 h to 12 h after inoculation 
resulted in a significant increase of the PD50 value from 3. 3 to 12.2 
mg/kg/day (P <0.05). Delay up to 24 h resulted in a further, although not 
significant, reduction in activity as shown by an increase of the PD50 up 
to 21.2 mg/kg/day (P >0.05). 
DISCUSSION 
The experiments described in chapter 5 show that single doses of ceftazi-
dime, gentamicin, or ciprofloxacin did not kill all K.pneumoniae organisms 
in the lungs of leukopenic rats. The experiments described in this chapter 
were performed in order to elucidate some factors that are responsible for 
this observation. Firstly, it was investigated whether this incapacity of 
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Figure 6.8 Numbers of K.pneumoniae in the lungs of untreated leukopenic 
rats (----), and after intravenous administration of ciprofloxacin (--·--) 
or ceftazidime (- --) at 3 mg/kg at 1 h (A) (same as figure 6. 7A) or at 
24 h (B) after inoculation of the lungs with 8 x 104 K.pneumoniae in the 
logarithmic phase of growth. 
Each point represents the geometric mean ± SEM for five rats. 
Table 6.1. Concentrations of ciprofloxacin and ceftazidime in lung tissue 
at various times after intravenous administration of 3 mg/kg to 
infecteda leukopenic rats 
Antibiotic 
ciprofloxacin 
ceftazidime 
Drug concn (~g/g of lung tissue)b at the following 
times (min) after administration: 
15 
1. 33 ± 0. 79 
1.72 ± 1.58 
30 
1.80 ± 0.89 
2.15 ± 0.60 
60 
1.21 ± 0.28 
1.16±0.59 
90 
0.56 ± 0.16 
0.94 ± 0.40 
aAntibiotics were administered 24 h after inoculation of the left lung with 
8 x 104 CFU of K.pneumoniae. 
bEach value represents the mean ± SD for five rats. 
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Table 6.2 Efficacy of ceftazidime and ciprofloxacin treatment schedulesa 
in leukopenic rats 
Start of 
treatment (h) 
5 
12 
24 
ceftazidime 
24.4 
52.2 
120.0 
Po50 (mg/kg/dayl 
ciprofloxacin 
3.3 
12.2 
21.2 
aAntibiotics were administered at 6-h intervals over a period of four days 
starting at different times after bacterial inoculation of the left lung 
with 8 x 104 CFU of K.pneumoniae. 
antibiotic to kill all bacteria in the lung was the result of insufficient 
concentrations of antibiotic at the site of infection due to rapid elimina-
tion of antibiotic. This appeared to be not an important factor as a second 
injection of the same antibiotic at the time of the maximum bactericidal 
effect of the first dose resulted only in a slight but not significant 
additional decrease in bacterial numbers. In addition the persisting bacteria 
appeared not to represent a less susceptible subpopulation selected after 
antibiotic administration. On the contrary, a shift to a more susceptible 
population was observed. Several investigators demonstrated, however, the 
selection of more resistant bacteria after exposure to antibiotic [10, 11, 
51, 53, 88, 89]. It has for instance been shown that exposure of entero-
bacteriaceae to aminoglycosides [88] as well as Pseudomonas aeruginosa to 
aminoglycosides or quinolones [ 1 0, 11 , 51 1 resulted in the selection of 
bacteria with increased resistance to the drugs used. These bacterial sub-
populations were responsible for the bacterial regrowth in an in vitro 
kinetic model [10, 11]. Regrowth of bacteria with increased resistance were 
also found after treatment of a thigh muscle infection due to P.aeruginosa 
with gentamicin [53]. It has been suggested that these resistant subpopula-
tions may be of clinical relevance [51, 89]. An explanation for the absence 
of resistant bacteria in our experiments may be that the occurrence of less 
susceptible bacteria only becomes substantial after multiple injections of 
antibiotic. 
In the experiments described in this study it was investigated by which 
factors the size of the persisting bacterial population was determined. In 
chapter 5 it was shown that the class of antibiotic used and in addition 
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for gentamicin and ciprofloxacin the dose that was used were important 
determinants in this respect. In this chapter it is shown that bacteria 
that could not be eliminated by a second injection of ceftazidime or 
gentamicin were killed to a large extent by ciprofloxacin. The additional 
killing was similar when ciprofloxacin was administered either after cefta-
zidime or after gentamicin. The total bactericidal effect, however, did not 
exceed that of ciprofloxacin alone, so total bacterial killing was 
determined by the antibiotic with the highest bactericidal activity. It was 
also demonstrated for the three drugs tested that the number of persisting 
bacteria increased with the duration of the infection. This effect was most 
pronounced for ciprofloxacin. The diminished bacterial killing in the lungs 
of leukopenic rats due to delay of antibiotic administration could not be 
explained by an inoculum effect because up at the time of administration 
bacterial numbers were similar in all experiments. Neither was a reduction 
in bacterial growth rate responsible for the effect. Similar results were 
obtained by Totsuka et al. [ 115]. In his experiments intensive treatment 
with several antibiotics did not result in eradication of K.pneumoniae from 
thighs of neutropenic mice. Persisting bacteria were fully susceptible to 
the drugs used. Delay of administration for only h resulted in a 
substantial decrease of bacterial killing. In a model of pseudomonas 
endophthalmitis in rabbits it was demonstrated that delay of treatment from 
24 up to 48 h after infection resulted in loss of bactericidal activity of 
ciprofloxacin, gentamicin and imipenem [29]. This appeared not to be 
related to a decrease of susceptibility of bacteria, as they were fully 
susceptible to drugs tested after subculture in vitro. Recently, similar 
observations were reported by Davey for the same drugs not only in vivo in 
a pseudomonas granuloma-pouch model in rats, but also in in-vitro batch 
cultures in which the drugs became less bactericidal with progressive 
incubation [30]. A possible explanation for our observations and those of 
others may be that changes in the environment induce phenotypic resistance 
to antibiotic [52], which cannot be demonstrated after bacterial isolation 
and standard susceptibility testing. The exact nature of these changes is 
not clear, but one of the important factors may be that of nutrient deple-
tion [17]. This may be responsible for a change of the bacterial phenotype 
and subsequent altered antibiotic susceptibility. Another responsible 
factor may be a diminished activity of antibiotic due to local factors such 
as altered pH or oxygen depletion. 
In further experiments the relevance of our observations with regard to the 
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therapeutic efficacy of ceftazidime and ciprofloxacin was investigated. As 
mentioned, early injection of a single dose ciprofloxacin killed a greater 
part of the bacterial population than ceftazidime, however, the activity of 
both drugs decreased with delay of administration. These findings related 
to the antibacterial activity of antibiotics in the lung were reflected in 
the therapeutic activity of both antibiotics. Ciprofloxacin appeared to be 
more effective than ceftazidime when administered intermittently, and the 
efficacy of both drugs decreased with delay of start of treatment. These 
data are in accordance with the observation that institution of empirical 
antibiotic treatment in granulocytopenic patients starting at the first 
signs of fever has reduced the morbidity and mortality due to gram-negative 
infections [121]. This, however, may not apply to gram-positive infections 
in those patients. In a recent study Rubin et al. demonstrated that waiting 
for the laboratory results, identifying gram-positive organisms and anti-
biotic susceptibility, did not affect the effectiveness of treatment with 
vancomycin [104). 
Another factor that probably progressively changes during the course of 
infection is the bacterial growth rate [39, 82]. As bacterial growth rates 
did not substantially change in the experiments described above, other 
studies were performed in order to investigate the relevance of this factor 
for the activity of antibiotic treatment. Rapid and strong bactericidal 
activity of ciprofloxacin against nongrowing P.aeruginosa and E.coli has 
been demonstrated in vitro [ 20, 127), whereas a lack of bactericidal 
activity of several B-lactam antibiotics, including ceftazidime, has been 
observed against nongrowing enterobacteriaceae [23]. Therefore we studied 
the bactericidal activity of ciprofloxacin versus ceftazidime against 
K.pneumoniae in relation to the bacterial growth rate. We demonstrated in 
vitro that ciprofloxacin was able to kill K.pneumoniae that were not 
actively growing, whereas ceftazidime was not. However, compared to its 
activity against logarithmically growing bacteria, the bactericidal effect 
of ciprofloxacin was reduced. In vivo ciprofloxacin was highly bactericidal 
against nongrowing bacteria in the lung, whereas bacterial killing by 
ceftazidime occurred only from the moment of bacterial multiplication. 
It has to be realized that the experimental set-up used is not directly 
related to the clinical situation. However, in an infection that is well 
established ·slowly growing or nongrowing bacteria form a substantial part 
of the total bacterial population. Therefore the activity of ciprofloxacin 
\ 
versus ceftazidime was also compared in K.pneumoniae pneumonia and 
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septicemia in relation to the time of start of administration. Antibiotics 
administered 1 h after bacterial inoculation resulted in a decrease in 
bacterial numbers cultured from the lungs of leukopenic rats by both 
agents, although ciprofloxacin was more effective than ceftazidime. 
Administration of the same doses of antibiotic at 24 h, when the infection 
had fur,ther progressed, reduced the activity of both ciprofloxacin and 
ceftazidime. At that time ciprofloxacin was still bactericidal, but 
ceftazidime was not. Besides a reduced bacterial growth rate other factors 
such as inaccessibility of bacteria, local inactivation of antibiotics or 
changes in the susceptibility of bacteria may also have contributed to the 
diminished bacterial killing observed. The capacity of ciprofloxacin to 
kill nongrowing bacteria in contrast to ceftazidime appeared not to be of 
major importance for its therapeutic efficacy in this experimental 
pneumonia/septicemia model, as the therapeutic effect of both antibiotics 
decreased with delay of start of treatment. However, this capacity may be 
relevant in treating infections in which bacteria grow very slowly or do 
not multiply at all. This is confirmed by the successful treatment with 
ciprofloxacin of experimental osteomyelitis, an infection that could not be 
cured by intensive treatment with B-lactams or aminoglycosides [94]. 
In conclusion, the experimental data obtained in our model of K.pneumoniae 
pneumonia and septicemia in leukopenic rats with antibiotics of three 
different classes underline the need to start antibiotic treatment of 
serious infection as early as possible, because the number of bacteria 
persisting in the lung despite administration of antibiotic increases with 
the duration of the infection, as shown for three antibiotics with 
different mode of action. The use of highly bactericidal drugs may be of 
advantage in this respect. Whereas ciprofloxacin was bactericidal against 
nongrowing K.pneumoniae in vitro and in vivo in lungs of leukopenic rats, 
no evidence was found that this property is of major importance for the 
treatment infection that has been in progress for a certain time. 
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CHAPTER 7 
GENERAL DISCUSSION AND CONCLUSIONS 
Clinical experience indicates that infections in patients who are granulo-
cytopenic due to underlying malignant disease or to treatment with anti-
cancer chemotherapeutic agents are often difficult to treat. In these 
patients antibiotics are given empirically and blindly at the first signs 
of fever. 
New antibiotics of different classes have been developed and introduced 
for the treatment of serious infections. Their selection for clinical use 
is partly based on their in vitro antibacterial activity in relation to 
currently-used antibiotics. MIC/MBC values are frequently used as a 
parameter for relative in vitro activity [60]. However, the application of 
recently-developed antibiotics with high bactericidal activity in vitro 
against frequently isolated pathogens, does not always result in a greater 
clinical effect in patients. Different strategies for the potentiation of 
antimicrobial treatment in severe infections were outlined by O'Grady [54]. 
One approach involves intensification of the antibiotic treatment in terms 
of modification of the dosage schedule. Because of the complicated, 
fulminant and life-threatening character of infections in granulocytopenic 
patients, clinical trials in this respect are only permissible when based 
on sufficient supporting data derived from studies in experimental 
infections. Reproducible, well-characterized infectious disease models 
allow for comparison of antibiotics or antibiotic dosage schedules under 
similar conditions of intensity and duration of infection. The present 
experimental study intends to contribute to a better understanding of the 
role of the antibiotic dosage schedule for its therapeutic efficacy. 
An experimental infection model of Klebsiella pneumoniae pneumonia and 
septicemia in immunocompetent or leukopenic rats was used, and is described 
in chapter 2. This model was selected because in leukopenic patients 
septicemia frequently occurs, originating from different sources, for 
instance a localized infection such as pneumonia. In addition, K.pneumoniae 
is one of the pathogens that are frequently recovered [68, 74, 99, 116, 
122, 124]. This model appears to have a certain clinical relevance, as many 
characteristics of the infection are also observed in human lung infections 
caused by K.pneumoniae [80]. In immunocompetent rats after inoculation of 
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the lung the numbers of bacteria increased. The histological features of 
the pneumonic lesion are characterized by an outer margin with edema fluid 
that mainly contained gram-negative bacteria. More to the center of the 
lesion a cellular infiltrate composed of gram-negative bacilli, polymorpho-
nuclear leukocytes and a few macrophages is observed. In the center of the 
lesion edema-filled alveoli are packed with leukocytes and tissue necrosis, 
small lung abscesses containing numerous polymorphonuclear leukocytes and 
large numbers of gram-negative bacilli are present. Host defenses were 
impaired by means of injections with cyclophosphamide (CY), which resulted 
in a substantial reduction of the number of circulating granulocytes and 
monocytes. The granulocyte plays an important role in the defense against 
K.pneumoniae infections in the lung in the early phase of infection as 
demonstrated by Rehm et al. [ 1 02]. This correlates with the observations 
that compared to immunocompetent rats, in leukopenic rats bacterial 
multiplication in the lung was very rapid, resulting in septicemia at an 
early stage of infection. A substantial cellular infiltrate in the lung of 
leukopenic rats was absent despite the presence of large numbers of gram-
negative bacilli. Alvolear macrophages also phagocytize encapsulated 
K.pneumoniae organisms but for optimal function they require the presence 
of antiserum [117]. CY acts in an aspecific way. It is suggested that CY 
does not influence the granulocyte function [61]. Other investigators found 
that alveolar macrophage numbers were not reduced by CY administration [62, 
83, 97], whereas their function was reduced only after prolonged exposure 
[62] but not after a single dose [83, 97]. 
I 
In this infectious disease model the role of the antibiotic dosage schedule 
as a determinant of therapeutic activity was investigated. This subject was 
studied in relation to various factors such as the severity of infection, 
the presence of host defense factors and the kinetics of antibacterial 
activity in vitro and in vivo in lungs of leukopenic rats. Antibiotics were 
chosen from three different classes that are important for the treatment of 
severe infections in the immunocompromised host, i.e. the B-lactams, the 
aminoglycosides and the quinolones. From the respective classes ceftazi-
dime, gentamicin, and ciprofloxacin were chosen because the in vitro 
susceptibility of the K.pneumoniae s'train used in terms of MBC values was 
similar for these antibiotics allowing a good evaluation of the therapeutic 
results. In addition, these antibiotics are considered to be clinically 
relevant on the basis of their in vitro activity and antimicrobial 
spectrum. 
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In chapter 3 the effect of different dosage schedules of the B-lactam 
antibiotic ceftazidime on the therapeutic efficacy is examined in immuno-
competent rats. It appeared in these experiments that continuous administra-
tion was more effective than intermittent treatment at relatively long 
intervals. The difference between both dosage schedules increased with 
increasing severity of infection. In addition, in order to obtain a sub-
stantial therapeutic effect steady state ceftazidime concentrations in 
serum needed not to exceed the MBC value of ceftazidime for the klebsiella 
strain used. 
In chapter 4 it was demonstrated that the therapeutic efficacy of cefta-
zidime decreased as a result of impairment of host defenses due to severe 
leukopenia. This decrease was again strongly dependent on the dosage 
schedule, in the sense that ceftazidime was moderately less effective when 
administered by continuous infusion but substantially less effective when 
given intermittently. In other words the dosage schedule plays an important 
role especially when host defense mechanisms are impaired. It appeared that 
under those circumstances the activity of ceftazidime was highly dependent 
on the maintenance of appropriate antibiotic concentrations in serum during 
the entire treatment period. Results of other experiments suggest that 
treatment with ceftazidime has to be continued until the return of 
circulating leukocytes. 
In chapter 5 it is described that the importance of the antibiotic dosage 
schedule as a determinant ·of therapeutic activity in leukopenic rats did 
not necessarily apply to other classes of antibiotics. Whereas for thera-
peutic activity of ceftazidime continuous antibiotic concentrations in 
plasma are more important than relatively high peak concentrations at 
intervals, for gentamicin and ciprofloxacin the schedule of antibiotic 
administration did not have a major impact on the therapeutic activity. 
Gentamicin was equally effective with both modes of administration, whereas 
ciprofloxacin demonstrated a slightly increased efficacy with intermittent 
dosage. As the efficacy of the different treatment schedules was evaluated 
in terms of daily doses of antibiotic, the data obtained for gentamicin and 
ciprofloxacin suggest that a dosage schedule resulting in relatively long 
periods of low antibiotic concentrations in serum are permitted, provided 
the serum peak concentrations are sufficiently high. The differences in 
therapeutic efficacy in relation to the antibiotic dosage schedule 
correlate with the differences between the three antibiotics with regard to 
their kinetic of antibacterial activity in vitro and in the infected lungs 
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of leukopenic rats. The bacterial killing rate of K.pneumoniae in vitro and 
in lungs of leukopenic rats by ceftazidime was gradual and not strongly 
dependent on the concentration or the dose administered, despite a large 
variation in plasma peak levels after injection of the various doses. In 
contrast, the bacterial killing rate effected by gentamicin or cipro-
floxacin was high and dose-dependent. Another difference is that the 
bactericidal activity of ceftazidime was more dependent on the time of 
exposure to antibiotic, whereas bacterial killing by gentamicin and 
ciprofloxacin was complete within a short time period after administration. 
These observations may explain why the therapeutic efficacy of ceftazidime 
in our model was mainly dependent on the maintenance of active concentra-
tions during treatment. Relative high concentrations did not substantially 
contribute to its activity. In contrast, due to their high and dose-
dependent bactericidal effect gentamicin and ciprofloxacin could be 
administered at relative long intervals without loss of efficacy. For the 
latter two agents therapeutic efficacy was mainly determined by the total 
dose administered. In various models of experimental gram-negative infec-
tions, especially those concerning animals with impaired host defenses, 
similar results were obtained with respect to the importance of the dosage 
schedule for the efficacy of antibiotics of different classes for the in 
vivo activity [18, 49, 52, 57, 64, 79, 101, 120]. Differences in efficacy 
are found to be in agreement with differences in kinetics of antibacterial 
activity between several antimicrobial agents belonging to the B-lactams, 
the aminoglycosides and quinolones [3, 10, 20, 49, 52, 55, 64, 93, 118, 
125]. These findings also correlate with the observation that with respect 
to B-lactam antibiotics from a number of pharmacokinetic parameters the 
time period serum drug levels remained above the MBC correlated the best 
with in vivo activity [79, 120]. On the contrary, for aminoglycosides it 
was demonstrated that the area under the concentration time curve mainly 
determined the in vivo efficacy, irrespective of the frequency of 
administration. With respect to the quinolones we are not aware of studies 
showing which pharmacokinetic parameters determine the in vivo activity of 
these antibiotics. In the present study ciprofloxacin behaved like genta-
micin with regard to the bactericidal activity against K. pneumoniae in 
vitro as well as in vivo, and no major differences were found between both 
drugs with regard to the impact of the dosage schedule on their therapeutic 
efficacy. 
Similar conclusions with respect to the dosage schedule-dependent efficacy 
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related to the class of antibiotic may be drawn with respect to infections 
caused by gram-positive bacteria [2, 24, 44, 45, 113]. 
Besides the kinetics of antibacterial activity, another factor that may be 
relevant with respect to the dosage schedule dependent activity of anti-
biotics is the post-antibiotic effect (PAE) [26]. After the early observa-
tions on the PAE of Bigger in 1944 related to the persistent suppression of 
bacterial growth of staphylococci and streptococci after removal of peni-
cillin G, Parker and Luse also demonstrated that bacterial growth of 
Staphylococcus aureus in vitro was suppressed for a certain time period 
after removal of penicillin G [ 9, 95] . Later on studies on the PAE were 
extended to various drug-pathogen combinations [19]. These studies allowed 
to formulate a number of conclusions on the occurrence of the PAE [19, 26]. 
B-Lactams induce PAEs of various duration against gram-positive cocci in 
vitro, whereas no or very short PAEs were found for gram negative bacilli. 
On the other hand inhibitors of protein synthesis, including aminoglyco-
sides, as well as quinolones [76, 91] induce PAEs of moderate to long 
duration against both types of micro-organisms. In general PAEs in vitro 
correlate well with PAEs in vivo, except for streptococci that did not show 
PAE with B-lactams in experimental infections [119]. In the present study a 
PAE in vitro was not found for K.pneumoniae with ceftazidime neither with 
gentamicin or ciprofloxacin (chapter 5). This is not completely in agree-
ment with what is generally found for gram-negative bacteria. As observed 
by others, such differences may be explained by strain variations [ 19, 
76]. Like in vitro, also in lungs of leukopenic rats there were no major 
differences between ceftazidime, gentamicin, and ciprofloxacin with 
respect to regrowth of K.pneumoniae after a single injection of the 
respective drugs. The regrowth patterns in lungs may have been influenced 
by sub-MIC concentrations of antibiotics which may explain that in contrast 
to the in vitro observations bacteria did not multiply for a relatively 
long period of time. This suggests that in our model differences in PAE are 
not contributing to the differences in antibiotic dosage schedule-dependent 
therapeutic efficacy as observed between ceftazidime, gentamicin and cipro-
floxacin. 
Although our experimental data on the efficacy of the different treatment 
schedules are in agreement with the findings of most other investigators 
there are some discrepancies. With respect to the studies in immuno-
competent animals some of them may be attributed to the simultaneous action 
of the host defense system and antimicrobial drugs in curing the infection 
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as suggested by results obtained by others for B-lactams [2, 49] and also 
found by us (chapter 4). Antibiotic free periods that remain without much 
consequence in immunocompetent animals resulted in a severe loss in 
efficacy when host defenses were impaired. Regarding the aminoglycosides 
the use of long treatment intervals relative to the short half lives of 
antibiotics in small animals may explain a suggested dosage schedule-
dependent activity [67, 96]. Few authors stated that the efficacy of 
B-lactams can be optimalized, by injecting these drugs at short intervals 
[ 48, 1 07] . This would bacteria allow to grow, and as a consequence make 
them more susceptible to the lethal action of cell-wall active antibiotics. 
However, this result is not necessarily conflicting with that found by 
others as not all investigators used more than two treatment intervals. A 
more substantial exception may be the treatment of pneumococcal meningitis 
with B-lactam antibiotics. In a rabbit meningitis caused by S.pneumoniae it 
was demonstrated that the efficacy of ampicillin was not dependent on the 
frequency of administration, despite drug levels in CSF that were below the 
MBC for about 50% at the longest dosage interval used [112]. It appeared 
that the most important determinant of in vivo activity was the peak level 
of ampicillin in CSF. This correlated with the observations that: with 
several B-lactams bacterial killing rates of S.pneumoniae in CSF increased 
with increasing doses to levels up to 30 times the MBC although in vitro no 
concentration dependent bactericidal activity was found [ 111]. Also the 
slow decline of ampicillin levels in CSF may have contributed to the 
efficacy of intermittent treatment with ampicillin. 
The pattern of bacterial killing in vitro and in vivo appeared to be 
related to the class of antibiotics as studied and discussed for B-lactams, 
aminoglycosides and quinolones. There may, however, be also some difference 
in bacterial killing rates between several B-lactams [22, 63]. Also 
B-lactam kill characteristics may not always be the same in vitro and in 
vivo as demonstrated in experimental meningitis [111]. However, in general 
increase of bacterial killing rates occurs over a much larger concentration 
range with aminoglycosides and quinolones than with B-lactams, and in addi-
tion their maximum killing rates are much higher. These differences in 
bactericidal kinetics are probably related to differences in mode of 
action. Whereas B-lactams inhibit cell-wall synthesis, and aminoglycosides 
inhibit protein synthesis, the quinolones do interact with the bacterial 
enzyme DNA-gyrase. An intact gyrase activity is essential for bacterial 
survival [110]. 
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Another factor that may be important with regard to the impact of the 
dosage schedule on the in vivo efficacy is the extravascular penetration of 
antibiotics [78]. This subject has been studied by several investigators 
[4, 7, 8, 38, 77, 98]. Some experiments revealed higher extravascular 
antibiotic levels obtained with intermittent dosage compared to continuous 
infusion [4, 7]. However, the study periods used were relatively short. 
Other studies show that, at steady state conditions, levels of antibiotics 
of different classes in Visking chambers implanted in rabbits were similar 
or even higher after continuous infusion than after administration at 
intervals [38, 98]. Some investigators have studied the mode of drug 
administration on the extravascular penetration concurrently with its 
impact on the bactericidal activity [8, 77]. Whereas continuous infusion of 
several antibiotics including B-lactams produced at equilibrium conditions 
similar mean levels in infected fibrin clots as compared to intermittent 
dosage, the resulting bactericidal effect was rather poor. This may be due 
to the slow drug penetration after continuous infusion, resulting in a 
substantial delay of killing of that part of the bacterial population, that 
is difficult to reach. This is suggested by the higher bactericidal effect 
after intermittent dosage and an even better bacterial killing after 
administration of the same total dose as a single bolus injection. These 
studies, however, concern relatively short treatment periods and the use of 
an artificial extravascular compartment which is extremely difficult to 
penetrate [4]. 
The studies in chapter 6 show that a single dose or multiple doses of 
antibiotic were unable to kill all bacteria at the site of infection. The 
number of bacteria persisting in the lung was dependent on the class of 
antibiotic used, and when gentamicin and ciprofloxacin were used, also on 
the dose administered. The incomplete eradication of bacteria was not due 
to insufficient antibiotic concentrations at the site of infection 
resulting from rapid drug elimination. In addition, persisting bacteria did 
not represent a less susceptible subpopulation selected after antibiotic 
administration as found by others [10, 11, 51, 53, 88]. Probably local 
factors present in the microenvironment of the infection are responsible 
for diminished susceptibility of the bacteria or reduced activity of the 
antibiotics used [56]. These factors can, however, not be analyzed ex vivo. 
The fact that diminished bacterial killing was due to local factors was 
confirmed by the observation that the nUmber of persisting bacteria 
increased with increase of the duration of infection as demonstrated for 
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antibiotics of three different classes. Corresponding to these observations 
the therapeutic activity of ceftazidime and ciprofloxacin also decreased 
after a four-day treatment when start of treatment was delayed. 
One factor that may be of major importance for the bactericidal activity of 
an antibiotic in established infection is the capacity to kill slow growing 
nongrowing bacteria. Bacterial growth rates are substantially decreased in 
established infection [39, 82]. Ciprofloxacin and ceftazidime differ 
extremely with regard to their growth rate-dependent bactericidal activity. 
Whereas ciprofloxacin is able to kill bacteria that are not actively 
growing, ceftazidime and almost all other B-lactams are not [20, 23, 127]. 
In the present study the difference in bacterial growth rate-dependent 
bactericidal activity between ceftazidime and ciprofloxacin was also 
demonstrated in vitro as well as in vivo in lungs of leukopenic rats. These 
findings are in accordance with data of other investigators [20, 23, 127]. 
The bactericidal activity of most of the B-lactams tested in a Chemostat 
(a continuous culture system in which the bacterial growth rate can be 
determined by the flow rate at which fresh medium is added) appeared to be 
proportional to the bacterial growth rate [23]. Ciprofloxacin was able to 
kill Escherichia coli in the so-called stationary phase of growth [ 20, 
127]. However, in this experimental pneumonia/septicemia model the capacity 
of ciprofloxacin to kill ilongrowing bacteria in contrast to ceftazidime 
appeared not to be of major importance for its therapeutic efficacy, as the 
therapeutic effect of both antibiotics decreased in infection that was well 
established. Substantial bactericidal activity that is not influenced by 
the bacterial growth rate may become increasingly important when treating 
infections where bacteria grow extremely slow or do not grow at all, such 
as osteomyelitis. 
Implications for the clinical use of antibiotics 
The experimental studies with regard to the impact of the dosage schedule 
on the therapeutic efficacy of antibiotic in immunocompromised animals, 
described in this thesis as well as in studies by other investigators come 
to more or less similar conclusions, although the studies differ in choice 
of infection model and animal species, of bacterial strain, of antibiotic 
and dosage schedule and, of parameter to measure efficacy. These animal 
data may provide a basis for clinical investigations on the treatment of 
serious infections in leukopenic patients with regard to mode of 
administration, start of treatment and duration of treatment. 
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Regarding dosage schedule, B-lactam antibiotics are in general administered 
at intervals and, taken into account their elimination half-lives, in 
relatively high doses resulting in high plasma peak concentrations in order 
to provide active drug levels for most of the infecting strains until the 
next dose. The experimental studies show that for successful treatment with 
B-lactams high peak concentrations in plasma do not contribute to a 
therapeutic effect, as long as antibiotic concentrations are maintained at 
a certain level during treatment. This suggests that lower daily doses of 
B-lactams might even be used provided they are administered more frequently 
or B-lactams with long half lives, for instance due to high serum protein 
binding, are used. This might result firstly in improvement of therapeutic 
effect, and secondly this may be favourable in terms of cost-effectiveness, 
as the newer B-lactams are relatively expensive. To date only few clinical 
data are available on this subject. Bodey et al. showed that patients with 
persistent granulocytopenia responded better to a regimen including, 
besides carbenicillin, the constant infusion of cefamandol as compared to 
intermittent administration of this drug [15]. In a recent clinical study 
in patients with serious systemic infections Hoepelman et al. demonstrated 
that a single daily dose of ceftriaxone resulting in prolonged plasma 
concentrations due to high protein binding, was more effective than a 
combination of gentamicin plus cefuroxime [59]. Recently two case reports 
were described in which neutropenic patients were cured from Pseudomonas 
aeruginosa infection with continuously infused ceftazidime where inter-
mittent treatment with the same antibiotic had failed [ 27] . Additional 
clinical data are needed to offer more support for the use of treatment 
schedules with constant levels of B-lactams. 
Aminoglycosides are in general administered intermittently in doses 
resulting in non-toxic plasma peak concentrations. There is no experimental 
evidence that the dosage schedule is an important determinant for efficacy. 
This is confirmed by clinical studies of Feld et al. who demonstrated no 
superiority of either continuous or intermittent treatment of febrile 
granulocytopenic patient with aminoglycosides [41, 42]. In view of the fact 
that the bactericidal effect of these antibiotics is strongly dependent on 
the peak concentration, and the bacterial killing is very fast, intermit-
tent administration at relatively long intervals seems permissible without 
loss of efficacy. The dose-dependent bactericidal effect which is important 
with intermittent treatment was confirmed by clinical studies described by 
Moore et al. [87]. They showed a strong correlation between the peak level 
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to MIC ratio in serum of a number of aminoglycosides and the clinical out-
come of the intermittent treatment of gram-negative infections. In relation 
to the peak concentration-dependent bactericidal effect individualizing 
aminoglycoside dosing in patients seems to be of major importance not only 
for the prevention of toxicity, but also for more effective treatment. 
Another question that needs further investigation is whether less frequent 
dosing with increased doses, causing infrequent relatively high serum 
concentrations, may be equally effective or even more efficacious in the 
irnrnunocompromised host, and in addition may be less toxic. In this respect 
several studies are of interest, demonstrating that animal nephrotoxicity 
[ 6, 43, 58, 1 01 , 1 03, 123] or ototoxicity [ 123] decreased with decreasing 
t 
frequency of administration, despite higher individual doses of aminoglyco-
sides. Less frequent dosing was not associated with loss of efficacy [58, 
101] or resulted even in increased efficacy [101, 123]. Several human 
studies did also not reveal nephro- or ototoxicity despite relative high 
doses of aminoglycosides given at 24-h intervals, which regimens proved to 
be effective [21, 40, 101]. 
The newer and recently introduced quinolones are administered intermittent-
ly. From the few experimental studies performed at this moment there are no 
indications that the dosage schedule is an important determinant for 
efficacy. No clinical data are available to support the superiority of 
either continuous or intermittent administration of these drugs. However, 
their high bactericidal effect which is dependent on the dose suggest that 
administration at intervals may be the most appropriate treatment schedule. 
Regarding start of treatment, the experimental data obtained with 
K.pneumoniae for the three antibiotics underline the need to start 
antibiotic treatment as early as possible, because the number of bacteria 
persisting in the infected tissue in spite of antibiotic administration 
increases with delay of treatment. The use of highly bactericidal drugs may 
be of advantage in this respect. The results do not give indications that 
the capacity of an antibiotic to kill nongrowing or slowly growing bacteria 
may be of importance for the outcome of treatment. This capacity, however, 
may be of relevance for the treatment of infections in which bacteria grow 
extremely slowly or do not multiply at all. 
Regarding the duration of antibiotic treatment in relation to the duration 
of leukopenia, the experimental data obtained for ceftazidime suggest that 
antibiotic treatment should preferably be continued until the return of 
circulating leukocytes. However, prolonged antibiotic treatment may cause 
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an increase in adverse side-effects. This must be outweighed against the 
risk on development of infections. In addition, the main factor determining 
the risk on development of serious infection in persistent granulocytopenic 
patients after stopping antibiotic treatment may be the number of days they 
are afebrile after initial therapy as suggested by DiNubile [31]. 
Implications for in vitro testing of antibiotics 
Besides the clinical implications for antibiotic treatment of patients, the 
experimental studies may also be of importance for the methods of determina-
tion of antimicrobial susceptibility in vitro. For in vitro determination 
of antibacterial activity of recently-developed antibiotics in relation to 
currently-used antibiotics MIC/MBC values are frequently used as a para-
meter. The present experimental study shows that despite similar MIC/MBC 
values, antibiotics of different classes may differ extremely with respect 
to their short-term killing capacity of bacteria. The therapeutic efficacy 
of antibiotic, administered at different dosage schedules appeared to 
correlate well with the in vitro short-term killing pattern of the anti-
biotic, but not with the MIC/MBC value as an in vitro parameter. In other 
words, determination of short-term bacterial killing patterns seems to be 
far preferable for comparison of antibacterial activity of antibiotics. 
The data on the bactericidal kinetics will have to be compared with the 
pharmacokinetic behaviour of the antibiotics tested as the outcome of 
treatment depends mainly on these parameters [32]. PAE determinations may 
give still more information. 
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SUMMARY 
Clinical experience indicates that infections in patients who are granulo-
cytopenic due to underlying malignant disease or its treatment with anti-
cancer chemotherapeutic agents are often difficult to treat. Despite the 
application of recently-developed antibiotics with high bactericidal 
activity in vitro against frequently isolated pathogens, a substantial 
percentage of treatments fail. One approach to improve therapeutic efficacy 
involves intensification of the antibiotic treatment in terms of modifica-
tion of the dosage schedule. Because of the complicated, fulminant and 
life-threatening character of infections in granulocytopenic patients, 
clinical trials in this respect are only permitted when based on sufficient 
supporting data derived from studies in experimental infections. The 
present experimental study intends to contribute to a better understanding 
of the role of the antibiotic dosage schedule as a determinant of 
therapeutic efficacy. This subject was studied in relation to various 
factors such as the severity of infection, the presence of host defense 
factors, and the kinetics of antibacterial activity in vitro and in vivo in 
the lungs of leukopenic rats. 
The experimental design is described in chapter 2. An experimental infec-
tion model of Klebsiella pneumoniae pneumonia and septicemia in immuno-
competent or leukopenic rats was used, which appeared to have a certain 
clinical relevance. Antibiotics were chosen from three different classes 
that are important for the treatment of severe infections in the immune-
compromised host, i.e. the B-lactams, the aminoglycosides and the quino-
lones. From the respective classes ceftazidime, gentamicin, and cipro-
floxacin, were chosen because the in vitro susceptibility of the 
K.pneumoniae strain used in terms of MBC values was similar for these 
antibiotics allowing a good evaluation of the therapeutic results. In 
addition, these antibiotics are considered to be clinically relevant on the 
basis of their in vitro activity and antimicrobial spectrum. 
In chapter 3 it is shown that continuous administration of ceftazidime was 
more effective than intermittent treatment at relatively long intervals. 
The difference between both dosage schedules increased with increasing 
severity of infection. In addition, in order to obtain a substantial thera-
peutic effect steady state ceftazidime concentrations in serum needed not 
to exceed the MBC value of ceftazidime for the Klebsiella strain used. 
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In chapter 4 it is demonstrated that the therapeutic efficacy of cefta-
zidime decreased as a result of impairment of host defenses due to severe 
leukopenia. This decrease was again strongly dependent on the dosage 
schedule in the sense that ceftazidime was moderately less effective when 
administered by continuous infusion but substantially less effective when 
given intermittently. In other words the dosage schedule plays an important 
role especially when host defense mechanisms are impaired. It appeared that 
under those circumstances the activity of ceftazidime was highly dependent 
on the maintenance of appropriate antibiotic concentrations in serum during 
the entire treatment period. Results of other experiments suggest that 
treatment with ceftazidime has to be continued until the return of 
circulating leukocytes. 
Chapter 5 describes that the importance of the antibiotic dosage schedule 
as a determinant of therapeutic activity of ceftazidime in leukopenic rats 
did not necessarily apply to other classes of antibiotic. Whereas for its 
therapeutic activity continuous antibiotic concentrations in serum are more 
important than relatively high peak concentrations at intervals, for 
gentamicin and ciprofloxacin the schedule of antibiotic administration did 
not have a major impact on the therapeutic activity. Gentamicin was equally 
effective with both modes of administration, whereas ciprofloxacin 
demonstrated a slightly increased efficacy with intermittent dosage. As the 
efficacy of the different treatment schedules was evaluated in terms of 
daily doses of antibiotic, the data obtained for gentamicin and ciprofloxa-
cin suggest that a dosage schedule resulting in relatively long periods of 
low antibiotic concentrations in serum are permissible , provided the serum 
peak concentrations are sufficiently high. The differences in therapeutic 
efficacy in relation to the antibiotic dosage schedule correlate with the 
differences between the three antibiotics with regard to their kinetic of 
antibacterial activity in vitro and in the infected lungs of leukopenic 
rats. The bacterial killing of K.pneumoniae by ceftazidime was gradual and 
not strongly dependent on the concentration or the dose administered, 
despite a large variation in serum peak levels after injection of the 
various doses. In contrast, the rate of bacterial killing achieved by 
gentamicin or ciprofloxacin was high and dose-dependent. Another difference 
is that the bactericidal activity of ceftazidime was more dependent on the 
time of exposure to antibiotic, whereas bacterial killing by gentamicin and 
ciprofloxacin was complete within a short time period after administration. 
These observations may explain why the therapeutic efficacy of ceftazidime 
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in our model was mainly dependent on the maintenance of active concen-
trations in serum during treatment. Relatively high concentrations did not 
substantially contribute to its activity. On the contrary, due to their 
high and dose-dependent bactericidal effect gentamicin and ciprofloxacin 
could be administered at relative long intervals without loss of efficacy. 
For the latter two agents therapeutic efficacy was mainly determined by the 
total dose administered. 
Besides the kinetics of antibacterial activity, another factor that may be 
relevant with respect to the dosage schedule-dependent activity of anti-
biotics is the post-antibiotic effect (PAE). In the present study a PAE in 
vitro was not found for K.pneumoniae with ceftazidime nor with gentamicin 
and ciprofloxacin (chapter 5). As in vitro, in lungs of leukopenic rats 
there were no major differences between ceftazidime, gentamicin, and cipro-
floxacin with respect to regrowth of K.pneumoniae after a single injection 
of the respective drugs. The regrowth patterns in lungs may have been 
influenced by sub-MIC concentrations of antibiotics which may explain that 
in contrast to the in vitro observations bacteria did not multiply for a 
relatively long period of time. Thus in our model differences in the PAE 
appeared not to contribute to the differences in antibiotic dosage schedule-
dependent therapeutic efficacy as observed for ceftazidime, gentamicin and 
ciprofloxacin. 
The studies in chapter 6 show that a single dose or multiple doses of anti-
biotic were unable to kill all bacteria at the site of infection. The number 
of bacteria persisting in the lung was dependent on the class of antibiotic 
used and in the case of gentamicin and ciprofloxacin also on the dose 
administered. The incomplete eradication of bacteria was not due to in-
sufficient antibiotic concentrations at the site of infection resulting 
from rapid drug elimination. In addition, persisting bacteria did not 
represent a less susceptible subpopulation selected after antibiotic 
administration. Probably local factors present in the microenvironment of 
the infection are responsible for diminished susceptibility of the bacteria 
or reduced activity of the antibiotics used. These factors can, however, not 
be analyzed ex vivo. The fact that the diminished bacterial killing was 
due to local factors was confirmed by the observation that the number of 
persisting bacteria increased with increase in the duration of infection, 
as demonstrated for antibiotics of three different classes. Corresponding 
to these observations concerning antibacterial activity in the lung a 
decrease in therapeutic efficacy due to delay of start of treatment was 
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shown for ceftazidime and ciprofloxacin. 
One factor that may be of major importance for the bactericidal activity of 
an antibiotic in established infection is the capacity to kill slow growing 
or nongrowing bacteria. In the present study the difference in the bacterial 
growth rate-dependent bactericidal activity between ceftazidime and cipro-
floxacin was demonstrated in vitro as well as in vivo in lungs of leukopenic 
rats. Whereas ciprofloxacin was able to kill bacteria that were not actively 
growing, ceftazidime was not. However, the capacity of ciprofloxacin to kill 
nongrowing bacteria in contrast to ceftazidime appeared not to be of major 
im?ortance for its therapeutic efficacy in the experimental pneumonia/septi-
cemia model, as the therapeutic effect of both antibiotics decreased in 
infection that was well established. 
The experimental studies with regard to the impact of the dosage schedule 
on the therapeutic efficacy of antibiotic in immunocompromised animals, 
described in this thesis as well as by other investigators, come to more or 
less similar conclusion, although the studies differ in choice of infection 
model, of bacterial strain, of antibiotic and dosage schedule, of parameters 
to measure efficacy. These animal data may provide a basis for clinical 
investigations on the antimicrobial 
leukopenic patients with regard to 
treatment and duration of treatment. 
treatment of serious infections in 
mode of administration, start of 
Regarding dosage schedule, in clinical practice B-lactam antibiotics are in 
general administered at intervals and, taken into account their elimination 
half-lives, in relatively high doses resulting in high serum peak concen-
trations in order to provide active drug levels for most infecting strains 
until the next dose. The experimental studies show that for successful 
treatment with B-lactams high peak concentrations in serum do not contribute 
to a therapeutic effect, as long as antibiotic concentrations are maintained 
at a certain level during the period of treatment. This suggests that lower 
daily doses of B-lactams might even be used provided they are administered 
more frequently or B-lactams with long half lives, for instance due to high 
serum protein binding, are used. This might result firstly in improvement 
of therapeutic effect and secondly this might be favourable in terms of 
cost-effectiveness, as the newer B-lactams are relatively expensive. 
Aminoglycosides are in general administered intermittently in doses 
resulting in non-toxic serum peak concentrations. There is no experimental 
evidence that the dosage schedule is an important determinant for efficacy. 
In view of the fact that the bactericidal effect of these antibiotics is 
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strongly dependent on the peak concentration, and the bacterial killing is 
very fast, intermittent administration at relatively long intervals seems 
permissible without loss of efficacy. In relation to the peak concentra-
tion-dependent bactericidal effect individualizing aminoglycoside dosing in 
patients seems to be of major importance, not only for prevention of 
toxicity, but also for effective treatment. Another question that needs 
further investigation is whether less frequent dosing with increased doses, 
causing infrequent relatively high serum concentrations, may be equally 
effective or even more efficacious in the immunocompromised host, and in 
addition may be less toxic. 
The newer and recently introduced quinolones are administered intermittent-
ly. From the few experimental studies performed at this moment there are no 
indications that the dosage schedule is an important determinant for 
efficacy. Their high bactericidal effect which is dependent on the dose 
suggest that administration at intervals may be the most appropriate 
treatment schedule. 
Regarding start of treatment, the experimental data obtained for the three 
antibiotics underline the need to start antibiotic treatment as early as 
possible, because the number of bacteria persisting in the infected tissue 
in spite of antibiotic administration, increases with delay of treatment. 
The use of highly bactericidal drugs may be of advantage in this respect. 
The results do not give indications that the capacity of an antibiotic to 
kill nongrowing or slowly growing bacteria may be of importance for the 
outcome of treatment. 
Regarding the duration of antibiotic treatment in relation to the duration 
of leukopenia, the experimental data obtained for ceftazidime suggest 
that antibiotic treatment should be preferably continued until the return of 
circulating leukocytes. 
Besides the clinical implications for antibiotic treatment of patients, the 
experimental studies may also be of importance for the methods of determi-
nation of antimicrobial susceptibility in vitro. The present experimental 
study shows that despite similar MIC/MBC values, antibiotics of different 
classes may differ extremely with respect to their short-term killing 
capacity of bacteria. The therapeutic efficacy of antibiotic, administered 
at different dosage schedules appeared to correlate well with the in vitro 
short-term killing pattern of the antibiotic, but not with the MIC/MBC 
value as an in vitro parameter. In other words, determination of short-term 
bacterial killing patterns seems to be far preferable for comparison of 
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antibacterial activity of antibiotics. 
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SAMENVATTING 
Klinische ervaring heeft aangetoond dat infecties bij patienten die granu-
locytopenisch zijn als gevolg van maligni tei ten of door toediening van 
chemotherapeutica vaak niet met succes zijn te behandelen. Ondanks de 
toepassing van recent ontwikkelde antibiotica met een goede bactericide 
werking in vitro ten opzichte van de frequent ge1soleerde bacteriele 
infectieverwekkers, faalt een aanzienlijk deel van de behandelingen. Een 
van de benaderingen om het therapeutisch effect te vergroten zou kunnen 
zijn, intensiveren van de antibioticumbehandeling door verandering van het 
doseringsschema. Vanwege het gecompliceerde en levensbedreigende karakter 
van infecties bij granulocytopenische patienten zijn klinische trials op 
dit punt aileen dan verantwoord wanneer ze gebaseerd zijn op voldoende 
ondersteunende gegevens verkregen uit dierexperimenteel onderzoek. Deze 
dierexperimentele studie beoogt bij te dragen tot een beter inzicht in het 
belang van het doseringsschema voor de therapeutische werkzaamheid van 
antibiotica. Deze vraagstelling werd bestudeerd in relatie tot verschil-
lende factoren, zoals de ernst van de infectie, de aanwezigheid van afweer-
factoren en de kinetiek van de antibacteriele werking in vitro en in vivo 
in longen van leukopenische ratten. 
De experimentele aanpak is beschreven in hoofdstuk 2. Als experimentele in-
fectie werd een pneumonie en sepsis veroorzaakt door Klebsiella pneumoniae 
in immunocompetente en leukopenische ratten gekozen, een infectie model 
dat een zekere klinische relevantie heeft. Antibiotica werden gekozen uit 
drie verschillende klassen die belangrijk zijn voor de behandeling van 
ernstige infecties bij patienten met verminderde weerstand, nl. de 
B-lactams, de aminoglycosiden en de quinolonen. Van deze klassen werden 
respectievelijk ceftazidime, gentamicine en ciprofloxacin gekozen, omdat 
de in vitro gevoeligheid van de K.pneumoniae stam in termen van MBC-waarden 
gelijk was voor de drie antibiotica. Hierdoor werd een goede evaluatie van 
de behandelingsresultaten mogelijk gemaakt. Bovendien zijn deze antibiotica 
thans in de kliniek relevant vanwege hun in vitro werkzaamheid en anti-
microbieel spectrum. 
De studies beschreven in hoofdstuk 3 laten zien dat voor de therapeutische 
werkzaamheid van het B-lactam antibioticum ceftazidime in immunocompetente 
ratten de wijze van doseren een bepalende factor is. Toediening door middel 
van continu infuus bleek effectiever dan intermitterende behandeling met 
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relatief lange intervallen. Het verschil in effectiviteit tussen beide 
doseringsschema's nam toe met toenemende ernst van de infectie. Bovendien 
bleek dat voor het verkrijgen van een therapeutisch effect het niet nodig 
was dat steady state concentraties in het serum de MBC-waarde van de 
Klebsiella stam voor ceftazidime overschreden. 
Hoofdstuk 4 laat zien dat de therapeutische werkzaarnheid van ceftazidime 
afnam als gevolg van vermindering van afweermechanismen in de vorm van een 
ernstige leukopenie. Deze afname in therapeutisch effect was opnieuw sterk 
afhankelijk van het doseringsschema, in die zin dat de afname slechts 
gering was wanneer ceftazidime via continu infuus werd toegediend, terwijl 
de effectiviteit drastisch verminderde bij intermitterende behandeling. Met 
andere woorden, het doseringsschema bleek in belangrijke mate bepalend te 
zijn voor de werkzaarnheid van ceftazidime, met name wanneer de weerstand 
van de gastheer verminderd is. De werkzaarnheid van ceftazidime bleek onder 
die omstandigheden voornamelijk afhankelijk van de permanente aanwezigheid 
van voldoende hoge antibioticumconcentraties in het serum gedurende de 
behandelingsperiode. Andere experimenten suggereren dat in de leukopenische 
gastheer behandeling met ceftazidime moet worden voortgezet totdat de 
circulerende leukocyten terugkeren. 
In hoofdstuk 5 wordt beschreven dat het belang van het doseringsschema als 
bepalende factor voor de therapeutische werkzaarnheid van het antibioticum 
in leukopenische ratten niet noodzakelijk van toepassing is op andere klas-
sen van antibiotica. Terwijl voor het therapeutisch effect van ceftazidime 
permanent aanwezige antibioticumconcentraties in serum belangrijker waren 
dan relatief hoge piekconcentraties met intervallen, had voor gentamicine 
en ciprofloxacin het doseringsschema geen belangrijke invloed op de effec-
tiviteit. Gentamicine was even effectief bij beide doseringswijzen, terwijl 
ciprofloxacin in geringe mate meer effectief was wanneer intermitterend 
toegediend. Aangezien de werkzaamheid van de diverse doseringsschema's werd 
geevalueerd aan de hand van totale dagdoses van antibiotica, suggereren de 
gegevens betreffende gentamicine en ciprofloxacin, dat een doseringsschema 
waarin relatief lange perioden van lage antibioticurn serumconcentraties 
toegestaan is, mits de piekconcentraties voldoende hoog zijn. De verschil-
len tussen de antibiotica met betrekking tot de invloed van het doserings-
schema op de werkzaarnheid komen overeen met hun verschillen betreffende de 
kinetiek van antibacteriele activiteit in vitro en in de ge:lnfecteerde 
longen van leukopenische ratten. De bactericide werking van ceftazidime was 
traag, maar ging door in de tijd en was niet sterk afhankelijk van de 
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gebruikte concentratie, c.q. dosis, ondanks dat piekconcentraties in serum 
na toediening van de gebruikte doseringen sterk uiteenliepen. Daarentegen 
was de bactericide werking van gentamicine en ciprofloxacin sterk, snel en 
gerelateerd aan de concentratie, c.q. de dosis. Deze waarnemingen kunnen 
een verklaring zijn voor het feit dat de beste therapeutische werkzaamheid 
van ceftazidime werd verkregen wanneer antibioticumconcetraties in serum 
blijvend aanwezig zijn. Relatief hoge concentraties dragen niet wezenlijk 
bij tot de effectiviteit van dit antibioticum. Daarentegen konden genta-
micine en ciprofloxacin als gevolg van hun sterke en dosisafhankelijke wer-
king intermitterend met relatief lange intervallen worden toegediend, zon-
der verlies aan effectiviteit. De therapeutische werkzaamheid van deze twee 
middelen werd voornamelijk bepaald door de totale toegediende dosis. 
Een andere factor die naast de kinetiek van de antibacteriele werking moge-
lijk relevant is voor de doseringsschema afhankelijke werking van anti-
biotica is het post-antibiotic effect (PAE). In deze studie echter werd in 
vitro geen PAE gevonden voor de gebruikte K.pneumoniae stam met ceftazidime, 
noch met gentamicine en ciprofloxacin (hoofdstuk 5). Overeenkomstig de in 
vitro gegevens werden in longen van leukopenische ratten geen verschillen 
in hergroei van bacterien gevonden na toediening van enkelvoudige doses van 
de verschillende antibiotica. De in vergelijking met in vitro tragere her-
groei van bacterien in de long is waarschijnlijk het gevolg van de aanwezig-
heid van lage antibioticumconcentraties onder de MIC-waarden. In het door 
ons gebruikte infectiemodel bleken verschillen in PAE niet bij te dragen tot 
de verschillen in doseringsschema-afhankelijke werkzaamheid gevonden voor 
ceftazidime, gentamicine en ciprofloxacin. 
In hoofdstuk 6 werd aangetoond dat enkelvoudige of meervoudige injecties 
met antibiotica niet in staat waren alle bacterien op de plaats van infectie 
te doden. Het aantal in de long overblijvende bacterien was afhankelijk van 
de gebruikte klasse van antibiotica en was voor gentamicine en ciprofloxacin 
bovendien afhankelijk van de toegediende dosis. Dat niet alle bacterien 
konden worden geelimineerd was niet het gevolg van onvoldoende concentraties 
van antibiotica op de plaats van infectie als gevolg van een snelle elimina-
tie. Bovendien bleken de overblijvende bacterien ook geen selectie van 
minder gevoelige bacterien te vertegenwoordigen. Waarschijnlijk zijn fac-
toren op de plaats van de infectie verantwoordelijk voor hetzij de vermin-
derde gevoeligheid van de bacterien, hetzij de verminderde activiteit van 
de antibiotica, factoren die echter ex vivo niet onderzocht kunnen worden. 
Het fei t dat verminderde bacteriele killing het gevolg was van locale 
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factoren werd bevestigd door de waarneming dat het aantal overblijvende 
bacterien toenam met toename van de duur van de infectie zoals aangetoond 
voor de 3 antibiotica van de 3 verschillende klassen. Overeenkomstig de 
waarnemingen met betrekking tot de antibacteriele activiteit in de long, 
nam de therapeutische werkzaamheid van ceftazidime en ciprofloxacin af als 
gevolg van uitstel van start van de behandeling. 
Een factor die van groot belang kan zijn voor de bactericide werking van 
een antibioticum in een gevestigde infectie is het vermogen om langzaam 
groeiende of niet-groeiende bacterien te doden. In de huidige studie werd 
het verschil in bacteriele groeisnelheid afhankelijke werking tussen cefta-
zidime en ciprofloxacin aangetoond zowel in vitro als in vivo in longen van 
leukopenische ratten. Terwijl ciprofloxacin in staat was bacterien te doden 
die zich niet actief vermenigvuldigen, was ceftazidime hiertoe niet in 
staat. Echter het vermogen van ciprofloxacin om in tegenstelling tot cefta-
zidime niet-delende bacterien te doden, bleek niet van groot belang te 
zijn voor de therapeutische werkzaamheid in het experimentele pneumanie/sep-
sis model, aangezien het therapeutisch effect van beide middelen in ongeveer 
dezelfde mate afnam in een gevestigde infectie. 
De experimentele studies met betrekking tot de invloed van het doserings-
schema op de therapeutische werkzaamheid van antibiotica in dieren met ver-
minderde afweer, zoals beschreven in di t proefschrift en de studies van 
andere onderzoekers, komen min of meer tot gelijkluidende conclusies, hoewel 
deze verschillen in o.a. keuze van infectiemodel en diersoort, van bacterie-
stam, van antibioticum, doseringsschema en parameter voor effectiviteit. 
Deze dierexperimentele gegevens zouden een basis kunnen vormen voor klinische 
onderzoek aangaande de antibioticum behandeling van ernstige infecties bij 
leukopenische patienten met betrekking tot de wijze van toediening, start 
en duur van de behandeling. 
In de kliniek worden B-lactam antibiotica over het algemeen intermitterend 
toegediend en, rekening houdend met hun eliminatie halfwaardetijd, in 
relatief hoge doseringen, resulterend in hoge piekconcentraties in serum 
zodat de spiegels niet onder de werkzame concentratie voor de meeste 
infectieverwekkers komen v66r de volgende dosis. De experimentele studies 
tonen aan dat voor succesvolle behandeling van infecties met B-lactam 
antibiotica, hoge piekconcentraties in het serum niet bijdragen tot het 
therapeutisch effect, zolang antibioticum concentraties op een bepaald 
niveau gehandhaafd blijven gedurende de behandelingsperiode. Deze resultaten 
suggereren dat lagere dagdoses van. B-lactam antibiotica gepermitteerd zijn, 
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mits ze meer frequent worden toegediend of B-lactams met een langere 
halfwaarde tijd, als gevolg van b.v. hoge eiwitbinding, worden gebruikt. 
Dit zou kunnen resulteren enerzijds in een verbeterde therapeutische 
werkzaamheid en anderzijds in een verlaging van de kosten van antimicro-
biele behandeling, aangezien de nieuwere B-lactam antibiotica relatief duur 
zijn. 
Aminoglycosiden worden in het algemeen intermitterend toegediend in doses, 
waarbij serum piekconcentraties geen toxiciteit tot gevolg hebben. Uit 
experimentele studies zijn geen aanwijzingen gevonden dat het doserings-
schema een bepalende factor is voor de werkzaamheid van deze antibiotica. 
Gezien het feit dat de bactericide werking van deze middelen sterk afhanke-
lijk is van piekconcentraties en bovendien erg snel is, lijkt intermitte-
rende toediening met relatief lange intervallen verantwoord, zonder dat de 
effectiviteit afneemt. In relatie tot de piekconcentratie-afhankelijke 
werking van deze middelen lijkt het bepalen van individuele doseringen van 
aminoglycosiden voor de patient van groat belang, niet alleen om toxiciteit 
te vermijden, maar oak uit het oogpunt van effectiviteit. Daarnaast zou 
moeten worden onderzocht of minder frequente toediening van hogere doses 
resulterend in relatief hoge serumconcentraties met relatief grate inter-
vallen even werkzaam of zelfs beter werkzaam is in de gastheer met vermin-
derde weerstand, en daarnaast leidt tot verlaging van toxiciteit. 
De nieuwere en recent geintroduceerde quinolonen worden intermitterend 
toegediend. Van de weinige thans beschikbare experimentele studies betref-
fende deze middelen, zijn er geen die aantonen dat het doseringsschema een 
belangrijke determinant is voor de therapeutische werkzaamheid. De sterke 
en dosisafhankelijke bactericide werking van deze middelen suggereert dat 
intermitterende toediening ervan de meest geschikte is. 
Met betrekking tot de start van de antimicrobiele behandeling onderstrepen 
de experimentele gegevens van deze studie verkregen voor de drie antibio-
tica het belang om antibioticumbehandeling zo vroeg mogelijk te beginnen, 
ongeacht de klasse van het antibioticum. Reden hiervan is dat het aantal 
bacterien dat overblijft in het geinfecteerde weefsel na de toediening van 
antibioticum toeneemt met toename van de duur van de infectie. Het gebruik 
van sterk bactericide middelen kan hierbij een voordeel zijn. Uit de resul-
taten worden geen aanwijzingen verkregen dat het vermogen van een antibio-
ticum om niet- of langzaam groeiende bacterien te doden belangrijk is voor 
het resultaat van de behandeling. 
Met betrekking tot de duur van de antibioticumbehandeling in relatie tot de 
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duur van de leukopenie, suggereren de experimentele gegevens verkregen voor 
ceftazidime dat de behandeling moet worden voortgezet totdat de circule-
rende leukocyten terugkeren. 
Naast de klinische implicaties met betrekking tot de behandeling van pa-
tienten, kunnen deze experimentele studies ook van belang zijn voor de 
bepalingsmethoden van gevoeligheid van bacterien voor antibiotica in vitro. 
De huidige experimentele studie laat zien dat ondanks gelijke MIC/MBC-waar-
den, antibiotica van verschillende klassen aanzienlijk kunnen verschillen 
ten aanzien van hun bactericide werking op korte termijn. De therapeutische 
werkzaamheid van antibiotica op verschillende wijze gedoseerd, bleek goed 
te correleren met de bactericide werking op korte termijn, maar niet met de 
MIC/MBC-waarden als in vitro parameter. Met andere woorden bet bepalen van 
de bactericide werking op korte termijn verdient de voorkeur bij bet 
vergelijken van de antimicrobiele activiteit van verschillende antibiotica. 
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APPENDIX PAPER I 
THERAPEUTIC EFFICACY OF CONTINUOUS VERSUS INTERMITTENT ADMINISTRATION OF 
CEFTAZIDIME IN AN EXPERIMENTAL KLEBSIELLA PNEUMONIAE PNEUMONIA IN RATS* 
Robert Roosendaal, I. A. J. M. Bakker-Woudenberg, J. C. van den Berg, and 
M.F. Michel 
ABSTRACT 
An experimental Klebsiella pneumoniae pneumonia in rats was used to study 
the influence of continuous or of intermittent (8-hr intervals) administra-
tion of ceftazidime on therapeutic efficacy. Antimicrobial response was 
evaluated with respect to the calculated total daily dose that protected 
50% of the animals from death (PDsol until 16 days after termination of a 
four-day treatment. When antibiotic treatment was started 5 hr after 
bacterial inoculation, the PDso values after continuous and after inter-
mittent administration of ceftazidime were 0. 36 and 1 . 42 mg/kg per day, 
respectively (P <.001). With a delay in the administration of the antibio-
tic to 34 hr after inoculation, the respective PD50 values were 1. 08 and 
13.06 mg of ceftazidime/kg/per day (P <.001). These studies show an 
improved therapeutic efficacy that increased with a delay in treatment when 
ceftazidime was administered by continuous infusion as compared with 
administration at 8-hr intervals. Continuous administration of PDso doses 
of ceftazidime resulted in serum levels that were constantly below the MIC 
of the infecting Klebsiella strain. 
INTRODUCTION 
Various aspects of the use of continuous vs. intermittent administration of 
antibiotics have been studied by a number of investigators [ 1-7]. Most 
antibiotic dose schedules are empirical [8-9]. Antibiotic serum levels 
*The Journal of Infectious Diseases (1985) 152:373-378. Reprinted with 
permission. [Data related to the dosage of ceftazidime at 6-h intervals 
have been added to tables 1 and 2]. 
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obtained after administration of the drug in relation to the MIC of the 
infecting strain form the basis for the development of dose regimens in 
most cases. In the past few years more attention has been directed to 
pharmacokinetic parameters of antimicrobial agents. Some studies deal with 
the effect of the mode of drug administration on the penetration of the 
extravascular compartment [2, 3, 5]. Only a few experimental infections 
and clinical trials deal with the efficacy of continuous or intermittent 
administration of antibiotics. These studies do not show a better 
therapeutic efficacy with either mode of administration [1, 4, 6, 7]. 
The present study was undertaken to investigate the in vivo activity of 
ceftazidime when administered intermittently i.m. or when administered by 
continuous infusion against experimentally induced Klebsiella pneumoniae 
pneumonia in rats. Treatment was started either 5 hr or 34 hr after 
bacterial inoculation in order to study whether the severity of infection 
resulting in tissue necrosis had an effect on the outcome of antibiotic 
treatment. The experimental model was selected because pneumonia and 
septicemia caused by K.pneumoniae and by other gram-negative bacilli are a 
major problem in patients undergoing anticancer chemotherapy [10-12]. 
MATERIALS AND METHODS 
Animals. Female R strain albino rats (specific-pathogen free; bred at the 
Laboratory Animals Centre of Erasmus University Rotterdam) were used in all 
experiments. These rats were 14-18 weeks old and weighed 185-215 g. 
Bacteria. A K.pneumoniae strain (capsular serotype 2) was used in these 
experiments. Inocula were prepared as previously described [13]. 
Pneumonia. Experimental pneumonia was produced as previously described by 
Bakker-Woudenberg [ 13] . In brief, rats were anesthetized with fluanisone 
(HypnormR; Duphar, Amsterdam, The Netherlands) and pentobarbital (Abbott 
Laboratories; Ceva, Paris). The left main-stem bronchus was intubated and 
the left lung was inoculated with 0. 02 ml of a saline suspension of 
K.pneumoniae containing 8 x 104 (6 x 104-10 x 104) cfu. Determination of 
the number of viable organisms in the left lung and in the blood, the 
method of obtaining pleural fluid for culture, and the course of untreated 
infection have been described earlier [13]. In brief, infection developed 
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within 24 hr and increased in severity afterwards. Animals died spontaneous-
ly, a mean of 5.1 ± 1.3 days (mean± SD; group of 10 rats) after inocula-
tion. The number of cfu in the left lung increased and on day 5 an average 
of 2. 1 01 0 cfu was reached. With the progression of the infection, an 
increasing number of animals had bacteria in blood and in pleural fluid. 
Histology. The histological features of the pneumonic lesions were studied 
at 5 hr and 34 hr after infection by the following method. Lungs were fixed 
by injecting the trachea with 10% formalin under constant pressure (to 
reexpand the lungs). Segments of the left lung were then dehydrated in 
ethanol and toluol, embedded in paraffin, sectioned, and stained with 
hematoxylin-eosin or by the gram-stain technique. 
Antimicrobial susceptibility test. Ceftazidime (Glaxo Laboratories, 
Greenford, Middlesex, England) was used in the experiments. The MIC of the 
drug defined as the lowest concentration that suppressed visible growth 
after inoculation of an inoculum of 105 cfu/ml for 18 hr at 37°C in tubes 
containing 4 ml of Todd-Hewitt broth (Oxoid Basingstoke, Hants, England) 
[ 14], was 0. 2 ]lg/ml. The MBC, defined as the lowest concentration that 
reduced the number of organisms in the 18-hr culture to fewer than 
50 cfu/ml [14], was 0.2 ]lg/ml. 
Antimicrobial treatment. Ceftazidime was administered either as intermit-
tent bolus injections or as continuous infusions over a period of four 
days. Treatment was started 5 hr or 34 hr after bacterial inoculation. 
Twofold increasing doses were administered, each dose to a group of ten 
rats. Intermittent injections were administered into the thigh muscles of 
the rear legs at 8-hr intervals. Because iv-infusion techniques did not 
function properly over such a long period of time, an alternative technique 
developed by Thonus et al. [15] was used. In brief, six weeks before its 
use, a tissue cage constructed of perforated teflon (length, 40 mm; outer 
diameter, 7 mm; inner diameter, 5 mm; 30% perforation) and connected with a 
50-mm polyethylene tube, was implanted sc. All junctions were sealed with 
silicone adhesive. Before the start of antibiotic treatment, animals were 
anesthetized with fluanisone and pentobarbital. The distal portion of the 
polyethylene tube was recovered through an incision in the neck of the 
animal and was connected, by means of a polyethylene tube and a swivel, to 
a 12-ml syringe. This syringe was placed on a varifusor pump (Breda 
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Scientific, Breda, The Netherlands). Ceftazidime, at the required 
concentration, was infused at a constant rate of 0.116 ml/hr. With this 
technique, prolonged, steady state levels were reached within 3 hr after 
the start of the infusion. These levels were 0.031 }.lg/ml (range, 0.024-
0.043) and 0.073 }.lg/ml (range, 0.059-0.086) after administration of Po50 
doses obtained after the start of treatment that was begun 5 hr and 34 hr 
after infection. 
Therapeutic results. Therapeutic activity was evaluated with respect to 
the calculated daily dose that protected 50% of the animals from death 
(median protective dose, PD50 ). Po50 values were calculated according to 
the method of Spearman-Karber (see Sachs [16]). Deaths were recorded daily 
for 16 days after the termination of antimicrobial treatment. After that 
time no change in death rate occurred. The left lung from each rat died was 
cultured to check for the presence of only K.pneumoniae. Only K.pneumoniae 
organisms were recovered from the lungs of both treated and untreated 
animals. 
Measurement of antibiotic concentrations in serum. Blood specimens 
obtained by orbital puncture under light ether anesthesia were collected 
from each rat and serum was separated. With use of a diagnostic-sensitivity 
agar (Oxoid) and an Escherichia coli test strain susceptible to 0.2 }.lg of 
ceftazidime/ml, all tests were done according to a standard large-plate 
agar diffusion procedure [17]. For determination of ceftazidime concentra-
tions above 0.2 v.g/ml, 100-v.l samples were assayed. For determination of 
concentrations below 0.2 }.lg/ml, some modifications were introduced in order 
to increase the sensitivity of the test. We applied 225-lll samples to metal 
rings (internal diameter, 6 mm) placed on the agar. To nine parts of each 
sample and of each standard concentration, one part of a solution of 0.8 }.lg 
of ceftazidime/ml of serum was added. Correlation coefficients of the 
calculated regression lines were >0.99 in all determinations. Determination 
of samples with known concentrations of ceftazidime in serum with both the 
modified and the original method yielded similar results. 
RESULTS 
Course of the untreated infection. At 5 hr after inoculation, the number 
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of organisms in the left lung had increased up to sevenfold. Blood and 
pleural fluid were sterile. Histological studies of the pulmonary lesion at 
that time revealed no signs of tissue necrosis. A moderate number of PMNLs 
and a few macrophages were observed at the site of infection. 
Thirty-four hours after bacterial inoculation, an average of 2 x 1 o8 
organisms were found in the left lung. One of 10 rats had bacteria in the 
blood (80 cfu/ml) and in the pleural fluid. The histological features of 
the pneumonic lesion were described earlier [13]. In brief, large numbers 
of PMNLs and gram-negative bacilli and a few macrophages were observed in 
the lesion. Tissue necrosis had occurred to some extent. 
Response to ceftazidime treatment. After both intermittent and continuous 
administration of ceftazidime, the number of surviving animals increased 
with increasing total daily doses. In a similar way the mean time of death 
of the animals increased (table 1). 
When ceftazidime treatments were started 5 hr after bacterial inoculation, 
the Po50 values obtained for continuous and intermittent administration of 
the antibiotic were 0.36 and 1.42 mg/kg per day, respectively (P <.001). 
With a delay in administration of the drug to 34 hr after inoculation, the 
difference in efficacy of continuous and of intermittent administration 
increased. PD5o values were 1.08 and 13.06 mg of ceftazidime/kg per day, 
respectively (P <.001). 
The mean time to death recorded with almost all continuous treatment 
schedules (started either 5 hr or at 34 hr) was prolonged, although not 
significantly, when compared with the mean time to death obtained with the 
same total daily doses given at 8-hr intervals. 
Multiple colonies of K.pneumoniae isolates were recovered from the lungs of 
rats that died of survived after antibiotic treatment. The MBC values of 
these isolates for ceftazidime were not different from the MBC value of the 
parent strain. 
Concentration of ceftazidime in serum. The concentrations of ceftazidime 
in the sera of uninfected rats after ·administration of Po50 doses obtained 
for the intermittent and the continuous treatment schedules are shown in 
tables 2 and 3. Serum concentrations of ceftazidime in infected rats are 
not significantly different from those in uninfected rats treated with 
similar doses. The serum concentrations at various intervals after 
administration of 0.47 or 4.35 mg of ceftazidime/kg (doses corresponding to 
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the Po50 daily doses of 1.42 and 13.06 mg of ceftazidime/kg administered at 
8-hr intervals) are shown in table 2. Peak concentrations were 1.32 ~g/ml 
(for the 0.47-mg dose) and 14.17 ~g/ml (for the 4.35-mg dose). Ceftazidime 
concentrations in excess of 0.2 ~g/ml (the MBC for the Klebsiella strain 
used) were present for 75 and 120 min at the respective doses. The 
concent;rations in serum at various intervals after starting continuous 
infusion of the Po50 doses of 0.36 and 1.08 mg of ceftazidime/kg per day 
are shown in table 3. Steady-state levels were reached within 3 hr after 
the start of the infusion. These levels corresponded to 0.032 ~g/ml (range, 
0.024-0.043) and 0.073 ~g/ml (range, 0.059-0.086) at the respective doses. 
DISCUSSION 
Few clinical data are available about the influence of continuous or 
intermittent dosage of antibiotics on the therapeutic efficacy in the 
treatment of serious infections. Bodey [4] showed that carbenicillin plus 
continuously infused cefamandole was more effective in the treatment of 
neutropenic cancer patients with gram-negative bacillary infections than 
was carbenicillin plus the same dose of cefamandole injected intermittent-
ly. 
Some investigators studied the influence of continuous or intermittent 
administration of antibiotics on the therapeutic efficacy in experimental 
infections. Sande et al. [7] showed that the time needed to sterilize the 
CSF in a rabbit model of pneumococcal meningitis was the same for both 
intermittent and continuous administration of penicillin. The conclusion 
derived from this study should be considered with caution, however, because 
both treatment schedules were compared at only one equivalent dose. A 
previous study in our laboratory [1] using rats with pneumonia caused by 
Streptococcus pneumoniae demonstrated that sterilization of lungs with 
penicillin administered either on a 12-hr schedule or continuously infused 
was equally effective, provided that host defenses were intact. Contrary to 
our earlier study, this study in rats with pneumonia caused by K.pneumoniae 
demonstrates that in terms of Po50 doses, continuous infusion of cefta-
zidime resulted in greater efficacy than did intermittent injections. 
Powell et al. [ 6] used a model of acute pneumonia due to Pseudomonas 
aeruginosa in guinea pigs and observed a better response to a once-daily 
dosing regimen of tobramycin when compared with continuous infusion of this 
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drug. Chronic pneumonia in rats and endocarditis in rabbits due to the same 
organism responded equally to both regimens [6]. The discrepancies between 
these in vivo studies may be explained by the postantibiotic effect that 
was demonstrated in vitro by Bundtzen et al. [18]. They demonstrated that 
the effect of B-lactam antibiotics on several gram-negative organisms in 
vitro persisted for a much shorter time than did the effect on a number of 
gram-positive organisms [18]. In addition the action of an aminoglycoside 
on P.aeruginosa showed a clear postantibiotic effect that may have 
contributed to the therapeutic efficacy of the widely spaced doses in the 
experiments of Powell et al. [6]. 
The effect of the mode of antibiotic administration on tissue penetration 
may provide a further explanation for the difference in efficacy between 
intermittent and continuous treatment. Investigations dealing with this 
subject produce somewhat contradictory results [2, 3, 5]. Experiments of 
Peterson et al. [5] showed that with a given amount of antibiotic, inter-
mittent administration is advantageous at an early stage but that eventual-
ly, in equilibrium conditions at 26 hr, the constant drug infusion led to 
higher extravascular levels.' These experiments were performed in uninfected 
animals. Nevertheless, the experiments of Peterson et al. are in agreement 
with our observations that continuous administration of ceftazidime was 
more effective than was intermittent treatment. 
We found that administration of PDso doses by continuous infusion resulted 
in serum levels of antibiotic that were constantly below the MIC of the 
infecting Klebsiella strain. Several authors studied the in vivo efficacy 
of sub-MIC concentrations in experimental infections. Zak et al. [ 19], 
Comber et al. [20], and Merrik and Rolinson [21] found that treatment of 
experimental infections due to lethal numbers of different gram-negative 
organisms with B-lactam antibiotics and aminoglycosides resulted in 
substantial survival rates, despite antibiotic serum levels that never 
reached the MIC of the infecting strain. Also, in our study, steady-state 
serum levels of ceftazidime below the MIC of the Klebsiella strain used 
were therapeutically active. Ceftazidime concentrations of 0.032 ~g/ml or 
0.073 ~g/ml in serum protected 50% of the animals from death when treatment 
was started 5 hr and 34 hr after inoculation, respectively. The MIC of the 
Klebsiella strain was 0.2 ~g of ceftazidime/ml. 
A possible explanation for the therapeutic efficacy of sub-MIC concentra-
tions of antibiotics in vivo may be found in data derived from in vitro 
experiments. Effects of sub-MIC concentrations of B-lactam antibiotics on 
117 
growth rate and morphology 
organisms) were demonstrated 
(including 
[22-24]. 
filamentation of 
The main effect 
gram-negative 
of antibiotic 
concentrations below the MIC may be reduction of bacterial growth, as 
suggested by Atkinson and Amaral [22] and Lorian [25]. In addition, the 
effects of low antibiotic concentrations on the susceptibility of bacteria 
to host defense mechanisms - in particular the phagocytosis process - have 
been widely investigated. The effects of low antibiotic concentrations of 
the action of host defense mechanisms have also been investigated. The 
results are to a large extent, however, controversial [22, 26]. 
From our studies we conclude that in normal rats ceftazidime given by 
continuous infusion resulted in a better therapeutic response to 
K.pneumoniae pneumonia than did administration of the antibiotic at 8-hr 
intervals. 
Although the clinical relevance of our findings in animals is highly 
speculative, one might at least envisage the possibility that certain 
patients, suffering from severe infections due to gram-negative bacteria, 
may get additional benefit from an antibiotic like ceftazidime when it is 
administered continuously. Moreover, the ratio of serum level to MIC 
required for curing the infection may be less important for determining 
dosage if the levels are maintained at a steady state rather than 
fluctuating. 
In further experiments the role of the dose and the administration schedule 
of antibiotics will be studied in neutropenic rats. 
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APPENDIX PAPER II 
CONTINUOUS VERSUS INTERMITTENT ADMINISTRATION OF CEFTAZIDIME IN EXPEI:UliFNl'AL 
KLEBSIELLA PNEUMONIAE PNEUMONIA IN NORMAL AND LEUKOPENIC RATS* 
Robert Roosendaal, Irma A.J.M. Bakker-Woudenberg, Marion van den Berghe-van 
Raffe, and Marc F. Michel 
ABSTRACT 
Experimental Klebsiella pneumoniae pneumonia was used to study the influence 
of cyclophosphamide-induced leukopenia on the relative therapeutic efficacy 
of continuous and intermittent (6-h intervals) administration of ceftazidime. 
The antimicrobial response was evaluated with respect to the calculated 
daily dose that protected 50% of the animals from death (PDsol until 16 days 
after the termination of a 4-day treatment. When ceftazidime was administered 
intermittently to leukopenic rats, the PD50 was 24.37 mg/kg per day, 70 times 
(P <0.001) the PDso of 0.35 mg/kg per day for normal rats. Continuous 
administration of ceftazidime to leukopenic rats resulted in a PDso of 
1.5 mg/kg per day, four times (P <0.001) the PD50 of 0.36 mg/kg per day for 
normal rats. Continuous administration of ceftazidime in daily doses that 
protected 100% of normal and leukopenic rats from death resulted in serum 
levels of 0.06 and 0.38 ~g/ml, respectively, whereas the MIC for the infecting 
K.pneumoniae strain was 0.2 ~g of ceftazidime per ml. The effect of the 
duration of ceftazidime treatment by continuous infusion on the therapeutic 
efficacy in relation to the persistence of leukopenia was then investigated 
in leukopenic rats. The administration of 3.75 mg of ceftazidime/kg per day 
for 4 days protected all leukopenic rats from death, provided the circulating 
leukocytes returned at the end of antibiotic treatment. When leukopenia 
persisted for 8 days this ceftazidime treatment schedule resulted in the 
mortality of rats (P <0.05). However, when ceftazidime treatment was continued 
for 8 days, until the return of the leukocytes, there was no significant 
mortality (P >0.05). 
*Antimicrobial Agents and Chemotherapy (1986) 30:403-408. Reprinted with 
permission. [Data with respect to the concentrations of ceftazidime in serum 
after administration of PDso doses (tables 6 and 7) have been added.] 
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INTRODUCTION 
Infections caused by gram-negative bacilli constitute a serious problem in 
patients with underlying malignant disease [ 9] . Few clinical data are 
available about the therapeutic efficacy of continuous or intermittent 
administration of B-lactam antibiotics in the treatment of serious infec-
tions. Bodey et al. demonstrated that carbenicillin plus continuously 
infused cefamandole was more effective in the treatment of neutropenic 
cancer patients with gram-negative bacillary-infections than was carbeni-
cillin plus the same dose of cefamandole injected intermittently [4]. There 
is limited experimental work on the effect of antibiotic drug schedules on 
therapeutic efficacy in animal infections. As will be discussed later, 
these studies have yielded somewhat contradictory results. 
The present study was undertaken first to evaluate the activity of ceftazi-
dime administered intermittently at 6-h intervals or by continuous infusion 
against experimentally induced Klebsiella pneumoniae pneumonia in normal 
and leukopenic rats. This model was selected because pneumonia and 
septicemia caused by K.pneumoniae and other gram-negative bacilli are often 
difficult to treat in patients undergoing intensive anticancer chemotherapy 
[9, 21]. Second, we studied whether antibiotic treatment should be 
continued during the persistence of leukopenia in leukopenic rats with 
K.pneumoniae pneumonia. 
MATERIALS AND METHODS 
Animals. Female R strain albino rats (specific pathogen free; 1 4 to 18 
weeks old; weight, 185 to 215 g; bred at REPGO-TNO, Rijswijk, The Nether-
lands) were used in al experiments. 
Bacteria. A capsular serotype 2 K.pneumoniae strain was used in these 
experiments. Inocula were prepared as described previously [2]. 
Antimicrobial susceptibility test. Ceftazidime ( Glaxo Pharmaceuticals, 
Ltd., Greenford, England) was used in the experiments. The MIC of the drug 
was defined as the lowest concentration that suppressed visible growth after 
incubation of an inoculum of 5 x 1 o5 CFU/ml for 18 h at 37°C in tubes 
containing 4 ml of Todd-Hewitt broth (Oxoid Ltd., London, England). The MBC 
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was defined as the lowest concentration that killed 99.9% of the original 
inoculum. The MBC was determined by spreading subculture volumes of 0.01 ml 
onto Iso-Sensitest Agar (Oxoid) plates. The concentrations of the serial 
dilutions decreased by steps of 0.2 ~g/ml. The MIC and MBC of ceftazidime 
for the K.pneumoniae strain were both 0.2 ~g/ml. 
Induction of leukopenia. Leukopenia was induced by intraperitoneal injec-
tions of cyclophosphamide (CY) (Koch-Light Limited, Haverhill, England) in 
two doses of 90 and 60 mg/kg at 5 days and day before bacterial inocula-
tion, respectively. In some experiments, a third dose of 60 mg/kg was 
administered at 4 days after bacterial inoculation. 
Quantitation of blood leukocytes. Blood samples obtained by orbital 
puncture under light co2 anesthesia from at least five rats were collected 
in plastic vials containing 1 mg of disodium EDTA per ml. For total leuko-
cyte counts, blood was diluted 1:10 with Tiirk solution (0.1% crystal 
violet in 1% acetic acid) , and numbers of leukocytes were determined in 
duplicate in a Biirkers hemacytometer. The total numbers of granulocytes and 
monocytes were calculated from the total number of leukocytes and differen-
tial counts of 400 leukocytes in cytocentrifuge preparations of buffy coats 
obtained by centrifugation of blood samples for 10 min at 1, 500 x g in 
hematocrit tubes. 
Effect of CY on the growth of K.pneumoniae in vitro. Blood specimens were 
collected from rats before treatment with CY and at 15 min and 1 day after 
the second CY injection, and serum was separated. Pooled serum from three 
rats was used. The effect of rat serum on the in vitro growth of 
K.pneumoniae was determined as follows. A stationary-phase culture which 
had been incubated for 16 h at 37°C was diluted in Iso-Sensitest broth 
(Oxoid) to a concentration of 2 x 1 o6 CFU/ml and reincubated for 2 h at 
37°C. An inoculum of 5 x 105 CFU/ml was incubated in Hanks balanced salt 
solution (Oxoid) with 90% serum at 37°C. The numbers of viable organisms 
were then determined at regular intervals over a 3-h period by plate counts 
on Iso-Sensitest agar. 
Pneumonia. Experimental pneumonia was produced as described previously by 
Bakker-Woudenberg et al. [2]. In brief, rats were anesthetized with fluani-
sone (Hypnorm; Duphar B.V., Amsterdam, The Netherlands) and pentobarbital 
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(Abbott Laboratories, North Chicago, Ill.). The left-main-stem bronchus was 
intubated, and the left lung was inoculated with 0. 02 ml of a saline 
suspension of K.pneumoniae containing 8 x 104 (6 x 104 to 10 x 104) CFU. 
After bacterial inoculation, the narcotic antagonists nalorphine bromide 
and pentetrazolum (Onderlinge Pharmaceutische Groothandel, Utrecht, The 
Netherlands) were injected. The numbers of viable organisms in the left 
lung, blood, and pleural fluid were determined as described earlier [2]. 
Histology. The histological features of the pneumonic lesions were studied 
in groups of two rats each at 2 days after bacterial inoculation of normal 
rat~ and CY-treated rats. Lungs were fixed by injecting the trachea with 
10% Formalin under constant pressure to reexpand the lungs. Segments of the 
left lung were then dehydrated in ethanol and toluol, embedded in paraffin, 
sectioned, and stained with haematoxylin-eosin or by the Gram stain 
technique. 
Antimicrobial treatment. Ceftazidime was administered either as intermit-
tent bolus injections over 4 days or as continuous infusions over either 4 
or 8 days. Treatment was started 5 h after bacterial inoculation. Twofold 
increasing doses of ceftazidime were administered, each dose to a group of 
10 rats. Intermittent injections were administered into the thigh muscles 
of the rear legs at 6-h intervals. Because intravenous infusion techniques 
did not function properly over such a long period, an alternative technique 
developed by Thonus et al. [22] was used. In brief, 6 weeks prior to its 
use, a tissue cage constructed from perforated Teflon (length, 40 mm; outer 
diameter, 7 mm; inner diameter, 5 mm; 30% perforation) connected to 50 mm 
of polyethylene tubing was implanted subcutaneously. Rats were anesthetized 
prior to treatment with antibiotics. The distal portion of the polyethylene 
tube was recovered via an incision in the neck of the animal and connected 
via a polyethylene tube and a swivel to a 12-ml syringe. This syringe was 
placed on a Varifusor pump (Breda Scientific, Breda, The Netherlands). 
Ceftazidime at the required concentration was infused at a constant rate of 
0.113 ml/h. By this technique, prolonged steady-state serum levels were 
reached within 5 h after the start of infusion. 
Therapeutic results. The response to antimicrobial treatment was evaluated 
with respect to the calculated daily dose that protected 50% of the animals 
from death (median protective dose, Po50 ). Po50s were calculated by the 
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method of Spearman-Karber as described by Sachs [ 18] . The effect of the 
duration of antimicrobial treatment on therapeutic efficacy was evaluated 
by comparing mortality rates obtained for the different treatment groups by 
the Fisher test. In all experiment, deaths of rats were recorded daily 
until 16 days after the termination of antimicrobial treatment. After that 
time, no changes in death rates occurred. The left lung of each rat that 
died was cultured to check for the presence of K.pneumoniae. Only 
K.pneumoniae was recovered from lungs of both treated and untreated animals. 
Measurement of antibiotic concentrations in serum. Blood specimens obtained 
by orbital puncture under light ether anesthesia were collected from each 
rat, and serum was separated. All tests were done by a standard large-plate 
agar diffusion procedure with diagnostic sensitivity test agar (Oxoid) and 
an Escherichia coli test strain susceptible to 0.2 ~g of ceftazidime per ml 
(3). For the determination of ceftazidime concentrations above 0.2 ~g/ml, 
100-~1 samples were assayed, for the determination of concentrations below 
0.2 ~g/ml, some modifications were introduced to increase the sensitivity 
of the test. We applied 225-~1 samples to metal rings (internal diameter, 
6 mm) placed on the agar. To nine parts of each sample and of each standard 
concentration of ceftazidime, one part of a solution of 1 ~g of ceftazidime 
per ml of serum was added. Correlation coefficients of the calculated 
regression lines were >0. 99 in all determinations. The determination of 
drug concentrations of samples with known concentrations of ceftazidime in 
serum by both the modified and original methods yielded similar results. 
RESULTS 
Effect of CY on the number of peripheral blood leukocytes. CY treatment at 
two doses of 90 and 60 mg/kg with a 4-day interval resulted in a sub-
stantial reduction in the number of blood granulocytes and monocytes to 
less than 100 and 30/mm3, respectively, 5 days after the first CY injection 
(Fig. 1). At that time rats were inoculated with K.pneumoniae. Granulocyto-
penia and monocytopenia continued for 4 days, with a return of circulating 
granulocytes and monocytes between 4 and 6. A third CY injection of 60 mg/kg 
given at day 4 resulted in a prolongation of granulocytopenia and monocyto-
penia until day 8 (Fig. 2) . The numbers of circulating granulocytes and 
monocytes in CY-treated, infected rats 1 and 4 days after bacterial inocula-
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Figure 1 Total granulocyte (--) and monocyte (---) counts following 
CY injections given intraperitoneally 5 days (90 mg/kg) and 1 day (60 mg/kg) 
before infection on day 0. 
Each value represents the mean ± SD for five rats. 
tion were not significantly different from those in CY-treated uninfected 
rats. 
Effect of CY on the growth of K.pneumoniae in vitro. Rat sera from normal 
rats at a concentration of 90% had no effect on the growth of K.pneumoniae 
in broth. Rat sera obtained from CY-treated rats either 15 min or 1 day 
after the second CY injection did not affect bacterial growth either. 
Effect of CY treatment on the course of K.pneumoniae pneumonia. The course 
of K.pneumoniae pneumonia in CY-treated rats was more severe than that in 
normal rats (table 1). The increase in the numbers of K.pneumoniae in the 
left lung during the first 5 h after inoculation was similar to both CY-
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Figure 2 Total granulocyte (---) and monocyte ( ---) counts following 
CY injections given intraperitoneally 5 days before (90 mg/kg), day 
before (60 mg/kg), and 4 days after (60 mg/kg) infection on day 0. 
Each value represents the mean ± SD for five rats. 
treated and untreated rats. From that time the numbers of K.pneumoniae in 
the left lung increased more rapidly in leukopenic rats than in normal 
rats. By 34 h an average number of 5 x 108 CFU was cultured from the left 
lung of both leukopenic and normal rats. At 24 h after inoculation 
K.pneumoniae was cultured from the blood of all leukopenic rats, whereas 
the blood of all normal rats was sterile. At 29 and 34 h after inoculation 
about half of the leukopenic rats had bacteria in the pleural fluid, 
whereas the pleural fluid of all normal rats was sterile. The mean time to 
death ± standard deviation (SD) recorded for CY-treated rats was 2.3 ± 0.3 
days, compared with 5.1 ± 1.3 days for normal rats. Histological studies at 
2 days after bacterial inoculation revealed that large numbers of gram-
negative bacteria, polymorphonuclear leukocytes, and a few macrophages were 
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present in the left lung of normal rats. Lungs of leukopenic animals did 
not show any substantial cellular infiltrate at the site of infection, 
whereas large numbers of gram-negative bacteria were present. 
Therapeutic efficacy of ceftazidime in normal and CY-treated rats. After 
both intermittent and continuous administration of ceftazidime, the number 
of surviving animals (both normal and CY-treated rats) increased with 
increasing total daily doses. In normal and leukopenic rats treated by 
continuous infusion, the mean time to death increased in a similar way 
(table 2). In normal rats intermittent administration and continuous 
administration of ceftazidime were equally effective, in terms of Po50s 
being 0.35 and 0.36 mg/kg per day for the respective treatment schedules 
(P >0.05). On the contrary, in leukopenic rats continuous administration of 
ceftazidime was significantly superior to administration at 6-h intervals, 
PD50s being 1.52 and 24.37 mg/kg per day, respectively (P <0.01). Compared 
to the PD5os in normal rats, the PD50s in leukopenic rats had to be 
increased 70-fold when ceftazidime was administered at 6-h intervals and 
4-fold when ceftazidime was administered by continuous infusion. 
Efficacy of ceftazidime treatment of various durations in relation to the 
persistence of leukopenia. A total daily dose of 3.75 mg of ceftazidime 
per kg administered by continuous infusion over a period of 4 days cured 
all rats that were leukopenic for 4 days, with a return of circulating 
leukocytes at the end of antibiotic treatment (day 4) (table 2). This 
ceftazidime treatment schedule was not successful in rats with leukopenic 
persisting for 8 days, resulting in the mortality of rats (P <0.05) 
(table 3). However, the survival rate increased, although not significant-
ly, when ceftazidime treatment was continued until the return of circula-
ting leukocytes (day 8). The survival rates of rats treated with cefta-
zidime during a leukopenic period of either 4 or 8 days were not 
significantly (P >0.05) different. 
Concentrations of ceftazidime in serum. The concentrations of ceftazidime 
in sera of infected rats at various intervals after administration of 0.94 
and 15 mg/kg (doses corresponding to the Po100s [daily doses that protected 
100% of the animals from death] of 3.75 and 60 mg/kg administered at 6-h 
intervals to normal and leukopenic rats, respectively) are shown in table 4. 
Peak concentrations were 2.16 and 23.81 ~g/ml, respectively. Ceftazidime 
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Table 3 Efficacy of ceftazidime treatmenta of various durations in relation 
to the persistence of leukopenia 
Persistence of Duration of 
leukopenia treatment 
(days) (days) 
4c 4 
ad 4 
ad 8 
No. of 
survivors 
10 
3 
7 
Time to 
death 
(days)b 
7.3 ± 1.0 
8. 0 ± 1. 0 
aTo groups of 1 0 rats each 3. 75 mg of ceftazidime per kg per day was 
administered by continuous infusion (infusion rate, 0.113 ml/h). Treatment 
was started 5 h after inoculation of the left lung with 8 x 104 CFU of 
K.pneumoniae. 
~ean ± SD; based on the time of bacterial inoculation (day 0). 
Ccy was administered intraperitoneally in two doses of 90 and 60 mg/kg at 
5 days and 1 day before bacterial inoculation, respectively. 
dey was administered intraperitoneally in three doses of 90, 60 and 60 mg/kg 
at 5 days before, 1 day before, and 4 days after bacterial inoculation, 
respectively. 
concentrations in excess of 0.2 ~g/ml, the MBC for the K.pneumoniae strain 
used, were present for about 90 and 190 min at the respective doses. The 
concentrations of ceftazidime in sera of infected rats at various intervals 
after the start of continuous infusions of 0.94 and 3.75 mg/kg per day (the 
PD100s obtained for normal and leukopenic rats, respectively) are shown in 
table 5. Steady-state levels in serum were 0.06 (SD, ± 0.03) and 0.38 (SD, 
± 0.12) ~g of ceftazidime per ml, respectively. 
DISCUSSION 
Gram-negative bacillary infections are often difficult to treat in granulo-
cytopenic cancer patients [21]. Most antibiotic dose schedules are empiric. 
Dose regimens are mostly based on achievable antibiotic levels in serum in 
relation to the MIC for the infecting strain [ 1 0, 13] . The number of 
clinical studies dealing with the effect of antibiotic dose schedules on 
therapeutic efficacy in the treatment of infections in immunosuppressed 
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Table 5 Concentrations of ceftazidime in serum at various intervals after 
continuous administration (infusion rate, 0.113 ml/h) of PD1oos to 
infected normal and leukopenic rats 
Dose (mg/kg 
per day) 
0.94 
3.75 
Drug concn 
5 
0.08 ± 0.05 
0.37 ± 0.10 
(Jlg/ml of serum)a at the 
times (h) after dosage: 
24 
0.06 ± 0.02 
0.38 ± 0.15 
aEach value represents the mean ± SD for five rats. 
following 
48 
0.05 ± 0.02 
0.40 ± 0.07 
Table 6 Concentrations of ceftazidime in serum at various intervals after 
intramuscular administration at 6-h intervals of PD5os to infected 
normal and leukopenic rats 
Dose 
(mg/kg) 
5 
Drug concn (Jlg/ml of serum)b at the following 
times (min) after dosage: 
15 30 90 120 
0.09 
6.10 
0.15 ± 0.04 0.14 ± 0.02 0.07 ± 0.01 0.02 ± 0.002 
10.60 ± 2.23 14.30 ± 0.70 9.58 ± 1.18 4.88 ± 2.55 
0.01 ± 0.01 
0.98 ± 0.08 
aDoses correspond to the PD50s of 0.35 and 24.4 mg/kg/d administered at 6-h 
intervals to normal and leukopenic rats, respectively. Sera were taken from 
rats at various intervals after injection 12 of ceftazidime. 
bEach value represents the mean ± SD for five rats. 
Table 7 Concentrations of ceftazidime in serum at various intervals after 
continuous administration (infusion rate, 0.113 ml/hl of PD50s to 
infected normal and leukopenic rats 
Dose (mg/kg 
per day) 
0.36 
1.52 
Drug concn (Jlg/ml of serum)a at the following 
times (h) after dosage: 
5 
0.04 ± 0.03 
0.17 ± 0.09 
24 
0.04 ± 0.01 
0.17 ± 0.05 
48 
0.03 ± 0.01 
0.22 ± 0.05 
aEach value represents the mean ± SD for five rats. 
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patients is small [4]. Therefore, animal experiments have been performed 
with the object of comparing the efficacy of intermittent and continuous 
administration of antibiotics [1, 17, 19, 20]. For infections in immuno-
compromised animals, it has, however, not been clearly established whether 
repeated of high serum drug concentrations of short duration are superior 
to continuously maintained lower concentrations. 
This study was undertaken to compare the efficacy of ceftazidime 
administered intermittently at 6-h intervals or by continuous infusion 
against experimental K.pneumoniae pneumonia in normal and leukopenic rats. 
CY was used to induce granulocytopenia and monocytopenia in rats. Circulat-
ing granulocytes play an important role in the defense against K.pneumoniae 
infections in the lung in the early phase of the infection, as demonstrated 
by Rehm et al. in normal and granulocytopenic mice [16]. In vitro experi-
ments demonstrated that macrophages also phagocytize encapsulated 
K.pneumoniae organisms in the presence of antiserum [7, 23]. The course of 
infection in CY-treated rats was more severe than in untreated rats, as 
reflected by increased numbers of K.pneumoniae cultured from the left lung 
and blood, as well as a shortened survival period. These changes were the 
result of CY-induced leukopenia, as CY itself did not influence the survival 
of K.pneumoniae in serum. We demonstrated that in rats with intact host 
defenses continuous infusion of ceftazidime was as effective intramuscular 
administration at 6-h intervals. However, in leukopenic rats continuous 
administration of ceftazidime was far more effective than intermittent 
administration. Our data are in agreement with those of a study by Bakker-
Woudenberg et al. demonstrating an equal therapeutic efficacy of penicillin 
G in experimental pneumococcal pneumonia in rats with intact host defense 
mechanisms given either as intramuscular injections at 12-h intervals or by 
continuous infusion [1]. When host defenses were impaired by cobra venom 
factor treatment, continuous infusion of penicillin G was superior to 
administration at 8-h intervals. These data are not in agreement with those 
of a study by Schmidt et al. indicating that penicillin G was more effective 
in rats with pneumococcal pneumonia when administered at 8-h intervals than 
when given in more frequent doses [20]. In a rabbit model of pneumococcal 
meningitis Sande et al. found that duration of penicillin treatment required 
for sterilization of the cerebrospinal fluid was not dependent on the mode 
of drug administration [19]. 
We demonstrated that in rats with impaired host defenses continuous 
administration of ceftazidime was far more effective than intermittent 
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administration. Compared with the Po50s in normal rats, the Po50s in 
leukopenic rats had to be increased 70-fold for the intermittent treatment 
schedule and 4-fold for continuous infusion. The superiority of the 
continuously infused antibiotic in rats with impaired host defenses may be 
partially explained by increased tissue penetration as a result of 
maintained antibiotic concentrations in serum [ 11 , 14] . Peterson et al. 
showed that, with a given amount of antibiotic, intermittent administration 
was advantageous at an early stage, but eventually, in equilibrium condi-
tions at 26 h, the constant drug infusion led to higher extravascular 
levels [ 14]. However, Lavoie et al. did not find higher extravascular 
concentrations of antibiotic at 24 h with either mode of drug administra-
tion [ 11 1 . Van Etta et al. demonstrated that, for three of four anti-
microbial agents tested, including two B-lactam and two aminoglycoside 
antibiotics, continuous infusion led to the same tissue levels under 
steady-state conditions as did intermittent administration [24]. The 
discrepancy among these results may be explained by differences in the 
antibiotics and dosage schedules used. The differences in tissue levels 
after intermittent and continuous dosing found in the studies by the above-
mentioned investigators are relatively small and therefore may not be the 
only explanation for the superiority of the continuous infusion regimen in 
our leukopenic rats. Another important factor contributing to the 
superiority of the continuous administration of antibiotic in leukopenic 
rats may be the prevention of bacterial regrowth, owing to the maintenance 
of active ceftazidime concentrations at the site of infection. Intermittent 
dosing results in fluctuating levels of ceftazidime, and drug levels in 
serum above the MIC are only present for a limited period of time during 
the dosing interval, with a maximum of about 190 min for leukopenic rats at 
the Po100 . Regrowth may occur as soon as ceftazidime levels have dropped 
below the MIC. As demonstrated in vitro by Bundtzen et al. [5], the effect 
of different B-lactam antibiotics on several gram-negative organisms only 
persisted for a very short period after the removal of the drug. These 
data, together with our observation that the PDso of ceftazidime was about 
16-fold lower in leukopenic rats with continuous dosing than with inter-
mittent dosing, suggest that maintaining an antibiotic at active concentra-
tion is of critical importance. 
The steady-state level in serum obtained for continuous administration of 
ceftazidime at a dose that protected all rats with intact host defenses 
mechanisms from death (PD1 00) was 0. 06 ]..lg/ml, below the MIC for the 
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K.pneumoniae strain used 0.2 ~g/ml). Also, other experimental studies, in 
which antibiotic concentrations in serum were related to therapeutic effect 
and antibacterial activity in vitro, showed that substantial survival rates 
could be obtained by treatment with concentrations of antibiotics in serum 
below the MIC's [6, 23, 26]. However, to cure leukopenic rats with impaired 
host defenses, a steady-state level of 0.38 ~g/ml of serum was needed. 
It is not clearly established whether antimicrobial treatment of neutro-
penic patients should be continued when neutropenia persists [8, 15, 25]. 
Pizzo et al. randomized a group of 33 granulocytopenic cancer patients who 
became afebrile during initial antimicrobial treatment although remaining 
granulocytopenic to either continue of discontinue antibiotic treatment 
[15]. Only in the group in which antimicrobial treatment was discontinued 
did infectious sequelae develop. They suggested that granulocytopenic 
cancer patients may profit from the prolongation of antimicrobial treatment 
when granulocytopenic persists. Our data on the efficacy of ceftazidime 
treatment of various durations, 
relation to the persistence of 
administered by continuous infusion, in 
leukopenia also suggest that treatment 
should be continued until the return of circulating leukocytes, although 
the differences in mortality between rats with prolonged or discontinued 
treatment were not statistically significant. 
From this study it can be concluded first that in rats with intact host 
defense mechanisms, a given amount of ceftazidime is equally effective when 
administered continuously or at 6-h intervals, whereas in rats with impaired 
host defense mechanisms, continuous administration of ceftazidime is 
superior to intermittent administration. Second, since a significant 
reduction in the therapeutic activity of continuously administered cefta-
zidime was observed when leukopenia persisted at the end of antibiotic 
treatment, antibiotic treatment should be continued until the return of 
circulating leukocytes. 
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APPENDIX PAPER III 
COMPARATIVE ACTIVITIES OF CIPROFLOXACIN AND CEFTAZIDIME AGAINST KLEBSIELLA 
PNEUMONIAE IN VITRO AND IN EXPERIMENTAL PNEUMONIA IN LEUKOPENIC RATS* 
Robert Roosendaal, Irma A. J. M. Bakker-Woudenberg, Marion van den Berghe-
van Raffe, Joke C. Vink-van den Berg, and Marc F. Michel 
ABSTRACT 
The antibacterial activities of ciprofloxacin and ceftazidime against 
Klebsiella pneumoniae in vitro and in vivo were compared. Although there was 
only a minor difference between MBCs of both drugs, the bacterial killing 
rate of ciprofloxacin in vitro was very fast in comparison with that of 
ceftazidime. Similarly, the intravenous administration of ciprofloxacin at 
1 h after bacterial inoculation resulted in effective bacterial killing in 
the lungs of leukopenic rats. This killing was dose-dependent, in contrast 
to the dose-independent bactericidal effect of ceftazidime. The high anti-
bacterial activity of ciprofloxacin in the lungs as compared with that of 
ceftazidime was also reflected in its therapeutic efficacy in K.pneumoniae 
pneumonia and septicemia in leukopenic rats when these infections were treat-
ed at 6-h intervals during 4 days, starting at 5 h after bacterial inocula-
tion. Concentrations of ciprofloxacin and ceftazidime in lung tissue were 
not significantly different. Regarding the antibacterial activity of both 
drugs against K.pneumoniae in relation to the bacterial growth rate in vitro 
and in the lungs of leukopenic rats, ciprofloxacin killed K.pneumoniae orga-
nisms that were not actively growing, whereas ceftazidime did not. In addi-
tion, it was demonstrated that when the intravenous administration of anti-
biotic was delayed from 1 h up to 24 h after bacterial inoculation, ceftazi-
dime lost its antibacterial activity in the lungs and blood of leukopenic 
rats,whereas ciprofloxacin was still very effective. These data suggest that 
the capacity of an antibiotic to kill bacteria at a slow growth rate may be 
relevant for its therapeutic effect in established infections, in which 
slowly growing bacteria form a substantial part of the total population. 
*Antimicrobial Agents and Chemotherapy (1987) 31:1809-1815. Reprinted with 
permission. 
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INTRODUCTION 
There is an ongoing search for antimicrobial agents which are more 
effective in treating infections than are currently used drugs. In the past 
few years, a group of quinolone carboxylic acid derivatives known as the 
fluoroquinolones has been developed [ 11 , 27] . One of its representatives 
is ciprofloxacin. This drug has some specific characteristics, such as a 
high bactericidal activity in vitro [7, 25, 27, 28], a large volume of 
distribution [11, 26], and a high capacity for tissue penetration [11, 21, 
23, 26]. In addition, ciprofloxacin has a substantial bactericidal activity 
against bacteria in the stationary phase of growth [ 7, 28], which is 
probably related to its specific mode of action [24, 27]. The significance 
of these new antimicrobial agents in relation to currently used drugs has 
been investigated in clinical trials [1, 4]. However, the relative 
importance of these characteristics of the quinolones with respect to their 
antimicrobial activity in vivo can only be investigated in experimental 
infection models, which allow comparison of antibiotics under similar 
conditions of intensity and duration of infection. 
In this study, a model of K.pneumoniae pneumonia and septicemia in leuko-
penic rats was used to compare the antibacterial activities of ciprofloxa-
cin and ceftazidime. Leukopenic rats were chosen because infections in 
granulocytopenic cancer patients are often difficult to treat [13, 14, 22]. 
Although there was a minor difference between the MBCs of both antibiotics 
for the K.pneumoniae strain, ciprofloxacin and ceftazidime differed 
considerably with respect to their rates of bacterial killing. We 
investigated first whether the difference between the bacterial killing 
rates in vitro of both drugs was reflected in their antibacterial 
activities in the lungs of leukopenic rats and second what the consequences 
were with regard to their efficacies in the treatment of pneumonia and 
septicemia in leukopenic rats. In addition, we compared the antibacterial 
activities in vitro and in vivo of both drugs against the K. pneumoniae 
strain in relation to the bacterial growth rate. 
MATERIALS AND METHODS 
Animals. Female R strain albino rats (specific pathogen free; 14 to 
18 weeks old; weight, 185 to 215 g; bred at REPGO-TNO, Rijswijk, The 
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Netherlands) were used in all experiments. 
Bacteria. A K.pneumoniae strain (capsular serotype 2) was used in these 
experiments. Stationary-phase cultures were obtained by incubation for 16 h 
at 37°C in Iso-Sensitest broth (Oxoid Ltd., London, England). After proper 
dilution and reincubation for 2 h at 37°C, suspensions of logarithmically 
growing bacteria were prepared. 
Antibiotics. Ciprofloxacin (Bayer AG, Leverkusen, Federal Republic of 
Germany) was supplied as powder or in ampoules of 100 mg of drug in 10 ml 
of diluent manufactured by Bayer. Dilutions were made in distilled water. 
Solutions were stored at 4°C and protected from light. Ceftazidime (Glaxo 
Pharmaceuticals, Ltd., Greenford, England) was supplied as powder. 
Solutions were made in accordance with the enclosed instructions. Dilutions 
were made in distilled water, and solutions were stored at -80°C. 
Antimicrobial susceptibility tests. The MICs of the drugs were defined as 
the lowest concentrations that suppressed visible growth after incubation 
of 5 x 105 CFU/ml for 18 h at 37°C in tubes containing 4 ml of Iso-Sensi-
test broth. The MBCs were defined as the lowest concentrations that killed 
99.9% of the original inoculum. MBCs were determined by spreading sub-
culture volumes of 200 lll onto Iso-Sensitest agar (Oxoid) plates. The 
concentrations of the serial dilutions decreased by steps of 0.2 llg/ml. The 
effect of the two drugs on the short-term growth of K.pneumoniae was 
studied in both Iso-Sensitest broth and in Hanks balanced salt solution 
(HBSS) (Oxoid) with 90% normal rat serum at 37°C. A stationary-phase 
culture was diluted in Iso-Sensitest broth to a concentration of 2 x 106 
CFU/ml. After reincubation for 2 hat 37°C, the number of CFU was 4 x 107, 
and antibiotic was added (zero time). Killing experiments were started with 
an inoculum of 5 x 105 CFU per ml. In studies of the antibacterial activity 
in vitro in relation to the bacterial growth rate, bacterial inocula were 
prepared as follows. At 2 h before or 2 h after the stationary growth phase 
in broth was achieved, bacteria were centrifuged, washed, suspended to 
their original number per milliliter in fresh, warm (37°C) Iso-Sensitest 
broth to which antibiotic had been added, and reincubated. During incuba-
tion, the numbers of viable organisms were determined at regular intervals 
by plate counts on Iso-Sensitest agar. Before plating, the concentrations 
of ciprofloxacin and ceftazidime were reduced to an inactive level by 
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centrifugation of 1-ml samples for 2 min at 1 0, 000 x g, followed by 
replacement of the drug- containing medium by physiological saline. 
Pneumonia. Experimental pneumonia was produced as described previously by 
Bakker-Woudenberg et al. [2]. In brief, rats were anesthetized with 
fluanisone (Hypnorm; Duphar B.V., Amsterdam, The Netherlands) and pento-
barbital (Abbott Laboratories, North Chicago, Ill.). The left main-stem 
bronchus was intubated, and the left lung was inoculated with 0.02 ml of a 
saline suspension of K.pneumoniae. The number of CFU used to inoculate the 
left lung in the different experiments was confirmed by plate counts on 
blood agar. After inoculation, the narcotic antagonists nalorphine bromide 
and Pentetrazolum (Onderlinge Pharmaceutische Groothandel, Utrecht, The 
Netherlands) were injected. 
Induction of leukopenia. Leukopenia was induced by intraperitoneal injec-
tions of cyclophosphamide (Koch-Light Limited, Haverhill, Suffolk, England) 
in two doses of 90 and 60 mg/kg at 5 days and 1 day before bacterial 
inoculation, respectively. Cyclophosphamide-induced leukopenia resulted in 
a more severe course of the untreated infection than that seen in immuno-
competent rats [17]. 
Antimicrobial treatment. Ciprofloxacin and ceftazidime were administered 
in two different schedules. In some experiments, antibiotic at various 
doses was administered intravenously as a single injection into the tail 
vein at different times after bacterial inoculation. The response to 
antimicrobial treatment was evaluated with respect to the numbers of 
bacteria in the left lung at different times after administration. Rats 
were sacrificed, and the left lung was removed and homogenized in 20 ml of 
physiological saline for 30 s at 10,000 rpm in a VirTis homogenizer (The 
Virtis Co., Inc., Gardiner, N.Y.). Serial 10-fold dilutions of homogenates 
in saline were prepared. Volumes of 0. 2 ml of each dilution and 1-ml 
volumes of the undiluted lung homogenate were spread on blood agar plates. 
The Mann-Whitney test was used for statistical analysis. In other 
experiments, antibiotic was administered intramuscularly into the thigh 
muscles of the rear legs at 6-h intervals over a period of 4 days, in 
twofold-increasing doses, each dose to a group of 10 rats, starting at 5 h 
after bacterial inoculation. The response to antimicrobial treatment was 
evaluated with respect to the daily dose that protected 50% of the animals 
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from death (median protective dose, Po50 ). Po50 values were calculated by 
the method of Spearman-Karber as described by Sachs [ 19] . The deaths of 
rats were recorded daily until 16 days after the termination of treatment. 
After that time, no changes in the death rate occurred. The left lung of 
each rat that died was cultured to check for the presence of K.pneumoniae. 
Only K.pneumoniae organisms were recovered from lungs of both treated and 
untreated animals. 
Measurement of antibiotic concentrations in serum and in lungs of infected 
rats. Blood specimens were collected from each rat by orbital puncture 
under light co2 anesthesia, and serum was separated. For the determination 
of antibiotic concentrations in lung tissue, the left lung was removed, 
exsanguinated, and homogenized in saline in a Potter-Elvejhem homogenizer. 
After centrifugation for 2 min at 10,000 x g, the supernatant was collected 
and used for the determination of antibiotic concentrations. With the use 
of diagnostic sensitivity test agar (Oxoid) and an Escherichia coli test 
strain susceptible to 0.025 ~g of ciprofloxacin and 0.2 ~g of ceftazidime 
per ml, all tests were done by a standard large-plate agar diffusion 
procedure [6]. Standard samples for the determination of antibiotic 
concentrations in serum were prepared from pooled normal rat serum. 
Standard samples for the determination of drug concentrations in lung 
tissue were prepared as follows. Ciprofloxacin and ceftazidime in standard 
concentrations were added to homogenates of lungs of untreated rats. After 
incubation for 1 h at 37°C and centrifugation for 2 min at 1 0, 000 x g, 
supernatants were collected. Samples of 100 ~1 were assayed. For the 
determination of concentrations in serum below 0. 2 ~g of ceftazidime per 
ml, some modifications were introduced to increase the sensitivity of the 
test. We applied 225-~1 samples to metal rings (internal diameter, 6 mm) 
placed on the agar. To nine parts of each sample and of each standard 
concentration, one part of a solution of 1 ~g of ceftazidime per ml of 
serum was added. Correlation coefficients of the calculated regression 
lines were >0. 99 in all determinations. Determination of samples with 
known concentrations of ceftazidime in serum by both the original method 
and the modified method yielded similar results. The Mann-Whitney test was 
used for statistical analysis. 
Protein binding. Protein binding of ciprofloxacin in serum was measured by 
the ultrafiltration technique with the Micropartition System (MPS1; model 
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4010; Amicon Corp., Lexington, Mass.) and YMT membranes (Amicon) by 
centrifugation at 2,000 x g for 30 min at 25°C. Concentrations of cipro-
floxacin were measured by high-pressure liquid chromatography. Separation 
was carried out by reverse-phase partitioning on a column (internal 
diameter, 4.6 mm; length, 25 em) packed with Spherisorb 5-0DS (Chrompack, 
Middelburg, The Netherlands). The eluent contained 150 ml of acetonitrile, 
150 ml of N,N-dimethylformamide, and 113 g of phosphoric acid plus 0.38 g 
of tetramethyl ammonium chloride diluted to liter of water. Column 
elution was carried out at a flow rate of 1 . 5 ml/min and a pressure of 
230 atm (ca. 23.3 MPa). The eluent was monitored at 278 nm. Protein binding 
of ceftazidime was measured as described earlier [3]. 
RESULTS 
Effect of ciprofloxacin and ceftazidime against K.pneumoniae in vitro. The 
MIC and the MBC of ciprofloxacin were both 0.2 ~g/ml, and the MIC and MBC 
of ceftazidime were both 0.4 ~g/ml. The rates of bacterial killing in broth 
at concentrations around the MBC differed considerably for both antibiotics 
(Fig. 1). Bacterial killing by ciprofloxacin was very fast as compared with 
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Figure 1 Effect of ciprofloxacin (A) or ceftazidime (B) at concentrations 
indicated against K.pneumoniae in the logarithmic phase of growth in broth. 
The solid line represents bacterial growth without antibiotic. 
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that by ceftazidime. At the concentration of 0. 2 ].Lg/ml, ciprofloxacin 
reduced the numbers of bacteria 105-fold within 1 h of incubation, whereas 
ceftazidime led to only a 1 0-fold reduction in bacterial numbers within 
3 h. Although the bactericidal activities of ciprofloxacin and ceftazidime 
in HBSS with 90% serum were not identical to those in broth, no major 
differences were found between the killing rates in both media. In HBSS 
with 90% serum, ciprofloxacin again demonstrated an immediate high 
bacterial killing rate, whereas the bactericidal activity of ceftazidime 
was more time dependent (Fig. 2). 
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Figure 2 Effect of ciprofloxacin (A) and ceftazidime (B) at the concentra-
tions indicated against K.pneumoniae in the logarithmic phase of growth in 
HBSS with 90% serum. The solid line represents bacterial growth without 
antibiotic. 
Effect of ciprofloxacin and ceftazidime against K.pneumoniae in lungs of 
leukopenic rats. The antibacterial activities of ciprofloxacin and ceftazi-
dime after intravenous administration of different doses at 1 h after inocu-
lation of the left lung with 8 x 104 K.pneumoniae in the logarithmic phase 
of growth are shown in Fig. 3. As compared with ceftazidime, ciprofloxacin 
was more effective in bacterial killing. Whereas the bactericidal effec~ of 
ciprofloxacin was dependent on the dose administered and was complete within 
1 h after administration of the antibiotic, the antibacterial activity of 
ceftazidime was not dose dependent but more time-dependent. The concentra-
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Figure 3 Numbers of K.pneumoniae in the lungs of untreated leukopenic rats 
(-.----) and after intravenous administration of ciprofloxacin (A) or cefta-
zidime (B) at 0.3 mg/kg (---), mg/kg (--·-),or 3 mg/kg (--··--), 1 h 
after inoculation of lungs with 8 x 104 K.pneumoniae in the logarithmic 
phase of growth. 
Each point represents the geometric mean ± SEM for five rats. 
tions of ciprofloxacin and ceftazidime in the serum of rats at various 
times after intravenous administration of 3 mg/kg are shown in Table 1 . 
Ciprofloxacin concentrations in serum were about 14-fold lower than cefta-
zidime concentrations in serum within 5 min after dosing. The elimination 
half-lives for ciprofloxacin and ceftazidime were 98 and 31 min, respectiv-
ely. Protein binding percentages were 41 and 14%, respectively. 
Therapeutic efficacy of ciprofloxacin versus ceftazidime in K.pneumoniae 
pneumonia and septicemia in leukopenic rats. The therapeutic efficacy of 
ciprofloxacin versus ceftazidime was determined in terms of PD5o values 
after administration at 6-h intervals for 4 days starting 5 h after 
bacterial inoculation with 8 x 104 K.pneumoniae (Table 2). For both cipro-
floxacin and ceftazidime, the numbers of surviving rats increased with 
increasing total daily doses. Ciprofloxacin treatment was significantly 
superior ~o ceftazidime treatment, Po50s being 3.3 and 24.4 mg/kg per day 
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for the respective drugs (P <0.001). Intramuscular injection of 0.82 mg of 
ciprofloxacin and 6.1 mg of ceftazidime per kg (doses corresponding to the 
daily PD50s of 3.3 and 24.4 mg/kg for the respective drugs administered at 
6-h intervals) into infected rats resulted in relatively low concentra-
tions of ciprofloxacin in serum (Table 3). Concentrations in serum above 
the MBC of 0. 4 lJ.g/ml after the administration of PD50s were present for 
about 220 min for ceftazidime, whereas the concentrations of ciprofloxacin 
in serum did not reach the MBC during the 6-h dosing interval. 
Table 3. Concentrations of ciprofloxacin and ceftazidime in serum at 
various times after intramuscular administration of PD50s at 6-h 
intervals to infected leukopenic rats 
Drug 
Ciprofloxacin 
Ceftazidime 
Dose 
(mg/kg)a 
0.82 
6.09 
Drug concn (lJ.g/ml of serum)b at the following 
times (min) after administration: 
15 
0.29 ± 0.07 
14.29 ± 0.70 
30 
0.20 ± 0.05 
9. 58 ± 1 . 18 
90 
0.07 ± 0.02 
4.88 ± 2.55 
aDoses correspond to the PD50s of 3. 3 and 24.4 mg of ciprofloxacin and 
ceftazidime per kg per day, respectively, administered at 6-h intervals. 
Sera were taken from rats at various times after injection eight of the 
respective drugs. 
bEach value represents the mean ± standard deviation for five rats. 
Concentrations of ciprofloxacin and ceftazidime in the lungs of infected 
rats. Concentrations of ciprofloxacin and ceftazidime at various times 
after the intravenous administration of 3 mg/kg at 24 h after bacterial 
inoculation are shown in Table 4. At the various times after administration 
there was no significant difference between the concentrations of cipro-
floxacin and ceftazidime in lung tissue. Concentrations of ciprofloxacin in 
lung tissue were higher than those in serum until 1 h after administration. 
Effect of ciprofloxacin and ceftazidime against K.pneumoniae in broth and 
in the lungs of leukopenic rats in relation to bacterial growth rate. 
Logarithmically growing bacteria in broth were killed by both ciprofloxacin 
and ceftazidime (Fig. 4A and 4B, respectively). At all concentrations 
tested, the bacterial killing rate of ciprofloxacin was higher than that 
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Table 4. Concentrations of ciprofloxacin and ceftazidime in lung tissue at 
various times after intravenous administration of 3 mg/kg to 
infecteda leukopenic rats 
Drug Drug concn (~g/g of lung tissue)b at the 
following times (min) after administration: 
Ciprofloxacin 
Ceftazidime 
15 
1.33 ± 0. 79 
1 . 72 ± 1 . 58 
30 
1.80 ± 0.89 
2.15 ± 0.60 
60 
1.21 ± 0.28 
1 . 16 ± 0. 59 
90 
0.56 ± 0.16 
0.94 ± 0.40 
aDrugs were administered 24 h after inoculation of the left lung with 
8 x 104 CFU of K.pneumoniae 
bEach value represents the mean ± standard deviation for five rats. 
of ceftazidime. In addition, the administration of ciprofloxacin resulted 
in immediate killing, whereas bacterial killing by ceftazidime was more 
gradual and time dependent. When the K.pneumoniae organisms were in the 
stationary phase of growth, ceftazidime at the same concentrations was no 
longer bactericidal (Fig. 4D). On the contrary, ciprofloxacin was still 
able to kill the bacteria effectively (Fig. 4C) , although the bacterial 
killing rates were lower than those observed for the logarithmically 
growing bacteria. 
The bactericidal effect of ciprofloxacin and ceftazidime against 
K.pneumoniae in relation to the bacterial growth rate in vivo was 
demonstrated by the following experiments. 
8 x 104 logarithmically growing K.pneumoniae 
Lungs were inoculated with 
(Fig. SA) . At h after 
inoculation, when the bacterial numbers in the lungs had increased about 
threefold up to 2.2 x 105 CFU, ciprofloxacin or ceftazidime was 
administered at a dose of 3 mg/kg. The actively growing bacteria were 
killed by both antibiotics, although ciprofloxacin was significantly more 
effective (P sO.OS). Inoculation of the lungs with 2.2 x 105 K.pneumoniae 
in the stationary phase of growth (Fig. SB) resulted in a 1-h delay of 
bacterial growth in the lungs. When antibiotic was administered immediately 
after inoculation, it was observed that ceftazidime at a dose of 3 mg/kg 
was not able to kill the bacteria during the first hour, whereas cipro-
floxacin was highly bactericidal during that period after inoculation. When 
bacterial numbers in the lung increased, bacterial killing by ceftazidime 
was also observed. 
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Figure 4 Effect of ciprofloxacin (A) or ceftazidime (B) against 
K.pneumoniae in the logarithmic phase of growth and of ciprofloxacin (C) or 
ceftazidime (D) against K.pneumoniae in the stationary phase of growth in 
broth. The solid line represents bacterial growth without antibiotic. 
Finally, we investigated the effect of delaying antibiotic administration 
from 1 h up to 24 h after bacterial inoculation upon the antibacterial 
activities of ciprofloxacin and ceftazidime. Whereas at 1 h·after inocula-
tion with logarithmically growing bacteria (Fig. SA) the bacteria in the 
lungs had increased 3-fold in number and were killed by both antibiotics, 
at 24 h after inoculation (Fig. 6), in an established lung infection, 
bacterial numbers had increased 4000-fold and had resulted in tissue necro-
sis. All rats had bacteria in the blood. Ciprofloxacin still had an anti-
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Figure 5 Numbers of K.pneumoniae in the lungs of untreated leukopenic rats 
(---) and after intravenous administration of ciprofloxacin (-·-) or 
ceftazidime ('---) at 3 mg/kg 1 h after inoculation of the lungs with 
8 x 104 K.pneumoniae in the logarithmic phase of growth (A), or immediately 
after inoculation of the lungs with 2.2 x 105 K.pneumoniae in the 
stationary phase of growth (B). 
Each point represents the geometric mean ± SEM for five rats. 
bacterial effect in the lungs and sterilized the blood of all rats. In 
contrast, ceftazidime was not effective in the lungs and blood cultures 
remained positive. 
DISCUSSION 
Several specific characteristics of ciprofloxacin may contribute to a high 
therapeutic efficacy. Ciprofloxacin has a high bactericidal activity 
against gram-negative bacteria [7, 25, 27, 28]. Another important 
characteristic of ciprofloxacin is a large volume of distribution and a 
high capacity of tissue penetration [21, 23, 26]. Wise et al. found that 
ciprofloxacin was very rapidly eliminated from serum after intravenous 
administration and had a volume of distribution of about two times the 
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Figure 6 Numbers of K.pneumoniae in the lungs of untreated leukopenic rats 
(-----), and after intravenous administration of ciprofloxacin (--·--) or 
ceftazidime (---) at 3 mg/kg 24 h after inoculation of the lungs with 
8 x 104 K.pneumoniae in the logarithmic phase of growth. 
Each point represents the geometric mean ± SEM for five rats. 
body weight, as demonstrated in healthy volunteers [26]. In addition, 
penetration of ciprofloxacin into blister fluid was rapid, with extra-
vascular concentrations exceeding those in serum from 30 min after intra-
venous administration. Siefert et al. also demonstrated that concentrations 
of ciprofloxacin in several tissues in rats exceeded those in plasma 4 h 
after intravenous administration and from 1 h after oral dose of 5 mg/kg 
[23]. As shown by Schlenkhoff et al., ciprofloxacin concentrations in human 
lung tissue were higher than those in serum up to 4 h after intravenous 
administration of 100 mg [21]. Another factor, the mode of action of cipro-
floxacin, may also contribute to its high therapeutic activity. Quinolones 
inhibit DNA gyrase, the enzyme that maintains the DNA in the supercoiled 
state and is essential for survival of the bacteria [24]. Thus, they are 
expected to act upon a greater part of the bacterial population than are 
many other classes of antibiotics whose activity depends on the bacterial 
growth rate. Rapid and strong bactericidal activity of ciprofloxacin 
against nongrowing Pseudomonas aeruginosa and E.coli has been demonstrated 
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in vitro [7, 28], whereas a lack of bactericidal activity of several 
B-lactam antibiotics, including ceftazidime, has been observed against 
nongrowing members of the family enterobacteriaceae [8]. Few studies have 
dealt with the measurement of bacterial multiplication at the site of 
infection [9, 15]. Maw and Meynell demonstrated that the generation time of 
Salmonella typhimurium in the spleens of mice was 10 h, as compared with a 
generation time of 30 min in broth [15]. Eudy and Burrows demonstrated that 
Proteus mirabilis and E.coli multiplied in the kidneys of rats, with 
generation times exceeding those in broth substantially and increasing with 
the duration of the infection [9]. These data indicate that growth rates in 
vivo are much lower than those in vitro. It is suggested that slowly or 
nongrowing bacteria form a substantial part of the total bacterial popula-
tion in established infections. In this respect, the bactericidal activity 
of ciprofloxacin against nongrowing bacteria may be of major importance. 
The relative importance of the specific characteristics of the quinolones 
in their therapeutic efficacy can be established only in experimental 
infections. The therapeutic efficacy of ciprofloxacin was investigated in 
several infection models [ 5, 1 0, 12, 1 6, 201 . Bayer et al. showed that 
ciprofloxacin was more effective in reducing bacterial counts and prevent-
ing mortality or relapse in experimental left-sided P. aeruginosa endo-
carditis in rabbits than was a combination of azlocillin plus netilmicin 
[5]. Another study revealed that acute P.aeruginosa pneumonia was more 
effectively treated with ciprofloxacin or tobramycin than with ticarcillin 
with respect to the number of CFU cultured from the infected tissue, 
whereas, using the same parameter, in a chronic pneumonia caused by the 
same microorganism, ciprofloxacin was superior to tobramycin or ticarcillin 
[20]. Gordin et al. and Rusnak et al. demonstrated retrospectively that 
ciprofloxacin was as effective as several combinations of B-lactams and 
aminoglycosides and superior to monotherapies with the same drugs in 
reducing bacterial counts in the lungs of neutropenic guinea pigs with 
P.aeruginosa pneumonia [10, 18]. Although in the above-mentioned studies a 
high therapeutic activity of ciprofloxacin was demonstrated, the relative 
efficacy of this quinolone cannot be directly related to the efficacy of 
the B-lactam antibiotics and aminoglycosides used. This is due to the fact 
that different dose schedules were applied and the bacterial strains used 
differed in their susceptibility to the respective drugs. Norden and 
Shinners used a P.aeruginosa strain which was equally susceptible to cipro-
floxacin and tobramycin in terms of MBCs in a model of osteomyelitis in 
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rabbits; they demonstrated that the therapeutic efficacy of ciprofloxacin 
was superior to that of the aminoglycosides [ 16] . However, it must be 
realized that different dose schedules were used. Ingerman et al. treated 
P.aeruqinosa endocarditis in rats with ciprofloxacin and the B-lactam 
BMY 28142 at doses that resulted in comparable peak serum concentration/MBC 
ratios and found a superior efficacy of the quinolone [12]. 
In the present study, the antibacterial activities of ciprofloxacin and 
ceftazidime against K.pneumoniae in the lungs of leukopenic rats were 
compared in relation to their activities in vitro. It was demonstrated that 
although there was a slight difference in the MICs and MBCs of both anti-
biotics for the K.pneumoniae strain, the agents differed extremely with 
respect to their rate of bacterial killing. The difference in bacterial 
killing rates between ciprofloxacin and ceftazidime in vitro was also 
observed in vivo in terms of a decrease in numbers of K.pneumoniae in the 
lungs of leukopenic rats after administration of the antibiotic intra-
venously at 1 h after bacterial inoculation. The high bactericidal activity 
of ciprofloxacin in the lungs of leukopenic rats as compared with that of 
ceftazidime was also reflected in the increased survival (lowered the 
PD50 l of leukopenic rats after antibiotic administration at 6-h intervals 
for 4 days. 
The high efficacy of ciprofloxacin may be explained by its high bacte-
ricidal effect, as demonstrated in vitro in broth as well as in vivo in 
lungs of leukopenic rats. Also, the relative long half-live of cipro-
floxacin as compared with that of ceftazidime may have contributed to its 
high efficacy. The superior bactericidal activity of ciprofloxacin in the 
lungs as compared with that of ceftazidime cannot be explained by higher 
ciprofloxacin concentrations at the site of infection. Although until 1 h 
after administration the concentrations of ciprofloxacin in lung tissue 
were higher than those in serum, the concentrations of ciprofloxacin in 
lung tissue were comparable to those of ceftazidime. Siefert et al. [23] 
and Schlenkhoff et al. [21] also demonstrated relatively high concentra-
tions of ciprofloxacin in lung tissue as compared to plasma and serum, 
respectively. 
In addition to a high killing rate, the mode of action may also be relevant 
to the therapeutic efficacy of ciprofloxacin. We demonstrated in vitro that 
ciprofloxacin was able to kill bacteria that were not actively growing, 
whereas ceftazidime was not. Also in the lungs of leukopenic rats the 
bactericidal effect of ceftazidime appeared to be dependent on bacterial 
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growth. This was demonstrated in rats that were inoculated with nongrowing 
bacteria. It must be realized that this experimental set-up is not directly 
related to the clinical situation. However, in established infections, non-
growing or slowly growing bacteria undoubtedly form a substantial part of 
the total bacterial population [9, 15]. Therefore, it may be expected that 
the success of antibiotic treatment is at least in part dependent on the 
capacity of the antibiotic to kill nongrowing bacteria. Because the failure 
of antibiotic treatment in established infections may be partly related to 
the fact that bacteria are inaccessible to antibiotics or have a slow 
growth rate, we studied the effect of delaying antibiotic administration 
on the antibacterial activities of ciprofloxacin and ceftazidime. While 
both antibiotics administered 1 h after bacterial inoculation resulted in a 
decrease in bacterial numbers cultured from the lungs of leukopenic rats, 
when administered 24 h after inoculation, ciprofloxacin was still very 
effective, whereas ceftazidime was not. The success of ciprofloxacin in the 
treatment of chronic P.aeruginosa pneumonia in guinea pigs or P.aeruginosa 
osteomyelitis in rabbits [ 16, 20] may also be related to its bacterial 
activity against at slowly growing bacteria. 
In summary, from animal infection models there is substantial evidence 
that the therapeutic efficacy of an antibiotic is related not only to the 
bacterial killing rate and to the capacity for tissue penetration but also 
to the bactericidal activity against slowly growing bacteria. The relevance 
of these antibiotic characteristics to therapeutic efficacy in infections 
in immunocompromised hosts needs to be established. 
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APPENDIX PAPER IV 
IMPACT OF THE DOSAGE SCHEDULE ON EFFICACY OF CEFTAZIDIME, GENTAMICIN, AND 
CIPROFLOXACIN IN KLEBSIELLA PNEUMONIAE PNEUMONIA AND SEPTICEMIA IN LEUKO-
PENIC RATS* 
R. Roosendaal, I.A.J .M. Bakker-Woudenberg, M. van den Berghe-van Raffe, 
J.C. Vink-van den Berg, M.F. Michel 
Leukopenic rats with Klebsiella pneumoniae pneumonia and septicemia were 
treated with antibiotic during 4 days either intermittently at 6-h inter-
vals or by way of continuous infusion. Daily doses (mg/kg) that protected 
50% of the animals from death obtained for intermittent or continuous 
administration were: ceftazidime 24.4 and 1. 5 (P <0. 001), gentamicin 2. 8 
and 3.8 (P >0.05), and ciprofloxacin 3.3 and 6.5 (P <0.05), respectively. 
The therapeutic results in relation to the dosage schedule correlate with 
the different patterns of short-term bacterial killing in vitro as well as 
in the lungs of leukopenic rats for the three antibiotics. Killing by 
ceftazidime was slow, but continuing, and relatively independent on the 
concentration c .q. dosage. This correlates with the highest therapeutic 
effect obtained when ceftazidime was administered continuously resulting in 
permanent concentrations in plasma during the entire treatment interval. In 
contrast, killing by gentamicin or ciprofloxacin was rapid, and related to 
the concentration c.q. dosage, which correlates with a good therapeutic 
effect even when administered intermittently resulting in high peak 
concentrations at relatively long intervals. 
INTRODUCTION 
Most antibiotic dose schedules are empiric and based upon achievable serum 
concentrations in relation to the MIC of the infecting strain [1, 2]. It 
is, however, not clearly established whether or not transient relative high 
antibiotic peak concentrations in serum are more effective than sustained 
drug concentrations at a lower level for the treatment of serious infec-
*(Submitted for publication) 
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tions. Optimal antimicrobial treatment is especially required with regard 
to infections in the compromised host, whose cure depends mainly on 
antibiotics. Only few clinical trials deal with the effect of the mode of 
administration, either intermittently or continuously, on the therapeutic 
efficacy of antibiotics [3, 4, 5]. During the past few years more attention 
has been directed to the impact of the antibiotic dosage schedule on the in 
vivo efficacy in experimental infections [6-15]. Data derived from these 
investigations suggest that the importance of the antibiotic dosage 
schedule as a determinant of therapeutic efficacy is related to the class 
of antibiotic. However, some of these studies were performed in infection 
models with limited clinical relevance. Other data were derived from 
therapy experiments in which only one class of antibiotic was studied. In 
the present study the impact of the dosage schedule on the therapeutic 
efficacy of antibiotics of three different classes was investigated in a 
Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. This 
experimental model was chosen because in leukopenic patients septicemia is 
a real threat and K.pneumoniae is one of the pathogens that are frequently 
recovered [16, 17]. The in-vitro susceptibility in terms of MBC values of 
the K.pneumoniae strain used for the selected drugs ceftazidime, gentamicin 
and ciprofloxacin was similar. The efficacy of the drugs was evaluated in 
terms of PD50 doses obtained after a four day treatment, starting 5 h 
after bacterial inoculation of the lung. Drugs were administered either 
intermittently at 6-h intervals or by way of continuous infusion. The 
therapeutic results obtained after a four day treatment were compared with 
the kinetics of antibacterial activity of the antibiotics against the 
K.pneumoniae strain in vitro as well as in lungs of leukopenic rats. 
MATERIALS AND METHODS 
Animals. Female R strain albino rats (specific pathogen free; 14 to 18 
weeks old; weight, 185 to 215 g; bred at REPGO-TNO, Rijswijk, The 
Netherlands) were used in all experiments. 
Bacteria. A K.pneumoniae strain (capsular serotype 2) was used in these 
experiments. Cultures were obtained by incubation for 16 hat 37°C in Iso-
Sensitest broth (Oxoid Ltd., London, England). After proper dilution and 
reincubation for 2 h at 37°C suspensions of logarithmically growing 
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bacteria were prepared. 
Antibiotics. Ceftazidime (Glaxo Pharmaceuticals, Ltd., Greenford, 
England), and gentamicin ( Schering Corporation Kenilsworth, N.Y., United 
States) were supplied as powder. Solutions were made in distilled water and 
stored at minus 80°C. Ciprofloxacin (Bayer AG, Leverkusen, Federal Republic 
of Germany) was supplied as powder or in ampoules of 100 mg of drug in 10 
ml diluent manufactured by Bayer. Solutions were made in distilled water, 
stored at 4°C and protected from light. 
Antimicrobial susceptibility tests. The MICs of the antibiotics were 
defined as the lowest concentrations that suppressed visible growth after 
incubation of 5 x 105 CFU/ml for 18 h at 37°C in tubes containing 4 ml of 
Iso-Sensitest broth (Oxoid Ltd., London, England). The MBCs were defined as 
the lowest concentrations that killed 99.9% of the original inoculum. MBC 
was determined by spreading subculture volumes of 200 ~1 onto Iso-Sensitest 
agar (Oxoid) plates. The concentrations of the serial dilutions decreased 
by steps of 0.2 ~g/ml. 
The effect of the three drugs on the short-term growth of K.pneumoniae at 
37°C was studied both in Iso-Sensitest broth and in Hanks balanced salt 
solution (HESS) (Oxoid) with 90% normal rat serum. A stationary phase 
culture was diluted in Iso-Sensitest broth to a concentration of 2 x 106 
CFU/ml. After reincubation for 2 h at 37°C the number of CFU was 
4 x 107/ml, and antibiotic was added (zero time). Killing experiments were 
started with an inoculum of 5 x 105 CFU/ml. For PAE (postantibiotic effect) 
determinations a stationary phase culture was diluted to 5 x 1 o6 CFU/ml. 
After reincubation for 2 h at 37°C the number of CFU was 108/ml and 
antibiotic was added (zero time). PAE experiments were started at an 
inoculum of 5 x 10 7 CFU/ml. After 1 h of incubation with antibiotic 
bacterial cultures containing ceftazidime and gentamicin were diluted 100-
fold in fresh prewarmed medium and cultures containing ciprofloxacin 250-
fold. Cultures without antibiotic were treated simularly. Control 
experiments revealed that at the dilutions used the highest residual 
antibiotic concentrations obtained for all experiments did not affect the 
growth of logarithmically growing K.pneumoniae. PAE was quantitated as 
described by Craig and Gudmundsson for PAE measurement by viable counts 
[ 18] . In both the killing experiments and the PAE determinations the 
numbers of viable bacteria were determined at regular intervals by plate 
165 
counts on Iso-Sensitest agar. Before plating the concentrations of cefta-
zidime, gentamicin, and ciprofloxacin were reduced to an inactive level by 
centrifugation of 1 ml samples for two minutes at 1 0, 000 g followed by 
replacement of the drug containing medium by physiological saline. 
Pneumonia. Experimental pneumonia was produced as described previously by 
Bakker-woudenberg et al. [19]. In brief, rats were anesthetized with 
fluanisone (Hypnorm; Duphar B.V., Amsterdam, The Netherlands) and pento-
barbital (Abbott Laboratories, North Chicago, Ill.). The left main stem 
bronchus was intubated and the left lung was inoculated with 0.02 ml of a 
saline suspension of 8 x 104 CFU of K.pneumoniae. The number of CFU used to 
inoculate the left lung in the different experiments was confirmed by plate 
counts on blood agar. After inoculation the narcotic antagonists Nalorphine 
bromide and Pentetrazolum (Onderlinge Pharmaceutische Groothandel, Utrecht, 
The Netherlands) were injected. 
Induction of leukopenia. Leukopenia was induced by intraperitoneal 
injections of cyclophosphamide (CY) (Koch-Light Limited, Haverhill, 
Suffolk, England) in two doses of 90 mg/kg and 60 mg/kg at five days and 
one day before bacterial inoculation, respectively. Compared to the course 
of infection in non-leukopenic rats, CY-induced leukopenia resulted in a 
rapid bacterial multiplication in the lung followed by septicemia at an 
early stage of the infection [20]. 
Antimicrobial treatment. Antibiotics were administered in different ways. 
In experiments in which the kinetics of antibacterial activity of the 
antibiotics in lungs of leukopenic rats was studied antibiotic at various 
doses was administered intravenously as a single injection into the tail 
vein, at h after bacterial inoculation. Response to antimicrobial 
treatment was evaluated with respect to the numbers of bacteria in the left 
lung at different intervals after administration. Rats were sacrificed, the 
left lung was removed and homogenized in 20 ml of physiological saline in a 
VirTis homogenizer (The VirTis Co., Inc., Gardiner N.Y.) during 30 s at 
10,000 rpm. Serial ten-fold dilutions of homogenates in saline were pre-
pared. Volumes of 0.2 ml of each dilution, and ml volumes of the 
undiluted lung homogenate were spread on blood agar plates. Statistical 
analysis was performed by use of two-sided analysis of variance and the 
Mann-Whitney test. In experiments in which the therapeutic efficacy of the 
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antibiotics was studied, antibiotic was administered in twofold increasing 
doses, each dose to a group of ten rats, during a period of four days, 
starting at 5 h after bacterial inoculation, either intermittently at 6-h 
intervals into the thigh muscles of the rear legs or by way of continuous 
infusion. Continuous infusion of antibiotic was achieved according to the 
method described by Thonus et. al [21]. Response to antimicrobial treatment 
was evaluated with respect to the daily dose that protected 50% of the 
animals from death (median protective dose, Po50 J. Po50 values were 
calculated according to the method of Spearman-Karber as described by Sachs 
[22]. Deaths of rats were recorded daily until 16 days after the termina-
tion of treatment. After that time no changes in death rate occurred. The 
left lung of each rat that died was cultured to check for the presence of 
K.pneumoniae. Only K.pneumoniae organisms were recovered from lungs of both 
treated and untreated animals. The MBC values of the recovered strains were 
unchanged as compared to the parent strain. 
Measurement of antibiotic concentrations in serum. Blood specimens, 
obtained by puncture of the retroorbital plexus under light co2 anesthesia, 
were collected from each rat, and serum was separated. With use of a 
diagnostic sensitivity agar (Oxoid) and an Escherichia coli test strain 
susceptible to 0.2 ~g of ceftazidime/ml, and 0.025 ~g of ciprofloxacin/ml, 
and a Staphylococcus epidermidis strain susceptible to 0. 2 llg of genta-
micin/ml, all tests were done according to a standard large-plate agar 
diffusion procedure [23]. Standard samples for determination of antibiotic 
concentrations in serum were prepared in pooled normal rat serum. Samples 
of 100 lll were assayed. For determination of concentrations in serum below 
0.2 llg ceftazidime/ml some modifications were introduced in order to 
increase the sensitivity of the test. We applied 225 lll samples into metal 
rings (internal diameter, 6 mm) placed on the agar. To nine parts of each 
sample and of each standard concentration, one part of a solution of 1 llg 
of ceftazidime/ml of serum was added. Correlation coefficients of the 
calculated regression lines were >0.99 in all determinations. Control 
determination of samples with known concentrations of ceftazidime in serum 
with both the original and the modified method yielded similar results. 
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RESULTS 
Effect of ceftazidime, gentamicin, and ciprofloxacin against K.pneumoniae 
in vitro. The MICs as well as the MBCs of ceftazidime and gentamicin for 
the Klebsiella strain used were both 0.4 ~g/ml. The MIC and MBC of cipro-
floxacin were both 0. 2 ~g/ml. Kinetics of bactericidal activity of the 
three drugs at concentrations of !, 1, and 2 times the MBC against 
K.pneumoniae in broth is shown in figure 1. Bacterial killing by ceftazi-
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Figure 1 Effect of ceftazidime (A), gentamicin (B), or ciprofloxacin (C) 
at concentrations indicated against K.pneumoniae in broth. 
Bacterial growth without antibiotic (-----). 
dime was slow but continued during the 4 h incubation period and relatively 
independent on the concentration. On the contrary both gentamicin and 
ciprofloxacin demonstrated a rapid bacterial killing that was related to 
the concentration of antibiotic. The killing rate by ciprofloxacin was 
extremely high. Although the bactericidal activities of ceftazidime, 
gentamicin and ciprofloxacin in HESS with 90% serum were not identical as 
compared to those in broth (figure 2), no major differences were observed 
between the killing patterns in both media. As shown in figure 3 a PAE was 
not observed for the three antibiotics: exposure of the bacteria during 1 h 
to 5 times the MBC for ceftazidime and gentamicin or 2 times the MBC for 
ceftazidime, gentamicin and ciprofloxacin did not result in a substantial 
delay of regrowth as compared to bacteria not exposed to antibiotic. 
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Figure 2 Effect of ceftazidime (A), gentamicin (B), or ciprofloxacin (C) 
at concentrations indicated against K.pneumoniae in HBSS with 90% serum. 
Bacterial growth without antibiotic (----). 
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Figure 3 PAE determinations of ceftazidime (---), gentamicin (--·--), or 
ciprofloxacin (-- .. --) after 1 h exposure of K.pneumoniae to concentrations 
of 2 times the MBC (A) or 5 times the MBC (B). At 1 h cultures were diluted 
100-fold for ceftazidime and gentamicin, and 250-fold for ciprofloxacin. 
Bacterial growth without antibiotic (----). 
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Effect of ceftazidime, gentamicin, and ciprofloxacin against K.pneumoniae 
in lungs of leukopenic rats. The antibacterial activity of ceftazidime, 
gentamicin and ciprofloxacin against K.pneumoniae in lungs of leukopenic 
rats after intravenous administration of different doses at h after 
bacterial inoculation is shown in figure 4. Bacterial killing by ceftazi-
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Figure 4 Numbers of K.pneumoniae in lungs of untreated leukopenic rats 
(--), and after intravenous administration of ceftazidime (A), genta-
micin (B), or ciprofloxacin (C), in doses of 0.3 mg/kg (---), 1.0 mg/kg 
(---), 3.0 mg/kg (-··-), or 9.0 mg/kg (------) at 1 h after inoculation 
of lungs with K.pneumoniae in the logarithmic phase of growth. 
Each point represents the geometric mean ± SEM for five rats. 
dime was not strongly related to the dosage administered although at the 
different doses used ceftazidime peak concentrations in serum ranged from 
1 to 48 ~g/ml (table 1). A significant increase in bacterial killing rate 
was only observed during the first hour after administration of the dosage 
3.0 mg/kg compared to 1.0 mg/kg (P <0.05 by Mann-Whitney). A further 
increase of the dose up to 9.0 mg/kg did not result in a stronger decrease 
of the numbers of bacteria in the lung (P >0.05). In contrast to cefta-
zidime killing rates by gentamicin and ciprofloxacin increased with each 
dose increment from 0.3 up to 9.0 mg/kg. (P <0.05). At similar doses 
bacterial killing by ciprofloxacin was. more rapid compared to gentamicin, 
whereas gentamicin exerted a higher bacterial killing rate compared to 
ceftazidime from the 3.0 mg/kg dose (P <0.05). Bacterial killing by cefta-
zidime continued until 2 h after injection (P <0.05 by two-sided analysis 
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Table 1 Concentrations of ceftazidime, gentamicin, and ciprofloxacin in 
serum at various intervals after intravenous administration to 
leukopenic rats 
antibiotic 
ceftazidime 
dose 
(mg/kg) 
0.3 
1.0 
3.0 
9.0 
gentamicin 3.0 
ciprofloxacin 3.0 
drug concentration (~g/ml of serum) at the following 
times (min) after dosage 
5 
1.1 ±0.19 
4.4 ±0.75 
13.1 ±0.76 
48.2 ±1.89 
14.1 ±1.04 
0.94±0.13 
15 
0.76±0.13 
2.3 ±0.15 
5.7±1.74 
23.9 ±1.32 
6.8 ±0.86 
0.67±0.15 
30 
0.42±0.08 
1 .1 ±0.04 
3.8 ±1.44 
12.2 ±0.58 
4.5 ±0.31 
0.55±0.08 
90 
0.12±0.03 
0.30±0.10 
1.5 ±0.42 
3.10±0.65 
0.95±0.06 
0.41±0.08 
NOTE. Each value represents the mean ± SD for five rats. 
of variance), the killing rate between the first and second hour after 
administration being independent on the dose administered (P >0.05). On the 
contrary the bacterial killing by gentamicin and ciprofloxacin was 
completed within 1 h after administration, thereafter no further decrease 
in bacterial numbers occurred, irrespective the dose administered 
(P <0.05). 
Figure 5 shows the numbers of bacteria in the left lung at various inter-
vals until 9 h after intravenous administration of 3. 0 mg/kg of cefta-
zidime, gentamicin, or ciprofloxacin at 1 h after bacterial inoculation. 
Substantial regrowth of bacteria in the left lung did not occur, although 
antibiotic concentrations in the lung were below the MBC from about 2.5 h 
after antibiotic administration (data not shown). Although bacterial counts 
started to increase from the third hour after injection of ciprofloxacin, 
this increase was only slightly significant. 
The concentrations of ceftazidime, gentamicin and ciprofloxacin in serum of 
rats at various intervals after intravenous administration of different 
doses are shown in table 1. Kinetics of ceftazidime and gentamicin in serum 
were comparable, with estimated elimination half-lifes (t!Bl of 30 minutes. 
Ciprofloxacin serum concentrations were about 14-fold lower as compared to 
those of ceftazidime and gentamicin, within 5 minutes after administration 
of a similar dose of 3. 0 mg/kg. The estimated t!B of ciprofloxacin was 
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approximately 100 minutes. 
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Figure 5 Numbers of K.pneumoniae in lungs of untreated leukopenic rats 
(----), and after intravenous administration of 3.0 mg/kg of ceftazidime 
(---), gentamicin (-.-) or ciprofloxacin ( -··-) at 1 h after inocula-
tion of lungs with K.pneumoniae in the logarithmic phase of growth. 
Each point represents the geometric mean ± SEM for five rats. 
Therapeutic efficacy of ceftazidime, gentamicin, and ciprofloxacin in 
K.pneumoniae pneumonia and septicemia in leukopenic rats. The therapeutic 
efficacy of ceftazidime, gentamicin, and ciprofloxacin determined in terms 
of PD5o values is shown in table 2. The therapeutic effect of ceftazidime 
was dependent on the dosage regimen, being far more effective when 
administered by continuous infusion as compared to intermittent treatment 
at 6-h intervals, resulting in Po50 values of 1.5 and 24.4 mg/kg per day, 
respectively (P <0.001). For gentamicin no significant difference in 
efficacy could be observed between both modes of administration: PD50 
values were 3.8 and 2.8 mg/kg per day (P >0.05) for continuous and 
intermittent administration, respectively. The therapeutic efficacy of 
ciprofloxacin was slightly increased when administered intermittently 
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compared to continuous infusion, demonstrated by PD50 values of 3. 3 and 
6.5 mg/kg per day, respectively (P < 0.05). 
The concentrations of ceftazidime, gentamicin and ciprofloxacin in serum 
after administration of Po 50 doses intermittently or by continuous infu-
sion, are shown in tables 3 and table 4, respectively. When administered 
intermittently, the time periods that serum concentrations were above the 
Table 3 Concentrations of ceftazidime, gentamicin and ciprofloxacin in 
serum at various intervals after intramuscular administration at 
6-h intervals of PD5os to infected leukopenic rats 
antibiotic drug concentration (].J.g/ml of serum) at the 
dose following times (min) after dosage 
(mg/kg) 15 30 90 
ceftazidime 6.1 14.3 ±0.70 9.6 ±1. 18 4.9 ±2.55 
gentamicin 0.7 1.6 ±0.31 1.4 ±0.58 0.28±0.05 
ciprofloxacin 0.8 0.29±0.07 0.20±0.05 0.07±0.02 
NOTE. Doses correspond to the Po50 daily doses of 24.4, 2.8, and 3.3 mg/kg 
obtained for ceftazidime, gentamicin, and ciprofloxacin, respectively. Sera 
were taken at various intervals after the 9th injection. 
Each value represents the mean ± SD for five rats. 
Table 4 Concentrations of ceftazidime, gentamicin and ciprofloxacin in 
serum at various intervals after continuous administration of 
PD5os to infected leukopenic rats 
antibiotic dose 
(mg/kg/day) 
ceftazidime 
gentamicin 
ciprofloxacin 
1 .5 
3.5 
6.5 
drug concentration (].J.g/ml of serum) at the 
following times (h) after dosage 
5 
0.17±0.09 
0.29±0.05 
0.15±0.03 
24 
0.17±0.05 
0.28±0.03 
0.16±0.03 
48 
0.22±0.05 
0.26±0.01 
0.12±0.02 
NOTE. Each value represents the mean ± SD for five rats. 
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MBC of the K.pneumoniae strain were about 170 and 75 minutes for cefta-
zidime and gentamicin, respectively. For ciprofloxacin serum concentrations 
were above the MBC for omly 40 minutes during the 6-h dosing interval. 
Steady state serum concentrations after administration of PD50 doses by 
continuous infusion were 0.19, 0.28, and 0.14 )lg/ml for ceftazidime, 
gentamicin, and ciprofloxacin, respectively. 
DISCUSSION 
The impact of the antibiotic dosage schedule for the treatment of serious 
infections is not clearly established. Particularly in the immune-
compromised host, the schedule of drug administration may play an important 
role in the outcome of antibiotic treatment of infections, as in these 
patients recovery from infection depends to a high degree on antibiotics, 
and therapeutic failure still occurs. During the past few years several 
investigators studied the efficacy of different antibiotic dosage schedules 
in experimental gram-negative infections [6-15]. In the present study the 
impact of the antibiotic treatment schedule of ceftazidime, gentamicin, and 
ciprofloxacin on the therapeutic efficacy was investigated in a model of 
K. pneumoniae pneumonia and septicemia in leukopenic rats. The in-vitro 
susceptibility in terms of MBC values of the K.pneumoniae strain used was 
similar for the three drugs. we observed that ceftazidime was far more 
effective when administered by continuous infusion compared to treatment at 
6-h intervals. It appeared that the therapeutic effect of ceftazidime is 
dependent on the maintenance of antibiotic concentrations in plasma during 
the entire treatment interval. This observation is in accordance with the 
gradual and relatively dose-independent bactericidal effect of ceftazidime 
seen in the lungs of leukopenic rats after administration of a single dose. 
Despite a variation in serum peak concentrations from 1 to 48 )lg/ml at the 
ceftazidime doses used no major differences in bacterial killing rate were 
observed. This relatively dose-independent antibacteridal effect in vivo is 
also corresponding to the concentration-independent bacterial killing 
pattern of ceftazidime in vitro at concentrations around the MBC. In 
contrast to ceftazidime the therapeutic efficacy of gentamicin was not 
related to the mode of administration. With gentamicin intermittent 
treatment resulting in relatively high peak concentrations at relatively 
long intervals seems to be permitted without loss of efficacy. This was 
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confirmed by the high and dose-dependent bacterial killing rate of 
gentamicin in lungs of leukopenic rats after intravenous administration of 
a single dose. Also in vitro the bacterial killing rate of gentamicin was 
related to the concentration used. These results show that the activity of 
gentamicin is strongly dependent on the peak concentration. The therapeutic 
efficacy of ciprofloxacin when administered at 6-h intervals was slightly 
increased compared to continuous treatment. This confirms the dose-
dependent and very rapid killing of K.pneumoniae in lungs of leukopenic 
rats after a single intravenous injection. At all doses tested cipro-
floxacin exerted a high bacterial killing rate which increased with 
increasing doses. A similar pattern of bactericidal effect was found in 
vitro. Differences in bactericidal kinetics between ceftazidime, genta-
micin, and ciprofloxacin are probably related to differences in mode of 
action. 
Besides the bacterial killing rate and the dose-response effect, the rate 
of bacterial regrowth after exposure to antibiotic may also be an important 
determinant for the dosage-regimen-dependent therapeutic effect of anti-
biotic [25, 26]. In this respect we found no major differences between the 
three antibiotics used. In vitro a PAE of the K.pneumoniae strain for the 
antibiotics was not observed. In addition, in vivo patterns of bacterial 
regrowth in the lung after administration of antibiotic were not sub-
stantially different. 
Our experimental data with regard to the impact of the antibiotic dosage 
schedule of ceftazidime and gentamicin on the therapeutic efficacy are in 
accordance with those of other investigations with respect to gram-negative 
infections [6-9, 12, 14, 15]. Gerber et al. demonstrated that ticarcillin 
was more effective in reducing the number of Pseudomonas aeruginosa 
organisms in thighs of leukopenic mice when the interval of administration 
was reduced from 3 hours to 1 hour [7]. In contrast, the activity of 
gentamicin was not dependent on the frequency of injection. Using the same 
infection model, they also demonstrated that the in-vivo efficacy of 
gentamicin and also of netilmicin was mainly dependent on the total dose 
administered and not on the mode of administration either as a single bolus 
injection or at very short intervals to mimic human serum kinetics [8]. On 
the other hand the B-lactams ticarcillin and ceftazidime were more effec-
tive when administered in fractional doses which resulted in longer periods 
of active drug levels in serum as compared to administration as a single 
dose. Other investigators using models of pneumonia and thigh muscle 
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infection in mice both caused by K.pneumoniae showed that the efficacy of 
the B-lactam cefazolin was related to the time period serum drug levels 
remained above the MIC of the infecting strain [12, 15]. On the contrary 
the efficacy of gentamicin was correlated with the total dose administered 
irrespective the frequency of administration. The conclusion derived from 
these experiments that the efficacy of B-lactam antibiotics increased with 
increasing dosing frequency, whereas the in vivo efficacy of amino-
glycosides was independent on the dosage interval, was also confirmed in an 
experimental high muscle infection in mice due to K. pneumonia [ 9] and 
pneumonia or endocarditis caused by P.aeruqinosa in rats, or rabbits, 
respectively [14]. In contrast to these findings there are some experi-
mental studies suggesting that the in-vivo activity of the aminoglycoside 
tobramycin is dependent on the antibiotic dosage schedule used [11, 13]. In 
these experiments, however, long treatment intervals in relation to the 
short elimination half life of tobramycin in small experimental animals as 
compared to that in humans were used. we are not aware of studies concern-
ing the impact of the dosage schedule of quinolones on the therapeutic 
efficacy in experimental infections. However, one study comparing the 
efficacy of the B-lactam BMY-28142 and the quinolone ciprofloxacin in a 
model of pseudomonas endocarditis, shows that although after administration 
of single doses the ratio of concentrations of both antibiotics to the MBC 
at the site of infection were similar, ciprofloxacin was superior to BMY 
after a 5 day treatment at 8-h intervals [10]. In order to obtain the same 
effect as compared to ciprofloxacin BMY had to be administered for a longer 
period at shorter intervals. This observation is in accordance with our 
observation that ciprofloxacin was very effective in contrast to cefta-
zidime, when rats were treated at 6-h intervals. 
Our results with respect to the kinetics of bactericidal activity of cefta-
zidime are in accordance with the slow and relatively dose-independent 
bacterial killing rate as observed generally for B-lactams in vivo [7, 8, 
10, 26] and in vitro [27-30]. Our observations with respect to gentamicin 
are also in agreement with the findings of several investigators 
demonstrating a fast and dose-dependent bactericidal activity of amino-
glycosides in vivo [7, 8] as well as a concentration-dependent bacterial 
killing rate in vitro [27, 30, 31]. Of interest in this respect is the 
study by Moore et al. who demonstrated a strong correlation between the 
peak level to MIC ratio in serum of a number of aminoglycosides and the 
clinical outcome of the treatment of gram-negative infections at 8-h 
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intervals [32]. With respect to ciprofloxacin several studies demonstrate a 
comparable dose-dependent bactericidal activity in vivo [10], a dose 
response effect which was also observed in vitro [10, 33]. 
In general, in accordance with our findings in vitro, gram-negative 
bacteria are found to regrow immediately after B-lactam concentrations have 
fallen below active levels. Contrary to our observations their regrowth is 
suppressed for variable periods of time after exposure to aminoglycosides 
and quinolones [34, 35]. However, PAEs of aminoglycosides in vitro appeared 
to be of short duration (with the exception of Pseudomonas) and may vary 
between the individual strains [34]. There is also strain variation with 
respect to the presence of a PAE for quinolones against K.pneumoniae [36]. 
Like in vitro no major differences were found between the individual drugs 
tested with respect to the bacterial regrowth in the lungs of leukopenic 
rats. 
The data derived from the experimental infection models may have implica-
tions for the treatment of infections in leukopenic patients. In general, 
B-lactams are administered at intervals and, taken into account their 
elimination half-lives, in relatively high doses resulting in high peak 
concentrations in order to provide active drug levels for most infecting 
strains until the next dose. The experimental studies show that for 
successful treatment with B-lactams it is of great importance that 
antibiotic concentrations are maintained at a certain level during the 
period of treatment. High peak concentrations in plasma do not contribute 
to therapeutic effect. These data suggest that lower daily doses of 8-
lactams may be permitted provided they are administered more frequently or 
8-lactams with long half lives are used. This might firstly result in 
improvement of therapeutic effect, and secondly this might be favorable in 
terms of cost-effectiveness. Bodey et al. showed that patients with 
persistent granulocytopenica responded better to a regimen including 
besides carbenicillin the constant infusion of cefamandol as compared to 
intermittent administration of this drug [3]. In a recent clinical study in 
patients with serious systemic infections Hoepelman et al. demonstrated 
that a single daily treatment with the highly protein-bound drug cef-
triaxone resulting in prolonged plasma concentrations, was more effective 
than a combination of gentamicin plus cefuroxime [37]. With regard to the 
aminoglycosides and the quinolones there is no experimental evidence that 
the dosage schedule is an important determinant for efficacy. In view of 
the fact that the bactericidal effect of these antibiotics is strongly 
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related to the peak concentration, and the bacterial killing is very fast, 
further studies are needed to demonstrate whether less frequent dosing with 
increased doses may be equally effective or even more efficacious in the 
immunocompromised host. In this respect several studies are of interest 
demonstrating that animal nephrotoxicity [14, 38-42] or ototoxicity [42] 
decreased with decreasing frequency of administration, despite higher 
individual doses of aminoglycosides. Less frequent dosing was not associated 
with loss of efficacy [14, 41] or resulted even in increased efficacy [14, 
42] . Several human studies did also not reveal nepro- or ototoxicity 
despite relatieve high doses of aminoglycosides given at 24-h intervals, 
which regimens proved to be effective [14, 43, 44]. 
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APPENDIX PAPER V 
IMPACT OF THE DURATION OF INFECTION ON THE ACTIVITY OF CEFTAZIDIME, 
GENTAMICIN 1 AND CIPROFLOXACIN IN KLEBSIELLA PNEUMONIAE PNEUMONIA AND 
SEPTICEMIA IN LEUKOPENIC RATS* 
R.Roosendaal, I.A.J.M. Bakker-Woudenberg, M. van den Berghe-van Raffe, 
J.C. Vink-van den Berg, M.F. Michel 
ABSTRACT 
An experimental Klebsiella pneumoniae pneumonia and septicemia in leuko-
penic rats was used to study the impact of the duration of infection on the 
efficacy of ceftazidime, gentamicin, and ciprofloxacin. It appeared that a 
single dose of each of the respective drugs administered intravenously at 
1 h after bacterial inoculation did not kill all the K.pneumoniae organisms 
in the lung. This was not due to the rapid elimination of antibiotic. 
Persisting bacteria did also not represent a less susceptible subpopulation 
selected after antibiotic administration. The size of this subpopulation 
was determined by several factors. The class of antibiotic and in addition 
for gentamicin and ciprofloxacin the dose administered were determinants in 
this respect. It was also demonstrated for the three drugs tested that the 
number of persisting bacteria increased with increase of the duration of 
the infection. This effect was most pronounced for ciprofloxacin. An 
inoculum effect could not explain this diminished bacterial killing. In 
further experiments the relevance of this observation for the therapeutic 
efficacy of ceftazidime and ciprofloxacin was investigated. Rats were 
treated for four days at 6-h intervals, starting at different times after 
bacterial inoculation. Ciprofloxacin appeared to be more effective than 
ceftazidime, which correlated with its higher bacterial activity. However 
the therapeutic efficacy of both drugs decreased as a result of delay of 
start of treatment. Our data underline the need to start antimicrobial 
treatment as soon as possible, because the number of bacteria persisting 
after antibiotic administration increases with the duration of the infec-
tion. 
*(Submitted for publication) 
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INTRODUCTION 
Granulocytopenic patients are treated with antibiotics empirically and 
blind at the first signs of fever. It appeared that early start of treat-
ment of gram-negative infections, instead of waiting for the laboratory 
results regarding identity and suscept;ibility of the causative organism, 
reduced mortality rates substantially [ 19] . It is, however, not clearly 
established which factors are responsible for the reduction of the activity 
of antibiotics as a result of delay of treatment. We used an experimental 
K.pneumoniae pneumonia and septicemia in leukopenic rats in order to 
investigate this phenomenon. This model was selected because in leukopenic 
patients septicemia is a real threat and K.pneumoniae is one of the 
pathogenes that is recovered [11,17]. 
In our model we observed that single doses of ceftazidime, gentamicin, or 
ciprofloxacin did not kill all K.pneumoniae organisms in the lungs of 
leukopenic rats. It is not clear which factors are responsible for the 
survival of bacteria at the site of infection. One explanation may be the 
absence of active antibiotic concentrations due to rapid drug elimination. 
Another possible factor is the occurrence of phenotypic resistance, a 
phenomenon reviewed by Greenwood [ 1 0] . Due to phenotypic heterogeneity 
within a susceptible bacterial population a fraction of the population may 
be resistant to concentrations of antibiotic that kill most of the 
bacteria. The role of both factors in survival of K.pneumoniae in the lung 
was investigated in the present study. Bacterial survival at the site of 
infection may also be the result of a change in the antibiotic suscep-
tibility of the infecting strain or of changes in the activity of 
antibiotic due to local environmental factors, which as a consequence is 
only expressed in vivo. In the present study it was investigated whether 
the number of persisting bacteria varied with the duration of infection 
and, in addition whether the persisting bacteria could be eliminated by 
administration of an antibiotic with a different mode of action. 
To study the impact of delay of start of treatment on the therapeutic 
activity of antibiotic ciprofloxacin or ceftazidime were administered for a 
-period of four days at 6-h intervals, starting at times after bacterial 
inoculation with K.pneumoniae. 
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MATERIALS AND METHODS 
Animals. Female R strain albino rats (specific pathogen free; 14 to 18 
weeks old; weight, 185 to 215 g; bred at REPGO-TNO, Rijswijk, The 
Netherlands) were used in all experiments. 
Bacteria. A K.pneumoniae strain (capsular serotype 2) was used in these 
experiments. Cultures were obtained by incubation for 16 h at 37°C in Iso-
Sensitest broth (Oxoid Ltd., London, England). After proper dilution and 
reincubation for 2 h at 37°C suspensions of logarithmically growing 
bacteria were prepared. 
Antibiotics. Ceftazidime (Glaxo Pharmaceuticals, Ltd., Greenford, 
England), and gentamicin (Schering Corporation Kenilsworth, N.Y., United 
States) were supplied as powder. Solutions were made in distilled water and 
stored at -80°C. Ciprofloxacin (Bayer AG, Leverkusen, Federal Republic of 
Germany) was supplied as powder or in ampoules of 100 mg of drug in 10 ml 
diluent manufactured by Bayer. Solutions were made in distilled water, 
stored at 4°C and protected from light. 
Antimicrobial susceptibility tests. The MICs of the antibiotics were 
defined as the lowest concentrations that suppressed visible growth after 
incubation of 5 x 105 CFU/ml for 18 h at 37°C in tubes containing 4 ml of 
Iso-Sensitest broth (Oxoid Ltd., London, England). The MBCs were defined as 
the lowest concentrations that killed 99.9% of the original inoculum. MBC 
was determined by spreading subculture volumes of 200 ~1 onto Iso-Sensitest 
agar (Oxoid) plates. The concentrations of the serial dilutions decreased 
by steps of 0.2 ~g/ml. 
For population analysis related to antibiotic susceptibility CFU counts 
were determined simultaneously on antibiotic-free ISO-sensitest agar plates 
and on agar plats containing various concentrations of the antibiotic 
studied. 
Pneumonia. Experimental pneumonia was produced as described previously by 
Bakker-Woudenberg et al. [1]. In brief, rats were anesthetized with 
fluanisone (Hypnorm; Duphar B.V., Amsterdam, The Netherlands) and pento-
barbital (Abbott Laboratories, North Chicago, Ill.). The left main stem 
bronchus was intubated and the left lung was inoculated with 0.02 ml of a 
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saline suspension of 8 x 104 CFU of K.pneumoniae. The number of CFU used to 
inoculate the left lung in the different experiments was confirmed by plate 
counts on blood agar. After inoculation the narcotic antagonists Nalorphine 
bromide and Pentetrazolum (Onderlinge Pharmaceutische Groothandel, Utrecht, 
The Netherlands) were injected. 
Induction of leukopenia. Leukopenia was induced by intraperitoneal injec-
tions of cyclophosphamide (CY) (Koch-Light Limited, Haverhill, Suffolk, 
England) in two doses of 90 mg/kg and 60 mg/kg at five days and one day 
before bacterial inoculation, respectively. Compared to the course of 
infection in non-leukopenic rats, CY-induced leukopenia resulted in a rapid 
bacterial multiplication in the lung followed by septicemia at an early 
stage of the infection [14]. 
Antimicrobial treatment. The in vivo activity of the selected antibiotics 
was examined in leukopenic rats in different ways. Bactericidal activity of 
antibiotic was examined after intravenous injection at various times after 
inoculation of the left lung with K.pneumoniae organisms in the logarithmic 
growth phase. The numbers of bacteria in the lung were determined at 
various intervals after administration of antibiotic. The Mann-Whitney test 
was used for statistical analysis. Therapeutic efficacy was determined 
after treatment at 6-h intervals, for a period of 4 days, starting at 
different times after bacterial inoculation. 
Response to antimicrobial treatment was evaluated with respect to the daily 
dose that protected 50% of the animals from death. PD50 values were 
calculated according to the method of Spearman-Karher as described by Sachs 
[ 16]. 
Measurement of antibiotic concentrations in serum. Blood specimens, 
obtained by puncture of the retro-orbital plexus under light C02 
anesthesia, were collected from each rat, and serum was separated. With use 
of a diagnostic-sensitivity agar (Oxoid) and an Escherichia coli test 
strain susceptible to 0.2 ~g of ceftazidime/ml, and 0.025 ~g of ciprofloxa-
cin/ml, and a Staphylococcus epidermidis strain susceptible to 0. 2 ~g of 
gentamicin/ml, all tests were done according to a standard large-plate agar 
diffusion procedure [2]. Standard samples for determination of antibiotic 
concentrations in serum were prepared in pooled normal rat serum. Samples 
of 100 ~1 were assayed. For determination of concentrations in serum below 
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0.2 ~g ceftazidime/ml some modifications were introduced in order to 
increase the sensitivity of the test. we applied 225 ~1 samples into metal 
rings (internal diameter, 6 mm) placed on the agar. To nine parts of each 
sample and of each standard concentration, one part of a solution of 1 ~g 
of ceftazidime/ml of serum was added. Correlation coefficients of the 
calculated regression lines were >0.99 in all determinations. Control 
determination of samples with known concentrations of ceftazidime in serum 
with both the original and the modified method yielded similar results. 
RESULTS 
Effect of ceftazidime, gentamicin, and ciprofloxacin against K.pneumoniae 
in lungs of leukopenic rats. The MICs as well as the MBCs of ceftazidime 
and gentamicin for the Klebsiella strain used were both 0.4 ~g/ml. The MIC 
and MBC of ciprofloxacin were both 0.2 ~g/ml. 
The effect of ceftazidime, gentamicin, and ciprofloxacin is shown in fig 1. 
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Figure Numbers of K.pneumoniae in lungs of untreaed leukopenic rats 
(-----) and after intravenous administration of 3 mg/kg of ceftazidime (A), 
gentamicin (B), or ciprofloxacin (C). Ceftazidime was administered at h 
hand 3 h <--·--), and gentamicin or ciprofloxacin at h <---) or at 
(_- -l or at h and 2 h (-----) after inoculation of lungs with 8 x 104 
K.pneumoniae in the logarithmic phase of growth. 
Each point represents the geometric mean ± SEM for five rats. 
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One intravenous injection of 3 mg/kg at 1 h after bacterial inoculation 
killed a large fraction of the bacterial population, although not to the 
same extent for all three antibiotics. Whereas ceftazidime and gentamicin 
killed about 90% of the bacterial population, ciprofloxacin killed about 
99%. A second injection of 3 mg/kg at the time the maximum bactericidal 
effect was reached resulted in a slight, but not significant further 
reduction in numbers of bacteria for the three drugs tested. 
Population analysis related to antibiotic susceptibility of the three anti-
biotics did not reveal the selection of a resistant bacterial subpopulation 
at the time the maximum bactericidal effect was reached (fig 2). In 
contrast, a shift to a more susceptible population was observed. 
"' ... 
2 
u 
"' .0 
<IJ 
::0 
:;::; 
a. 
<IJ 
u 
til 
::l 
til 
.... 
0 
o\0 
100 
75 
50 
25 
0 
Figure 2 
A B 
control treated control treated 
c 
control treated 
iJg/ml 
.O.ij 
Ill 0. 2 
[ill 0.1 
liTI 0. OS 
0 0.025 
Susceptibility distribution of K.pneumoniae. Bacteria were 
isolated from lungs of leukopenic rats immediately before administration of 
antibiotic (control), 2 h after injection of 3 mg of ceftazidime/kg (A), 1 h 
after injection of 3 mg of gentamicin/kg (B), or 1 h after injection of 3 mg 
of ciprofloxacin/kg (C). Antibiotics were administered intravenously at 1 h 
after inoculation Of the lungs With 8 X 104 of logarithmically growing 
K.pneumoniae. 
Fig 3 shows the bactericidal activity of ceftazidime, gentamicin, and cipro-
floxacin in lungs of leukopenic rats after administration of 3 mg/kg at 
different times after inoculation with K.pneumoniae. At the time of injec-
tion of antibiotic the mean number of bacteria per left lung was similar in 
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Figure 3 Numbers of K.J2neumoniae in lungs of untreated leukopenic rats 
(-----) and at various times after intravenous administration of 3 mg/kg of 
ceftazidime, gentamicin, or ciprofloxacin (---). Lungs of leukopenic rats 
were inoculated with K.J2neumoniae in the logarithmic phase of growth at the 
same time (0 h) or at various times before injection with antibiotic (-1 h, 
-2 h, or -3 h). Antibiotic was injected at 0 h. At the time of antibiotic 
administration the mean number of bacteria per left lung was 2.2x10S in all 
experiments. Each point represents the geometric mean ± SEM for five rats. 
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all experiments (2.2 x 105 CFU). Delay of antibiotic administration resulted 
in a decrease in bacterial killing for all three drugs tested. Killing by 
ceftazidime continued during 3 h except when administered at 1 h after 
inoculation. When injection of ceftazidime was delayed from 0 h until 1 h 
after inoculation with K.pneumoniae bacterial killing decreased significant-
ly (P <0.05). Further delay of administration of ceftazidime resulted in a 
slight but not significant decrease of bactericidal activity (P >0.05). For 
gentamicin delay of administration also resulted in a decrease of bacterial 
killing in the lung. This decrease was significant for each successive hour 
injection of gentamicin was postponed (P <0.05). For ciprofloxacin similar 
results were obtained. 
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Figure 4 Numbers of K.pneumoniae in the lungs of untreated leukopenic rats 
(----) and at different times after administration of ceftazidime at h 
(-- -) or ceftazidime at 1 h and 2 h (-·-) (A), of ceftazidime at h 
(---) or ceftazidime at 1 hand ciprofloxacin at 2 h (-··-) (B) after 
inoculation of the lungs with 8 x 104 K.pneumoniae in the logarithmic phase 
of growth. Antibiotic was administered in doses of 3 mg/kg. 
Each point represents the geometric mean ± SEM for five rats. 
Although after administration of 3 mg of ceftazidime/kg at 1 h a second 
dose of 3 mg of ceftazidime/kg at 2 h was not able to reduce the bacterial 
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numbers in the lung significantly (fig 4A), a second dose of 3 mg of cipro-
floxacin/kg at 2 h resulted in a significant additional bacterial killing 
(P <0.05) (fig 4B). Similar results were obtained for administration of 
ciprofloxacin after gentamicin (fig SA and 5B). 
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Figure 5 Numbers of K.pneumoniae in the lungs of untreated leukopenic rats 
(--) 
(---) 
and at different times after administration of gentamicin at 
or gentamicin at h and 2 h (-·-) (A), of gentamicin at 
h 
h 
(--- l or gentamicin at h and ciprofloxacin at 2 h (-··-) (B) after 
inoculation of the lungs with 8 x 104 K.pneumoniae in the logarithmic phase 
of growth. Antibiotic was administered in doses of 3 mg/kg. 
Each point represents the geometric mean ± SEM for five rats. 
Finally the effect of delay of start of treatment on the therapeutic 
efficacy of ceftazidime and ciprofloxacin is shown in table 1. The PD50s of 
ceftazidime after a four-day treatment at 6-h intervals, when starting at 
5, 12 or 24 h after bacterial inoculation increased significantly (P <0.05), 
and were 24.4, 52.2 and 120 mg/kg/day, respectively. Delay of start of 
treatment with ciprofloxacin from 5 h to 12 h after inoculation resulted 
in a significant increase of the PD50 value from 3. 3 to 12.2 mg/kg/day 
(P <0.05). Delay up to 24 h resulted in a further, although not significant, 
reduction in activity as shown by an increase of the PDso up to 
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21.2 mg/kg/day (P >0.05). 
Table 1 Efficacy of ceftazidime and ciprofloxacin treatment schedulesa 
start of 
treatment (h) 
5 
12 
24 
ceftazidime 
24.4 
52.2 
120.0 
Po50 (mg/kg/day) 
ciprofloxacin 
3.3 
12.2 
21.2 
aAntibiotics were administered at 6-h intervals over a period of four days 
starting at different times after bacterial inoculation of the left lung 
with 8 x 104 CFU of K.pneumoniae. 
DISCUSSION 
It was observed that single doses of ceftazidime, gentamicin, or cipro-
floxacin did not kill all K.pneumoniae organisms in the lungs of leukopenic 
rats. The experiments described in this study were performed in order to 
elucidate some factors that are responsible for this observation. Firstly, 
it was investigated whether this incapacity of antibiotic to kill all 
bacteria in the lung was the result of insufficient concentrations of 
antibiotic at the site of infection due to rapid elimination of antibiotic. 
This appeared to be not an important factor as a second injection of the 
same antibiotic at the time of the maximum bactericidal effect of the first 
dose resulted only in a slight but not significant additional decrease in 
bacterial numbers. In addition the persisting bacteria appeared not to 
represent a less susceptible subpopulation selected after antibiotic 
administration. In contrast to our observation the selection of more 
resistant bacteria after exposure to antibiotic has been demonstrated by 
several investigators [3, 4, 8, 9, 12, 13]. It has for instance been shown 
that exposure of enterobacteriaceae to aminoglycosides [ 12] as well as 
Pseudomonas aeruginosa to aminoglycosides or quinolones [3, 4 ,8] resulted 
in the selection of bacteria with increased resistance to the drugs used. 
These bacterial subpopulations were responsible for the bacterial regrowth 
in an in vitro kinetic model [3, 4]. Regrowth of bacteria with increased 
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resistance was also found after treatment of a thigh muscle infection due 
to P.aeruginosa with gentamicin [9]. It has been suggested that these 
resistant subpopulations may be of clinical relevance [8, 13]. An explana-
tion for the absence of resistant bact-eria in our experiments may be that 
the occurrence of less susceptible bacteria only becomes substantial after 
multiple injections of antibiotic. 
In the experiments described in this study it was investigated by which 
factors the size of the persisting bacterial population was determined. It 
was shown that the class of antibiotic used and in addition for gentamicin 
and ciprofloxacin the dose that was used were important determinants in 
this respect. In this chapter it is shown that bacteria that could not be 
eliminated by a second injection of ceftazidime or gentamicin were killed 
to a large extent by ciprofloxacin. The additional killing was similar when 
ciprofloxacin was administered either after ceftazidime or after genta-
micin. The total bactericidal effect, however, did not exceed that of 
ciprofloxacin alone, so total bacterial killing was determined by the 
antibiotic with the highest bactericidal activity. It was also demonstrated 
for the three drugs tested that the number of persisting bacteria increased 
with increase of the duration of the infection. This effect was most 
pronounced for ciprofloxacin. The diminished bacterial killing in the lungs 
of leukopenic rats due to delay of antibiotic administration could not be 
explained by an inoculum effect because at the time of administration 
bacterial numbers were similar in all experiments. Neither was a reduction 
in bacterial growth rate responsible for the effect. Similar results were 
obtained by Totsuka et al. [ 1 8] . In his experiments intensive treatment 
with several antibiotics did not result in eradication of K.pneumoniae 
from thighs of neutropenic mice. Persisting bacteria were fully susceptible 
to the drugs used. Delay of administration for only 1 h resulted in a 
substantial decrease of bacterial killing. In a model of pseudomonas 
endophtalmitis in rabbits it was demonstrated that a delay of treatment 
from 24 up to 48 h after infection resulted in loss of bactericidal 
activity of ciprofloxacin, gentamicin and imipenem [6]. This appeared not 
to be related to a decrease of the susceptiblity of bacteria as they were 
fully susceptible to the drugs tested after subculture in vitro. Recently 
similar observations were reoprted by Davey for the same drugs not only in 
vivo in a pseudomonas granuloma-pouch model in rats, but also in in-vitro 
batch cultures in which the drugs became less-bactericidal with progressive 
incubation [ 7]. A possible explanation for our observations and those of 
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others may be that changes in the environment induce phenotypic resistance 
to antibiotic [10], which cannot be demonstrated after bacterial isolation 
and standard susceptibility testing. The exact nature of these changes is 
not clear, but one of the important factors may be that of nutrient 
depletion [5]. This may be responsible for a change of the bacterial 
phenotype and subsequent altered antibiotic susceptibility. Another 
responsible factor may be a diminished activity of antibiotic due to local 
factors such as altered pH or oxygen depletion. 
In further experiments the relevance of our observations with regard to the 
therapeutic efficacy of ceftazidime and ciprofloxacin was investigated. As 
mentioned, after early injection of a single dose ciprofloxacin killed a 
greater part of the bacterial population than ceftazidime, however, the 
activity of both drugs decreased with delay of administration. These 
findings related to the antibacterial activity of antibiotics in the lung 
were related to the therapeutic activity of both antibiotics. Ciprofloxacin 
appeared to be more effective than ceftazidime when administered inter-
mittently, and the efficacy of both drugs decreased with delay of start of 
treatment. These data are in accordance with the observation that institu-
tion of empirical antibiotic treatment in granulocytopenic patients 
starting at the first signs of fever has reduced the morbidity and 
mortality due to gram-negative infections [ 19] . This, however, may not 
apply to gram-positive infections in those patients. In a recent study 
Rubin et al. demonstrated that waiting for the laboratory results, 
identifying gram-positive organisms and antibiotic susceptibility, did not 
affect the effectiveness of treatment with vancomycin [15]. 
In conclusion, the experimental data obtained with antibiotics of three 
different classes underline the need to start antibiotic treatment of 
serious infections as early as possible because the number of bacteria 
persisting in the lung despite administration of antibiotic increases with 
the duration of the infection. The use of highly bactericidal drugs may be 
of advantage in this respect. 
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